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Generation Of In Vitro B-Cell Chronic Lymphocytic Leukaemia-Specific T Cell Responses Using 
Dendritic Cells. RV Goddard. 
Immunotherapy using dendritic cells has shown encouraging results in both haematological and non-
haematological malignancies. In this study, monocyte-derived dendritic cells from patients with B-ccll 
Chronic Lymphocytic Leukaemia were generated by culture in lntcrleukin-4 and Granulocytc Macrophage-
Colony Stimulating Factor. Lysate-pulsed autologous dendritic cells were used as antigen presenting cells in 
eo-culture with autologous B-cell Chronic Lymphocytic Leukaemia T -cells. B-ccll Chronic Lymphocytic 
Leukaemia T-cells stimulated with B-cell Chronic Lymphocytic Leukaemia lysate-pulsed autologous dendritic 
cells showed a significant increase in cell surface expression of Interleukin-2 Receptor (CD25), Interferon-
gamma secretion and cytotoxicity against autologous B-ccll Chronic Lymphocytic Leukaemia B-ccll targets 
hut not against targets from healthy volunteers. Responses were only stimulated by the B-ccll Chronic 
Lymphocytic Leukaemia B cell lysate. Cytotoxicity was Major Histocompatibility Complex Class 11 restricted. 
The addition of maturation agents such as Lipopolysaccharide, Tumour Necrosis Factor-alpha and 
Polyriboinosinic Polyribocytidylic Acid to monocyte derived dendritic cells was unsuccessful at increasing 
anti-tumour responses. Pre-treatment of T cells with lnterleukin-15 before stimulation by lysate pulsed 
autologous dendritic cells increased numbers of activated cells, cytokinc secretion and specitic cytotoxicity to 
B-ccll Chronic Lymphocytic Leukaemia 8-cells. Fusion of monocyte derived dendritic cells and B-cell 
Chronic Lymphocytic Leukaemia B-cclls generated both Major Histocompatibility Complex Class I and Class 
11 restricted cytotoxicity to B-ccll Chronic Lymphocytic Leukaemia B-cell targets. When B-ccll lysates were 
analysed using reducing sodium dodecyl sulphate-polyacrylamide gel electrophoresis, a B-cell Chronic 
Lymphocytic Leukaemia specific hand at 42,000 Dalton and other patient specific bands were observed. Only 
the 65.000 Dalton and 42.000 Dalton hands were capable of stimulating comparable T cell responses as the 
whole lysate. The 65,000 Dalton band from normal healthy volunteers showed a dominant peptide that closely 
matched Human Serum Albumin. The 42.000 Dalton band from B-cell Chronic Lymphocytic Leukaemia 
patients showed a possible match with Human Actin. 
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1. INTRODUCTION 
The Immune system 
The immune system is divided into the innate and the adaptive compartment . The 
innate immune system is the first line of defence of the human body against pathogens. If an 
infection is able to overpower these defences then the adapti ve immune system is activated. 
The adaptive immune system is capable of produci ng a specific reaction to the pathogen 
and maintaining an immunological memory of that pathogen so that a more effective 
response can be generated upon re- infection. The most important cells of the immune 
system are the white blood cells or leukocytes. Leukocytes consist of either cells which 
form a major part of the innate immune system (natural ki ller cells, neutrophils, 
polymorphs, monocytes, and macrophages) or lymphocyte (T and B cells) which mediate 
the adaptive immune response. The innate system and the adaptive system do not act in 
i solation of each other. Antigen uptake, processing and presentation is one of the main ways 
for phagocytes to activate lymphocytes. Once activated the lymphocytes secrete either 
lymphokines or antibodies, which in turn aid the phagocytes to destroy the infectious agent 
more effectively. 
1.2 B lymphocytes CB-cell ) 
B-lymphocytes possess three functions: (i) antigen presentation by presenting 
peptides upon the numerous Major Histocompatibility Complex (MHC) class IJ molecules 
on their cell surface, (ii ) antibody recognition of foreign proteins and (i ii) by effector cell 
13 
function through antibody production. Some but not all B-cells wi ll ex press the foll owing 
markers; cell surface designation (CD) I. CD4, CD5, CD6, CD9, CD 10, CD 19, CD20, 
CD2 1, CD22, CD23, CD24, CD37, CD38, CD40, CD 53, CD 54, CD72, CD73, CD74, 
CD79, CD80, CD81, CD82, CD83, CDw84, CD86, CDI 38, CDI39, CDI50, CDI78, 
CD 179, CD 180, CD229111. 
1.2. 1 B-cell development 
B-cells initially develop from lymphoid stem cells in the haemopoietic ti ssue of the 
foetal li ver. However, during the neonatal period the production of B-cells moves to the 
bone marrow where it continues in adult life. B progenitor cells express markers such as 
CD I 0, CD 19, CD38 and MHC class Ll. After re-arrangements of the heavy chain gene pre-
B cells emerge expressing J..l heavy chains in the cytoplasm and CD20 on the cell surface 
and CDIO expression is lost. Proliferating pre-B cells give rise to smaller pre-B cells. Light 
chain gene re-arrangement occurs and the resulting immature B-cell expresses assembled 
surface immunoglobulin and CD2 1. Loss of CD38 expression then occurs. The resulting 
mature B-cell can be stimulated to secrete soluble immunoglobulin (antibody) by clonal 
selection driven by the presence of a pathogen's antigen within the body. However, B cells 
which bind cell-associated self an tigens can undergo apoptosis by clonal deletion or 
undergo receptor editing and fu rther recombi ne Ig genes. Initially the anti body will be an 
IgM type. However in further response to the antigen, the type of immunoglobulin changes 
(class switching) and B-cells of that clone become either plasma cells or memory B-cells. 
Although the structure of the antibody changes the antigen specificity rarely does. Plasma 
cells regain CD38 expression and show a new marker, PCA- 1, on their cell surface 121. 
1.2.2 Antibody production 
B-cells' definitive feature 1s thei r ability to produce immunoglobulins which, with the 
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addition of transmembrane section and cytoplasmic tail , can act as unique antigen receptors 
called B cell receptors (BCR). The immunoglobulin (lg) molecu le is made up of four 
protein chains, two light chains and two heavy chains (Figure I ). Each chain consi ts of a 
variable region at the amino-terminal end referred to as YL and YH. Differences in the 
variable regions create a plethora of antigen specificities (idiotypic) enabling the B cells to 
recognise many pathogen antigens. The remaining part of the molecule has a constant 
structure. The l ight chain is called the CL region. The heavy chain is further divided into 3 
globu lar regions, CH 1, CH2, CH3 stabilised by intra-chain disulphide bonds. Between CH 1 and 
CH2, the two heavy chains are linked by two disulphide bonds at the hinge region. This 
allows each variable region to bind antigen independently as it provides spatial flexibili ty 
{3} 
There are five different classes of immunoglobulin (lg) produced in humans; l gG, 
IgM , IgA, lgE, lgD. They vary in structure, particularly in the constant regions of the heavy 
chain amino acid structure. Hence each class of Ig's heavy chain is designated as y, 
1..1. , a , £, 8 and is highly conserved within each class of Ig (isotypic). IgM is a pentameric 
version of the basic Ig structure with a central 1 chain. The two heavy chains (1..1.-chains) 
have an additional constant region (CI..l4) with a penultimate cysteine enabling binding to 
the 1 chain or other Cl..l4 chains. The basic lg structures are held together by disulphide 
bonds between constant heavy chain regions 3 (CI-13). IgM secretion is conf ined to the intra-
vascular pool and predominates in early responses. lgD has a high concentration of 
carbohydrate due to variations in amino acid sequence of the three constant 8-chains. lgD is 
found in human serum at low concentrations and is susceptible to proteolysis. lgE contains 
a fourth constant domain on the heavy chain (C£4). The hinge region is organised 
differently with C£2 placed between two disulphide bonds. The Fe porti on (released by 
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digestion with papain) of the lgE binds mast cells. lgG and lgA are further subdivided into 
sub-classes; lgG I , lgG2, lgG3 and lgG4 and lgGA 1 and lgGA2. IgG sub-classe differ in 
their hinge regions by the number of inter-heavy chain bonds. JgG is the major Ig found in 
serum and is present equally in intra-vascu lar and extra-vascular pools. lgGs are the major 
antibodies involved in secondary responses and anti -tox in function. IgA possesses an 
additional C-terminal octapeptide with a penultimate cysteine residue that can bind to a J 
chain. IgA is the main component of secretions such as sali va, colostrum, milk, 
tracheobronchial and genito-urinary secretions. It is found in serum mainly in a dimeric 
form. Secretory lgA, found in seromucous secretions, can occur in either subclass as a 
dimeric form binding the secretory component by cysteine residues in Ca l and Ca2 ' 41. 
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Figure 1: Antibody basic structures 
Soluble lgA 
""'' 
Basic structure of lgG 
Pentameric structure of IgM 
I 
~L____---
Takenfrom Turner M, Molecules which recognise antigen. In : Roit /M, Brostoff J, Male DK, Eds. 
Immunology 2m1 Edn. London: Cower medical publishing. 1989. 
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1.2.2 Importance ofT cell help 
Although 8-lymphocytes express receptors for lymphokines and chemokines, 
contact-mediated signals from T-cells are required to produce a highly effective humoral 
response 151. Firstly, signalling through the 8CR primes the 8-cell to be more responsive to 
signals from T cells 161. Engagement of MHC class 11 molecules stimulates early 
biochemical events and lead to 8 cell proliferation and differentiation !71_ MHC class 11 
engagement by T-cells enhances both 8CR signalling via 2 8CR co-receptors (CDI9 and 
CD22/'111 and CD40 191 signalling by eo-localisation with cholesterol and glycosphingolipid 
enriched membrane microdomains 1101. Direct signalling through CD40 occurs by ligation 
with CD 154, a trimer Tumour Necrosis Factor (TNF) family member, expressed on 
activated T cells. CD40 engagement can stimulate proliferation, antibody secretion, 
cytokine production, increased ability for antigen presentation, isotype switching, 
development of germinal centres and establishment of humoral memory responses fllf_ 
These many complex roles of CD40 engagement rely on the complicated interaction of 
CD40 with TNF-associated factors (TRAP's) 1121. Engagement of CD 134-Iigand (CD 134L) 
(OX40L) is thought to play a role in the secondary antibody response and immunoglobulin 
isotype switching 1131. Signalling through enhanced adhesion molecules such as intercellular 
adhesion molecule -I (ICAM-1) 1141, CD81 /1.1/ and CD22 1161 have been shown to amplify 
activation signals from T helper cells. Engagement of CD72 by its ligand CD I 00 enhances 
B cell activation via CD40 and inhibits lgG production but not initial lgM production 1171. 
CD27, a tumour necrosis factor receptor (TNF-R) family member, expressed by a subset of 
memory 8 cells is ligated by CD70 expressed by T lymphocytes at the later stages of their 
activation 1181. CD27-CD70 interactions are particularly important for the development of 
antibody secreting plasma cells 119'. 
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Due to thymic selection ofT cells, self- reactive T cells are more tightly regulated 
than B cell s. Hence any self-reactive B cells cannot become activated and produce high-
affinity autoreacti ve antibodies without T cell help. 
1.3 B-cell Chronic Lymphocytic Leukaemia CB-CLL) 
B-cell chronic lymphocytic leukaemia is one of the most common types of 
leukaemia among adults in Europe and North America 1201. B-CLL affects twice as many 
males as females. The median age at diagnosis is between 65 and 70 years. B-CLL is 
characteri sed by the accumulation of a clone of malignant B-cells in lymphoid tissue, the 
bone marrow and the peripheral blood. The first indication of the disease is often a 
consistent lymphocyte count of higher than 4.5. x 109/L in peripheral blood samples (often 
taken for other clinical reasons). The phenotype of these B-cells includes the expression of 
pan-B-cell associated cell surface markers such as CD 19, CD20, CD40, CD45RA, MHC 
class ll OR and CD37. The B-CLL cells also express high levels of COS, a molecule that is 
usually found upon the surface of T cell s but also on a small subset of peripheral B-
lymphocytes 1211 and CD23 which are not usually expressed on other B-cell lymphomas. B-
CLL cells usually express low levels of CD2 1, MHC class Il DP, CD I c and surface 
immunoglobulin . B-CLL cells sometimes express CD25. However, CLL cells can be 
differentiated from pro-lymphocytic leukaemia (PLL), mantle cell lymphoma or hairy cell 
leukaemia (HCL) by the absence FMC7 and CD 10 1221, from acute lymphoblastic leukaemia 
(ALL) and fo ll icular lymphoma (FL) by the absence of CD22, CD35, CD79b, CD I 0 and 
from myeloma by the absence of CD38 1231 . 
The B cells that accumulate in CLL patients are functionally inactive as they do not 
respond to B cell stimuli such as lipopolysaccharide (LPS), Ep. tein-Barr virus (EBV) 
proteins and anti -lgM antibodies. CLL B cells do not act as good stimulator cell s in an 
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al logeneic mixed lymphocyte reaction and fun ction as poor antigen presenting cells JNJ . The 
CLL clone persists wi thin the periphery due to its fai lure to respond to apoptoti c stimuli 
rather than increased proliferation of B-cells. In the majority of patients the CLL cells are in 
the quiescent Go phase of the cell cycle 1251• Hypomethylation of the bc/-2 promoter region 
results in high levels of bcl-2 protein in 85% of patients. bc/-2 is one of the proteins that 
control the apoptosis caspase cascade. Therefore, the high expression of bc/-2 has been 
linked along with other factors to the B-CLL cells' ability to resist apoptosis. 
Chromosome abnormalities were originally shown in 50% of B-CLL patients. 
However with the adoption of fluorescence in situ hybridisation (FISH) this has risen to 
80% of B-CLL patients. Deletion of the retinoblastoma suppressor gene (RBI) at 13q 14 is 
one of the most common chromosome abnormalities. However, RBI has not been shown to 
be involved in the pathogenesis of B-CLL. Patients wi th on ly a single deletion at 13q have a 
better average survival than patients with other chromosome abnormalities 1261. The next 
most common chromosome abnormality is deletions at the 11 q2 1-23 region disrupting the 
atax ia telangeictasia mutated (ATM), radixin (RDX) and FDX genes. This genetic 
abnormality may be responsible for fami lial CLL as germline mutations in the ATM gene 
have been identified. Deletions at 11 q usually correlate with a poor prognosis for CLL 
patients 1271 . Trisomy or partial trisomy of chromosome 12 is another common abnormal 
karyotype found in B-CLL. Tri amy 12 is as ociated with atypical cell morphology, bright 
expression of surface immunoglobulin, CD20 and FMC7 and absence of CD23, higher 
proliferative rate, advanced disease and poor prognosis 1281. Inactivation by the p53 tumour 
suppressor gene as a result of a mutation at chromosome 17p is associated with resistance to 
chemotherapy. Decreased p53 function can result in an increase in B-cell proliferation and 
prolonged cell survival. Therefore it is unsurprising that it is closely associated with 
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advanced disease and a more aggressive form of the di ·ease i .e. those patienrs with 
Richter' s transformation 171 . Trans l ocation~ of chromosome 14 at 32q have been ob ·erved in 
B-CLL The Immunoglobulin heavy chain is encoded at 32q. However, the frequency of 
these translocations amongst B-CLL patients is dependent upon the laboratory technique 
used. The most common translocation is from 14q32 to 11 q 13. The immunoglobulin heavy 
chain and bcl-2 genes become adjacent. This translocation is more commonly found in 
mantle cell lymphoma. Hence high frequency of translocation 14q32 to I I q 13 may be a 
re ult of misdiagnosis of mantle ce ll lymphoma as B-CLL 171 . 
B-CLL is an indolent disease but as the disease advances there is a progressive 
enlargement of the spleen and lymph nodes. Lymphoid cells accumulate in the bone 
marrow through diffuse interst itial infiltration resulting in the complete filling of the inter-
trabecular space. Anaemia, thrombocytopenia and netropenia will develop due to failure of 
the bone marrow or because of plenic pooling or hypersplenism. A utoimmune haemolytic 
anaemia, thrombocytopenia or both (Evan's syndrome) can occur due to polyclonal 
autoantibody production by normal non-malignant B cell . Hypogammaglobulinaemia 
occurs due to the disordered immune function of B-CLL patients. B-CLL patients are more 
susceptible to infection such a S. pneumoniae, S. aureus, £. coli, or Herpes zoster and 
have a higher incidence of olid tumours probably also because o f the di ordered immune 
function. 
A lthough chemotherapy can induce partial or complete remission 1291, long-term 
disease-free survival is unusual. Therapy for CLL is given generall y with palliative intent 
rather than curative. The patients age, quality of life and immune status all influence choice 
of treatment. Cun·ently patients in the earlier stages of disease are reviewed regularly and 
only receive treatment when the disease progresses. For most B-CLL patients chlorambuci l 
2 1 
(an alkylating drug) is the front line treatment. In 50% of patients chlorambuci l produces a 
reduction in lymphocytosis, an improvement in haemoglobin and platelet count and 
shrinkage of lymphadenopathy and splenomegly. In these patients chlorambucil delays the 
rate of disease progression but does not increase overal l survival. The treatment is often 
discontinued when lymphocyte counts have returned to normal ranges. Patients can often 
develop resistance to chlorambucil. Corticosteroids alone such as prednisolone are only 
partial ly effecti ve. However, they may inhibit the infi ltration of lymphocytes into the bone 
marrow prior to treatment with an alkylating drug. Combination therapy of alkylating drugs 
and steroids increase response rates to 70% but not increase overall survival. Purine 
analogues such as fludarabi ne have widened treatment options for patients no longer 
responsive to chlorambucil. Early results are promising as treatment with fludarabine has 
been shown to increase complete remission rates, overall response rates and prolong disease 
free-survival 1301. However no change in overall survival rates has been seen. Recent tri als 
of bone marTow transplantation or monoclonal antibodies are promising 1311. New treatment 
modalities for this disease are requi red and trial s of bcl-2 antisense have begun. In view of 
the fact that B-CLL is a tumour of the immune system it seems challenging and logical to 
attempt to harne s that system to treat this disease. 
1.4 T -cells 
T cells are critical in developing cell-mediated immune response . 
I .4. 1 T cell receptor (TCR) 
There are 2 types of TCR. TCR I consists of a y-receptor chain encoded by chromosome 13 
and a 8-receptor chain encoded by chromosome 14. TCR2 consists of a 45kDa a -receptor 
chai n encoded by chromosome 14 and a 40kDa ~-receptor chain encoded by chromosome 7 
joined by a disulphide l ink near the cell membrane (Figure 2). Each chain contai ns a 
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variable domain and a con tant domain maintained by intra-domain disulphide bonds 1321. 
TCR are generated by a series of omatic site- pecific deoxyribonucleotide acid (D 
recombination reaction collectively termed variable diversity j oining (V(D)J) 
recombinations. The formation of the receptors 2 protein chains is dependent upon three 
recombination events; the recombination of V , D and J gene to form the variable domain 
of the a chain and the j oining of V and J to form the variable region of the p chain. Each 
variable region then associate with the recombined constant domains. This generate a 
large repertoire of T cells which can recognise many antigens. Rearrangement is tightly 
regulated and TCR genes are only fu lly assembled in T cell f .H/. 
Figure 2: TCR interaction with MHC 
cos• T cell C04• T cell 
Adapted from Schwart::. RH, Science. 1990; 248: I 350. 
The development of TCR I positive T cells is separate from TCR2 positive T cells. 
TCR I cells do not express either CD4 or CD8. TCR I cells are capable of recognising 
antigens such as tetanus toxin (IT), staphylococcal enterotoxin A , mycobacterial antigens 
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and heat shock proteins (HSP). TCR I cells can recognise highly polymorphic antigens 
such as tumour idiotypes from B cel l lymphoma. Recogni tion of antigen does not occur 
using the MHC system but by recognis ing intact antigens by HSP 70 ' 341. 
M ost T cel l in the periphery have the TCR2 receptor. Each heterodirner is 
noncovalently linked to invariant chains of the CD3 complex (CD38, CD3y and CD3£ 
homodimer) and s-homodirner. Within seconds of antigen receptor cross- linking the 
phosphotyrosine content of Src family of non-receptor protein tyrosine kinases (PTKs) 
increases perhaps by autophosphorylation at the Src homology I (SH-1 ) si te. In resting 
lymphocytes key Src PTKs are kept in poorly phosphorylated states by phosphotyrosyl 
phosphatases such as those found on CD45. Src PTKs phosphorylate the immunoreceptor 
tyrosine activation motifs (ITAMs) of the invariant chains until binding wi th SH2-
contai ning proteins occurs. Zap contains two tandem SH-2 domains before the catalytic 
domain. Zap is recruited to sand £ subunits of TCR-CD3 complex by interaction with the 
activated ITAM' . This interaction in turns acti vates Zap{351. 
1.4.2 Major Histocompatibility Complex (MHC) 
The TCR2 molecu le is responsible for the recognition of antigens presented in the 
context of another molecule, the human leukocyte antigen (HLA), coded for by the M ajor 
Histocompatibili ty complex (MHC). Three maj or sets of molecu les are encodecl within this 
region on chromosome 6, class I, class U and class m. MHC class 11 molecules are made up 
of two polypeptides, an a-chain and a P-chain each with two domains. Genes wi thin the 
MHC class ll region that encode for many genes are arranged into three groups, DP, DQ 
and DR and contain genes for at least one a-chain and one P-chai n. MHC class I molecules 
are made up of an a-chain consisting of three domains and P2-microglobulin (Figure 4). 
Genes within the MHC class l region encode for twenty genes including the classical 
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Human Leukocyte Antigens (HLA) -A, -B, -C, and -E heavy chains (Figure 3). Class Ill 
genes encode complement components involved in the cleavage of C3. Other genes reside 
in this region such as TNF and HSP 70 '361. At each gene locus there are many di fferen t 
alleles within the human population. Since any region of A, B, C, D-relatecl , or E may be 
linked together and with two non-identical chromosomes the number of haplotypes is very 
large. HLA haplotypes do not associate in a completely random manner. Paired specificities 
have been discovered with linkage disequil ibrium e.g. if 16% of the population have HLA-
A 1 and I 0% of the population have HLA-8 8, then 1.6% of the population would be 
predicted to possess both HLA-A I and HLA-B8 if the association was random. However, 
8.8% of the population carry HLA-A I and HLA-8 8 genes rm. 
Figure 3: Arrangement of MHC 
Class 11 region 
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Taken from Owens M. Major Histocompatibility complex. In: Roit /M, Brostoff J, Male DK, Eds. 
Immunology 2"" Edn. London: Gower medical publishing. 1989. and Parham Naw re. 1990; 348: 674 
The crystal structure of MHC class I molecule revealed a groove on its surface 
constructed by 2 domains of the a chain (a l and a2) formi ng the sides and a P-pleated 
sheet forming the floor. Along the groove there are 6 bi nding sites for the antigen peptide 
fJBJ which is usually 8 or 9 peptides long. Deep and highly conserved pockets at each end 
bind the carboxyl and amino termini by hydrogen bonding f39J. A deep polymorphic pocket 
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in the middle of the groove plays a major role in allele-specific peptide binding 1401. The 
MHC class Il crystal structure ha, now been de ·cri bed and it also contains a peptide binding 
groove which binds peptides usually 13 or 14 peptides long 1411. Therefore MHC-binding 
motifs can now be predicted to bind certain HLA alleles f.Jll. 
Figure 4: Schematic representation of MHC class 11 and MHC class I 
MHC class n molecules MHC class I molecu les 
Taken from Roitt, Brostoff, Male. Immunology chapter 4, 2"d Ed. Cower medical publishing. 1989. 
CD4 or CD8 become intimately associated with the TCR and can enhance the 
binding of the TCR by binding nonpolymorphic portions of MHC molecules l.f3l or by 
affecting signal transduction 1441. T cells which have CD4 on their cell surface recognise 
antigens by engagement with MHC class II molecules. T cells which are posi tive for CD8 
recognise antigens by MHC class [ molecules. In general , CD8 positive T cells are 
responsible for cell-mediated ki lling and CD4 positi ve T cell s provide T cell help in the 
form of cytokine and chemokine secretion. There is a minority population of CD8 positi ve 
T cell s involved in cytokine secretion and a CD4 positive population of T cells that can 
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mediate cell cytotoxicity. 
Peripheral T cells that traffic through lymph nodes and the vasculature are 
susceptible to chemokine sjgnals to attract them and arrest their movement. T cells in this 
state have a 'hand-mirror' shape, with the nucleus pushed into the leailing edge of the cell 
and the cytoplasm concentrated in a trun 'handle-like projection that lags behind as a 
uropod. These rnghly polarised T ce11s have Integrins, TCR and co-receptors, CD43, CD44, 
cytoplasmic organelles (such as endoplasmjc reticulum (ER)/Golgi and microtubule-
organising centre) and secretory vesicles all located in the uropod region £451. Chemokine 
receptors CCR2 and CCR5 are found at the leailing edge of the T cell. 
1.4.3 T cel1 development 
T lymphocytes develop in the thymus fTom a few progenitor stem cells which 
originate from the fetal liver or adult bone marrow. Initially the thymic T cells ilifferentiate 
from stem cells by interaction with the thymic epithelial microenvironment. The 
thymocytes become organised into cortical and medullary regions within the thymus. T cell 
maturation occurs in three stages starting in the thymjc cortex and maturing in the thymjc 
medulla until they emerge as peripheral T cells (Figure 5). 
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Figure 5: T ceU development 
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At the earliest stage, in the thymic cortex, the cells undergo gene re-arrangements of 
the T cell receptor (TCR) p chain. The TCR-associated complex CD3 is expressed in the 
cytoplasm after the gene re-arrangement/"'61. The TCR2 thymocytes differentiate further 
and molecules such as CD l , CD4 and CD8 are expressed upon the cell surface 
simultaneously. It is at this stage that the T cells are educated by the thymic epithelial 
binding of the MHC and self-antigens. Firstly positive selection ensures that TCR receptors 
that bind "self MHC" haplotypes with low affinity "self antigens" on thymic cortical 
epithelial cells receive a positive signal for further differentiation. Thymocytes which do 
not bind MHC, because of errors in TCR rearrangement, undergo programmed cell death. 
Cells which bind "self MHC'" and show high affinity binding to "self-antigens" on thymic 
DCs (DCs) are deleted ' 471. During the final stage of maturation the mature thymocytes 
loose CD l molecules from the cell surface and become either CD4 positive T cells or CD8 
positive T celJs ' 461. Single positive ceJis that bind to "self-antigens" presented by thymic 
epithelial ceiJs in the context of "self-MHC" are anergised 1471. Hence by negative selection 
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T cells with the ability lo recognise foreign antigens in the context of ''self MHC" travel to 
the periphery. 
Once T cells are activated by antigen presenting cells (APCs) and become effector T 
cells they migrate to non-lymphoid organs and migrate to sites of infection directed by 
integrins and inflammation related cytokines and chemokines. T-cells with high-affinity 
TCRs become dominant in the primary response and are specifically selected as memory T 
cells 14x1. A small subset of these cells may persist as memory effector T cells capable of 
launching an in si/11 secondary response to re-infection 1491. However, T cells that receive 
only a short stimulation proliferate but do not acquire effector function of cytokine 
secretion or cytotoxicity. These non-polarised cells retain their ability to home into the 
lymph nodes and become a different subset of long-term memory T cells which have no 
defined effector function until the establishment of secondary responses 1501. In this way T 
cell memory is able to establish more rapid and effective responses to a repeat infection 
whilst still retaining the flexibility in the nature of that response. 
I .5 Antigen presentation 
The mechanism for the initial formation of the T ceii-APC contact is not clear but 
may involve villus/villus contact 1511 with leukocyte functional antigen-) (LFA-1) or C02 
mediating adhesion 1521. Once initial contact has been made a slop signal occurs to enable 
the T cell to resist chemokine gradients that would otherwise stimulate the T cell to 
continue chemotaxis t5.il. The stop signal is raised intracellular calcium and this coincides 
with the T cell becoming a more spherical shape 1541. The nature of the calcium signal is 
related to the antigen encountered on the MHct.w. T cell activation is generated at the 
immunological synapse, a specialised area of contact between T cells and APC 1561 . Small 
TCR-MHC clusters form with CD4 eo-clusters and strong calcium signals are recorded. 
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The CD3 coalescence directs clustering of TCR molecules to form the central 
suprarnolecular activating complex with a surrounding peripheral supramolecular activating 
complex of ICAM-LFA-1 ligand pairs1571. Exclusion of CD45, CD43 and ICAM from the 
MHC-CD3 complex1581 stabilise the central supramolecular activating complex. 
Reorganisation of the microtubule-organising centre mediated by CD3 occurs following 
antigen recognition'59i. 
The maintenance of the central supramolecular activating complex requires eo-
stimulation by engagement of CD28 at this point1601. Both CD28 and CD 152 are 
immunoglobulin supergene family glycoproteins expressed as homodimers that play a 
major role in eo-stimulation ofT cells by signal transduction via cytoplasmic tails with 
tyrosine- containing motifs /61/. T cells express CD28 on the cell surface at relatively 
constant levels apart from small fluctuations which occur during T cell activation 1611. CD28 
enhances T cell activation by increasing proliferation, cytokine secretion and T cell survival 
in the presence of TCR stimulation that would otherwise be insufficient for T cell 
proliferation1611. CD28 also upregulates CD40L which is vital for the development of fully 
functional T cell effector cells1621. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
(CD 152) plays an inhibitory costimulatory role in regulating T cell activation. Although 
both CD28 and CD 152 bind CD80 and CD86 on APCs, CD 152 has I 00-fold higher avidity 
for CD86 than CD2816·11 . The CD 152 inhibitory signal will predominate when T cells 
encounter antigen on APCs 1641. The majority of CD 152 is localised within the peri-nuclear 
Golgi even at times of maximal expression, 36-48 hours after T cell activation 1"51 . 
Intracellular CD 152 traffics to the cell surface at the site of the TCR-APC interface and is 
quickly endocytosed 1651. Hence the inhibitory effect of CD 152 can be controlled by tightly 
restricted expression at the cell surface as it can compete with CD28 for its ligand and 
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downregulate aT cell response1641. Na"ive T cells do not express CD 152. 
The formation of the supramolecular activating complex allows high binding 
avidities to be achieved by summation of a variety of independent avidities 1601. Signal 
transduction molecules such as protein kinase C8 migrate to the central supramolecular 
activating complex 1661. Once the T-cell coupling signal has progressed, the TCR is down 
regulated. CD8+ T cells, after stimulation, internalise class I MHC ligands and CD281671. 
Serial triggering of additional TCR by low affinity peptide-MHC complexes results in 
sustained signalling whilst the T cell and the APC maintain cellular contact 16111. Eventually 
the T cell disengages from the APC having become fully committed to effector function. 
However, the early T-ceii-APC contact is highly dynamic as it can be disrupted by APC 
loaded with higher antigen concentrations1691, increased levels of T-cell cAMP, 
modifications of the T-cell cytoskeleton1701 or the presence of collagen1711. Prolonged 
contact at lymph nodes may be facilitated by the lack of collagen. 
1.6 Cytokine secretion 
There are principally two phenotypes of cytokine secreting T cell. Type I T helper 
cells (Th I cells) provide protection against intracellular pathogens such as bacteria and 
viruses and are also implicated in organ specific autoimmune disease 1721. Type 2 helper T 
cells (Th2 cells) are specialised to eradicate parasites such as tlatworms and roundworms 
and are involved in allergic reactions 1721. One of the defining features of Th I versus Th2 T-
cells is the range of cytokines that they secrete 1731. Conversely the microenvironment of 
cytokines can affect the differentiation of any one particular na"ive T cell into one Th type or 
the other 1731. Figure 6 illustrates that development of Th I type response is driven by 
interleukin-12 (IL-12) by stimulating the production of interferon-y (IFN-y) 1741. Increased 
IFN-y secretion up-regulates receptors to IL-12 and inhibits the growth of Th2 T cells 1741. 
31 
Signal transducer and acti vator of transcription-4 (Stat-4) 1751, ezrin , radi xin and moe in 
fam ily (ERM) 1761 and T box tran cription factor (T-be£)'771 are all involved in Th I 
differentiation. IL-4 on the other hand induces Th2 responses by the production of IL-4, IL-
5 and [L- 13 through act ivation of Stat-6 1751, c-Maf 17111 and guanine, adenine, thymine, 
adenine contain ing (GATA-3) 1791. IL-4 down-regulates the expression of IL-12 receptors 
and so inhibits the growth of Th I type T cell s1731. Th lrfh2 cytokine profiles become more 
fi xed as T cells are exposed to repeated or sustained culture conditions. However, even 
committed Th2 cells can be converted to Th I cells by T-bet 1771. A sustained TCR 
engagement is required not only to stimulate na'lve T cells but also for proliferating cells to 
differentiate into effector T cells especially the Th2 type 180· 811. Long-term clones reach a 
point when they are fully committed to one or other Th phenotype/771 . 
Figure 6: Thl/Th2 T cell phenotypes 
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Taken from 0 'Garra A. Nmure. 2000: 404: 720. 
Generation of antigen-specific T cells that express CD8 is thought to require two 
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signals. Firstly, the engagement of the TCR by the peptide-MHC class I complex and 
secondly, a eo-stimulatory signal stimulating C02S on the T cell by engagement of COSO 
or COS6 on the APC 1611. Ligation of C02S provokes the release of IL-2 from antigen 
specific COS+ T cells which is necessary for the acquisition of cytolytic function 11121. CTL 
generation is often dependent upon T cell help supplied by C04+ T cells. Stimulation of 
cytotoxicity can be triggered by a single peptide-MHC I complex. There is rapid localised 
calcium release at the uropodium when cytotoxic T lymphocytes encounter target cells 1831. 
cos+ cytotoxic T cells kill targets by the perforin pathway. When effector-target 
cell contact is made the Golgi apparatus is re-orientated 1871. Perfmin normally stored in the 
cytoplasmic granules is exocytosed by the cytotoxic T cell !851. Perforin inserts into the 
plasma membrane of the target cell and forms pores in the target membrane by 
polymerisation fli41. Polarised secretion of a family of eleven granule-stored serine proteases 
(granzymes) occurs tx41 . Granzyme B has clearly been linked to promote DNA 
fragmentation by identification of substrates including pro-caspases ' 841. The eleven 
granzymes have one of four specificities; tryptase cleaving after arginine or lysine , asp-ase 
(cleaving after asparagine), met-ase (cleaving after methionine or leucine) and chymase 
(cleaving after phenylalanine, tyrosine or tryptophan) 1841. The proteolytic activity is 
associated with the induction of DNA fragmentation and apoptosis. Perforin mediated 
cytotoxicity is common when there are high levels of IL-2 1851. The Perforin and granzyme 
killing pathways' principle function is to eliminate parastized, infected cells that resist 
apoptosis clue to pathophysiological changes. Hence it is the perforin mechanism that is 
linked to killing of virus-infected and tumour cells 186'. 
An alternative pathway mediated by Fas-FasL (C095/CD95L) is also involved in 
cytotoxicity. Fas-FasL killing has a primary function of control of normal cell renewal by 
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inducing apoptosis of actively proliferating cells 1871. Interleukin-1 converting enzymes are 
activated within the target cell after attack by a cytotoxic effector cell flill_ IL is well 
established that CD4+ T cells express cytotoxic activity. Cell-mediated cytotoxicity is 
associated with Th I cells. CD4-mediated target cell death is by DNA fragmentation. CD4+ 
T cells preferentially kill their targets by Fas-FasL pathway but can also kill by the perforin 
pathway. CD4+ T cells preferentially lyse MHC-class 11 cells such as APCs. CD4+ T cells 
are capable of killing tumour cells by bystander lysis 1881• 
1.8 Antigen presenting cells (APC) 
B cells, monocytes, macrophages and DCs are capable of presenting antigens to 
both B and T cells. Both B-cells and T-cells express reciprocal adhesion molecules such as 
!CAM-I (CD 54) and LFA-1 (CD 11 a-CD 18) and thus, by establishing close cell-cell 
contact, facilitate antigen presentation and T cell activation 1891• CD40 has been shown to 
play a crucial role in enhanced antigen presentation by B-cells to T-cells 1901. Activated B 
cells can induce proliferation and differentiation of un-activated B cells by means of the 
CD 134L-CD 134 (OX40) interaction 191f. The interaction of CD 137 on activated T cells and 
CD 137L on B cells delivers important eo-stimulatory signals to the T cell 1921. 
1.8.1 Dendritic cells <DCs) 
Dendritic cells are easily identifiable under the microscope by their dendrite cellular 
processes around the cell lamellae. Dendritic cells vary in their differentiation stale and 
cellular origin. The first dendritic cell to be described was the Langerhans cell. These are 
na"lve skin DCs. Their primary function is antigen uptake and they are highly adapted to 
that. Langerhans cells express Lag antigens, and Langerin or Birbeck granules can easily be 
observed 1931. Follicular DCs do not originate from the bone marrow but retain antigen for 
longer periods and re-stimulate B cells within the B lymphoid follicle. In general, DCs of 
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myeloid origin associate with T cells within the lymph nodes to initiate proliferation and 
activation ofT and B cells. These cells are MHC n+, CD4+, CD33"'ong+, CDI23Jim+. 
CD 13'"''"g+, CD29+, CD58+, COS+, C02+ and CD86+ and produce large amounts of IL-l~. 
IL-6, IL-12 TNF-a and IL-8 upon stimulation ' 941 . Thymic or lymphoid DCs have an 
altogether different role in the deletion of maturing T cells 1951 • They possess unique 
markers CD8q ' 961 as well as COlic+, DEC205+, CDIIbdim, 3301- and CD4-f931. Thymic 
DCs also have a mature phenotype although the maturation stimulus is unclear it is not 
related to pathogens or inflammatory stimuli like myeloid DCs. A further type of dendritic 
cell, plasmacytoid DC, was identified as the dendritic cell present at inflamed lymph nodes 
surrounding high endothelial venulesf97J_ They are distinct from monocytes and myeloid 
DCs in that they are CD 123+, CD45RA +, CD4+, IL-3R+ and CD lie' and CD I a· and present 
in low levels in peripheral blood'981. When cultured in vitro in the presence of CD40L 
myeloid and plasmacytoid DCs mature into DC I and DC2 which selectively trigger Th I 
and Th2 responses respectivel/991. Although the degree to which the responses are 
polarised is also dependent upon the maturation state of the DC and the DC: T-cell 
ratio' 1001. Thymic and plasmacytoid DCs appear to share a common lymphoid precursor 
which is COlic-, CD la- and IL-3R+ whereas, interstitial DCs and Langerhans cell derived 
DCs appear to share a myeloid precursor which is COlic+, COla+ and IL-3R·f9.if_ 
Dendritic cells are a discrete population of "professional APC". They are referred to 
as such because they are capable of stimulating both a primary and secondary immune 
response. In fact DCs secrete specific chemokines such as CCLI8/DC-CK I, CCLI9/ELC, 
CCL22/MDC and CCLI7/TARC that attract na'ive, recently activated and memory T cells 
that express CCR7 and CCR4' 101· 1021• They present antigens in the context of MHC class I 
and ll and express the vital eo-stimulatory molecules such as CD80, CD86 and CD40. 
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Immature resident DC's are present in the peripheral tissues where they are highly 
specialised for antigen uptake by micropinocytosis via aquaporins 3 and 7, clathrin-
mediated endocytosis, specific uptake by DEC205, mannose receptor, Fe receptors, heat 
shock proteins by CD91 and phagocytosis by CD36 through Crkll-Dock 180-Rac I complex 
11031
. Immature resident DC's spontaneously migrate at a low rate to the draining lymph 
node. MHC class Il complexes on these cells are not stably expressed on the cell surface but 
accumulate in lysosomes 11041. These DC's have not received danger signals and are not 
mature hence they do not induce effector T cell responses. These DCs have a low density of 
antigen and low levels of eo-stimulation molecules and have been shown to stimulate 
regulatory T cells to secrete IL-l 0(1°51. Once antigens and "danger signals"11061, in the form 
of cytokines and chemokines, have been detected, the DCs migrate to the closest draining 
lymph node. Monocytes are recruited from the blood and rapidly differentiate into DCs11071• 
These replacement DCs are stimulated to continue antigen sampling in the periphery by the 
secretion of chemokines by the originally stimulated DCs110111. During this migration the 
dendritic cell becomes a highly specialised antigen-presenting cell and secretes a different 
set of chemokines(IOH/. Mature DCs have high levels of MHC molecules on their cell 
surface but low rates of new MHC biosynthesis thus making them insensitive to new 
antigens 11041. Macropinocytosis and phagocytosis is down-regulated by mature DCs and 
this mechanism involves a small GTPase, Cdc42 (1 031. In vitro studies have demonstrated 
that DCs mature in response to inflammatory stimuli such as LPS11091 and TNF-a11101 and T 
cell feedback signals such as CD40L11111.0nce an interaction between DCs and 
lymphocytes has been formed the dendritic cell matures further in response to signals from 
the lymphocytes. Activated DCs express the lectin DC-SIGN which binds ICAM-3 and 
hence stabilise the DC-T cell synapse 11121. The kind of response stimulated is dependent 
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upon the nature of the antigen and the adjuvant properties of any microbial products, upon 
the receptor through which DC maturation agents signal, upon the origin of the responding 
DC subset, upon the microenvironment in which the antigen is encountered and upon the 
cytokines released by neighbouring cells1931. The evolution of an immunodominant T cell is 
due to interclonal competition for APCs. The competition has been decreased 
experimentally by increasing the number of available antigen loaded DCs 11131. Hence a 
more common pathogenic antigen will stimulate a broader spectrum ofT cells. Eventually 
the DCs will die. Interaction between DCs and na·lve CD4+ T cells results in the DCs' 
disappearance from the lymph node1" 41. 
1.9 Antigen processing 
1.9.1 MHC class 11 antigen processing 
Exogenous proteins are taken up into APCs by phagocytosis, by fluid-phase 
endocytosis or by specific receptors such as the mannose receptor 1051. Such receptors 
target and concentrate the antigen into the intracellular compartments for processing and 
interaction with class II molecules and hence can recognise rare antigens 1" 61 . The invariant 
chain Ii directs class 11 molecules into the endocytic pathway and protects them from 
binding peptides before reaching the endosomal compartment (as illustrated in Figure 7). 
The Ii is proteolysed in a sequential multi-step process to form a class 11 associated Ii 
peptide (CLIP) which is replaced by peptide antigen 1" 61. Exogenous antigen is unfolded by 
exposure to acidic pH. Unfolding is also aided by y-IFN-inducible lysosomal thiol reductase 
(GILT) which reduces the inter-molecular and intra-molecular disulphide bonds and tertiary 
protein structure 1" 71. Antigen is unlocked by initial cleavage by endopeptidases and is 
attributed to the cysteinyl protease asparaginyl endopeptidase (AEP). AEP has been shown 
to be essential in proteolysis of carboxy-terminal domain of tetanus toxin antigen in order to 
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order to produce antigenic peptides associated with tetanus toxin T cell responses fliBJ_ 
Specific exopeptidases further degrade the protein into peptides by trimming protein 
residues from the ragged amino or carboxyl termini. The endocytic proteases most 
commonly found in APCs are the aspartic protease cathepsins (Cat) D,B,F,H,L,S,Z and 
AEP fJ/ 91. These proteases are synthesised in the endoplasmic reticulum (ER) as 
proenzymes with a propiece that occupies the active site. The propiece is removed by 
autocatalytic or paracatalytic enzyme action and the mature active form of the enzyme is 
generated 11201. The final step of Ii proteolysis was mediated by Cat S in B cells and DCs 
whereas Cat L performed this final cleavage in cortical thymic epithelial cells fli6J. Once Ii 
proteolysis is complete the peptide is loaded onto the MHC class II molecule. Long 
polypeptides can bind with the immunogenic epitope anchored in the MHC groove. The T 
cell epitope is thus protected whilst the peptide is trimmed. Factors which influence 
antigens presented by class ll molecules can involve the antigen, its glycosylation state, its 
interaction with internalisation receptors and its early binding of MHC class II molecules 
11211
. Other factors which regulate the class Il restricted peptides are the cathepsin genes 
expressed by each APC e.g. Cat S, Cat F and Cat Z are found in bone-marrow derived 
APCs (B cells, DCs and macrophages) whereas Cat Lis found in macrophages and cortical 
thymic epithelial cells 11221. The strength of proteolysis in the endocytic compartments is 
regulated by factors such as cytokines (IFN-y, IL-6, TNF-a, ll.r I b and ll.r I 0), pathogen 
products (Bm-CPI-2 secreted by the nematode Bn1gia malayi and toxin secreted by 
Helicobacler pylori) and endogenous competitive inhibitors (propiece of the enzyme, 
cystatin inhibitor family and p41) fJ/61. 
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Figure 7: Classical MHC class Il antigen presentation pathway 
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1.9.2 MHC class 1 antigen processing 
1-lliC class I pathway (Figure 8) is involved in antigen presentation of endogenously 
synthesised proteins to cytotoxic T lymphocytes (CTLs). Antigenic peptide fragments are 
generated by the multicatalytic proteasome complex. The 20S proteasome core is barrel 
shaped and composed of four stacked rings of seven subunits each with two outer a rings 
and two inner ~ rings. The cleavage of peptide bonds is performed by ~ 1, ~2 and ~5 with 
their active face inside the proteasome lumen. Assess to the catalytic lumen is controlled by 
19S cap made up of fifteen different sub-units. IFN-y treatment stimulates the replacement 
of ~1 , ~2 and ~5 with subunits lymphoblastoid type of latency-2 (LMP-2), MACLl and 
LMP-7 to form the immunoproteasome and thus changing the cleavage preferences fllJJ_ 
The peptides are shuttled into the ER by a nucleotide triphosphate (NTP)-dependent 
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heterodimeric complex composed of the transporters associated with antigen processmg 
(TAP), TAP I and TAP2 1124· 12-'1. The TAPl ffAP2 complex select peptides of a di tinct 
length (8- 10 amino acids) and according to the binding affinities of the 3 N-terminal and C-
terminal end amino acid peptide residues 1126· m. m. 1291. The expression of TAPl and 
TAP2 can be increased by IFN-y stimulation ' '301. Peptides can also be processed by the 
TAP independent pathway which involves proteolysis of hydrophobic signal peptides from 
proteins translocated directly into the ER ''31· 1321. TAP is physically as ociated with MHC 
class I molecules and mediates the loading of peptides into the MHC class I binding cleft 
either directly or via chaperone molecules such as tapasin 1133·1341. Export of the MHC class 
I -~2-microglobu li n -peptide complex is regulated by the chaperone molecule calreticulin . 
The fin al trimeric complex of MHC class I heavy chain, ~2-microglobulin and peptide is 
transported to the cell surface by the trans-golgi complex ' 135· 136· 1371. At the cell surface the 
peptide is presented in the context of a specific MHC class I molecule and interacts with the 
clonotypic T-cell receptor. 
Figure 8: Classical MHC class I antigen presentation pathway 
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based upon Figure I from Seliger B, Maeurer MJ, Soldano Ferrone. Immunology Today. 1997; 18:293. 
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1.9.3 Cross-priming 
The term cross-priming was first described by Bevan/1381 and describes the ability of 
host APCs to prime cytotoxic T lymphocyte responses against minor histocompatibility 
antigens captured from foreign donor cells. lt is primarily used to describe the uptake and 
re-presentation of cell associated antigens in the class I pathway /1 391 but has more recently 
been applied to the class IT pathway as well /1 401 . Cross-presentation has been shown to be 
involved in tolerogenic responses (cross-tolerance) by inducing tolerance to parenchyma! 
antigens 1140· 1411 and immunogenic responses (cross-priming) by inducing CTLs to tumours 
I 142· 1431, grafts I 144' and DNA-encoded antigens 11451• The cell type responsible for cross-
presentation of antigens has not been isolated in vitro it has been found that macrophages 
1146· 1471, DCs fl 48' and B cells 1149' can all be induced to cross-present exogenous antigens of 
high concentration. A possible candidate for the cell responsible for cross-presentation was 
isolated from a genetically modified tumour model and this cell bore characteristics of both 
DCs and macrophages 11501. Dendritic cells have been shown to be able to capture apoptotic 
cells and cross-present class-1-restricted antigens whereas macrophages could capture 
apoptotic cells but not cross-present the antigens 11481. Dendritic cells express avP3 integrin 
which may play an important role in this process 1151 1. 
Several heat-shock proteins, HSP70 /1 521, HSP90 and gp96 /1 531 have been shown to 
immunise CTL responses that are specific for antigens derived from donor cells. The HSPs 
act as chaperones, carrying precursors of cellular peptide antigens that can be presented by 
any MHC haplotype . However, proteins such as gp96 can be absent and cross-presentation 
will still occur 11541• 
For CTL development by cross-presentation, antigen has to be cross-presented by 
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the same cell to COS+ and CD4+ T helper cells'1551 . This implies either a three cell cluster 
enabling short range soluble signals such as IL-2 or a sequential interaction with the C04+ 
T cell which modifies the APC enabling it to stimulate the COS+ effector cell. C040 has 
arisen as one of the molecules that could mediate this sequential stimulation11561• Other 
signals provided by virus infection can transform the APC into a CTL priming cell ' 157'. 
Hence some CTL responses require CD4+ help and others do not. 
1.10 Tumour antigens 
Several human (MHC) HLA class !-restricted tumour-associated antigens (TAAs) have 
been isolated. They can be segregated into the following groups. 
a) Oncofetal antigens 
T AAs encoded by normal, non-mutated genes may be persistently expressed by tumour 
cells and encode differentiation antigens associated with an earlier fetal stage which are 
silent in normal adult cells fl 581. Of the twelve members of the melanoma antigen-
encoding gene (MAGE) family six are expressed in melanoma, head and neck cancer, 
non-small cell lung cancers and bladder carcinomasfl59· 1601. MAGE-1 expressed on 
testis is not presented in terms of MHC class I fl 58'. Therefore it has potential as MHC 
class I specitic cytotoxic T cells will be unable to recognise it on the testis. Other 
oncofetal antigens include BAGE fl 611, GAGEfl621 in melanoma, a-fetaprotein in 
hepatic carcinoma/1631, Carcino-embryonic antigen (CEA) in colonic cancer ' 1681• 
b) Tissue-specific differentiation antigens 
These are non-mutated antigens specifically expressed by a specific cell type whose 
expression levels may change in individuals with cancer. Melanoma antigens from 
melanocytes such as tyrosinase {1641, gp I 00 11651 , Mart-1/melan A, ' 1661 were some of the 
42 
first antigens to be described. The membrane tyrosinase kinase receptor her-2/neu 
normally expressed in epithelia has been associated with breast and ovary cancer 11581 . 
c) Neoepitopes 
These antigens are generated by point mutations in ubiquitously expressed genes such 
as CDK4, ~-catenin 11671 and MUM-IIL33-B. 
d) Point mutations in oncogenes 
Point mutations in oncogenes are usually found in carcinogen induced tumours such as 
the tumour suppressor gene p53 or K-Ras codon 12, 13 or 61. p53 mutations have been 
associated with human colorectal cancer and human lung carcinomas 11681. K-Ras has 
been associated with patients with gastrointestinal cancer 11581 • 
e) Recombined proteins 
Fusions between 2 proteins results in production of new antigen such as the bcr/abl 
fusion gene found in CML patients. 
f) Viral epitopes 
After infection with certain viruses, genes of the virus express cellular oncogenes which 
cause growth and uncontrolled cellular division hence resulting in malignant 
transformation. Viruses associated with cancer such as Epstein-Barr Virus (EBV) in 
lymphomas, Human T cell leukaemia virus- I (HTL V -I}, Hepatitis B virus in 
hepatocellular cancer and papilloma virus in cervical cancer all express viral epitopes 
(15/ij 
g) ldiotypic epitopes 
The malignant B cell in B cell lymphomas secrete immunoglobulins of the same 
idiotype which can act as antigens. The malignant T cell clone in T cell lymphoma all 
bear TCR of the same idiotype 11581. 
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h) Mucin rich epitopes 
Tn is a blood group-related carbohydrate epitope consisting of a-N-acetyl-galactosamine 
linked to the hydroxyl group of serine or threonine in glycoproteins. TAG-72 is a 
common glycoprotein marker that results from the addition of sialic acid on to Tn and is 
found in gastrointestinal, breast and ovarian carcinomas. Thomse-Friedenreich antigen 
(T-antigen) is generated by the addition of P-linked galactose to the Tn and is found on 
epithelial tumours particularly colon cancer. Normally the expression of these antigens 
is masked by the additional terminal sugar moiety 11681. MUC I gene mucin is found in 
breast, pancreatic and ovarian cancer. A mucin is encoded that is heavily glycosylated in 
normal cells and exposed in malignant cells revealing a glycoprotein which is antigenic 
[169/ 
1.11 Recognition and presentation of tumour antigens 
Cell surface expression of MHC class I molecules is reduced on human tumours 1170· 
1711
• Loss of functional LMP-2, LMP-7, TAP! and TAP 2 has been shown, in tumour cell 
lines from small-cell lung carcinoma /172/, Burkitts lymphoma /1 731 and hepatocellular 
carcinoma /1 741 and in surgically removed malignant tumours /175/, to correlate with low 
surface expression of MHC class I. However, in some human prostate carcinoma cell lines, 
despite high cell-surface expression of MHC cla<>s I, there are low levels of TAP2 rnRNA 
/1 761• Down-regulation of TAP molecules, impairing the assembly of MHC class I molecules 
in the ER, resulted in low expression and stability of tumour antigen bearing complexes on 
tumour membranes. TAP defects therefore offer an explanation of how tumour cells may 
escape MHC class I restricted CTL-mediated recognition /1 771. Some tumour epitopes are 
processed more efficiently such as MAGE-A3 by the immunoproteasomes and others are 
not such as Tyrosinase, gp I 00, Melan-A. Cells unable to catabolise the tumour proteins to 
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expose MHC class l binding epitopes do not express these epitopes on the cell surface and 
so evade reactive T cells to those epiotopes {1 231. Cells with TAP abnormalities show 
enhanced lysis by natural killer (NK) cells. Therefore, TAP-independent loading of antigens 
should still occur. Other methods of antigen presentation such as MHC class li antigens, 
nonpolymorphic CD I molecules, minor histocompatibility antigens such as TL and heat 
shock proteins may be the remaining anti-tumour immune surveillance mechanisms. 
I .12 Immunotherapy 
Early attempts at cancer immunotherapy were relatively crude, such as injecting 
patients with killed tumour cells or adjuvants such as Bacillus Calmette Guerin fJlR/ and 
Cotynebacterium parvwn. That the immune system had the potential to eradicate residual 
leukaemia became apparent during allogeneic bone marrow transplantation. The graft-
versus-leukaemia (GVL) effect of the incoming donor immune system was a consequence 
of graft-versus-host disease (GVHD) f 179' 180· 1811• GVL is based upon direct donor T cell 
recognition of the recipient's allogeneic MHC molecules. This would also encompass 
recognition of recipient 'self peptide sequences held within the recipient's allogeneic MHC 
molecules. Amongst the donor T cells stimulated by allogeneic differences in MHC would 
be a small proportion ofT cells able to recognise antigens on the tumour cells. CD4 + T cell 
allo-recognition of MHC class 11 molecules would provide T cell help for responses to 
tumour peptides which had previously been inhibited due to lack of presentation of tumour 
antigens in the context of MHC class 11. The background cytokine profile generated by a 
large anti-MHC response would infiuence cells such as DCs and natural killer cells too 
[!/ill. T cell depletion of the donor bone marrow has decreased GVHD but also increased the 
relapse rate and engraftment failure of HLA-matched allogeneic bone transplantation. 
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Donor lymphocyte infusions have now become a more effective treatment for patients after 
allogeneic bone marrow transplantation in CML, but not so for other haematological 
malignancies such as AML, myelodysplasia and multiple myeloma 1 tXJJ_ Analysis of the T 
cells from successful allogeneic transplants that had received cos+ depleted donor 
lymphocyte infusions have found HLA class !-restricted CTLs that recognise broadly 
expressed minor histocompatibility antigens IIMJ. Reduced intensity conditioning treatments 
prior to transplant has also resulted in less GVHD in allogeneic MHC-matched setting in 
CML (IX51. 
Initial attempts al vaccination with autologous or allogeneic tumour cells were 
largely unsuccessful {IX6/. Identification of tumour antigens such as MAGE, BAGE and 
GAGE advanced the prospects of vaccination for immunotherapy (!Ill!_ More tumour 
associated peptide sequences were determined by peptide elution (!Bill, motif analysis 11891 
d . "d" "b d. (190 191 1921 A I .. d. . .b d" b f I an ant1-1 10type anti o 1es · · . s a resu t ant1-1 1otyp1c anti o 1es ecame use u 
as therapeutic agents 11931. Peptide vaccination to target antigens such as MUC-1 showed 
strong responses 11941 . However, peptide vaccines were susceptible to proteolytic digestion. 
Peptides were designed with a pan-reactive DR epitope, a CTL activating epitope and a 
fatty-acid moiety in order to overcome this 11951. Heat-shock proteins offered a mechanism 
by which peptides could be isolated and more effectively used as a vaccine. The heat-shock 
protein would have non-covalently bound peptides generated from the tumour cell. 
Vaccination with tumour derived HSP-peptide complexes has shown protective immunity 
in animal studies 1196· 1531. 
The isolation of tumour associated antigens made it possible to use the humoral 
arm of the immune system as therapy. There are two main mechanisms by which antibodies 
can mediate tumour lysis. Complement-fixing antibodies bind to the tumour cell membrane 
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and promote the attachment of complement components that create pores in the tumour cell 
membrane and disrupt the cell by loss of membrane integrity. Antibody-dependent-cell-
mediated cytotoxicity (ADCC) occurs when antibodies usually of the lgG class form an 
intercellular bridge by binding the variable region to a tumour antigen on the tumour cell 
and binding effector cells such as NK cells macrophages and granulocytes, by Fe receptors 
such as CD64, CD32 and CD 16. In vitro and in vivo ADCC has been shown to be more 
innuential in tumour lysis than complement fixation 11631. However, ADCC effector cells 
have shown poor infiltration of large tumour masses and loss of the tumour antigen 
frequently interferes with antibody therapy 0631 . Anti-idiotypic responses have been 
generated in non-Hodgkin's lymphoma (NHL), lymphomas and B-cell neoplasms such as 
multiple myeloma 131. Analysis of differentiation specific cell surface molecules lead to the 
development of Campath-1 H (target is CD52), Rituximab (target is CD20) and Bexxar 
(target is CD20) which are now being used in the treatment of 8-cell malignancies 
including B-CLL 11971. Bispecific antibodies were generated which bound target cells with 
one domain and effector cells with the other 11981. More effective than this was the grafting 
of effector cells with a chimeric receptor, consisting of a heavy and light chain variable 
region of a monoclonal antibody (that binds a tumour associated antigen) and an 
intracellular signalling domain fl 99• 200· 201· 202 1. 
Adoptive cellular immunotherapy was demonstrated in animal models. Tumour 
specific syngeneic T cells were transferred into hosts bearing tumours. These experiments 
showed that complete tumour elimination required an extended presence of transferred T 
cells within the host. Tumour reactive lymphocytes that had infiltrated solid tumours (TlL) 
were isolated and expanded ex vivo with IL-2, tumour or both. TILs were re-infused into 
patients. These TIL were able to home to the tumour and mediate a significant effect in 
47 
melanoma 11631 . Recently DCs are being used to generate T cell clones that could be re-
infused 12031. 
Lymphokine-activated killer (LAK) cells have been activated in vitro by IL-2 
treatment. They are non-MHC restricted in their tumour killing. Clinical studies with 
infusion of LAK cells and IL-2 induced remissions in patients with malignant melanoma 
and renal cell carcinoma. However, toxicity levels were very high 1204· 2051• It was found that 
lower doses (less toxic) of IL-2 were as effective and that LAK cells did not add to the 
efficacy of IL-2. Systemic administration of cytokines was complicated by their widespread 
and varying functions. Cytokines considered for immunotherapy included IL-l, IL-2, IL-4, 
IL-6, IL-7, IL-l 0, IL 12, TNF-a and p, interferon (IFN) a,p, and y and granulocyte 
macrophage- colony stimulating factor (GM-CSF) 131• Systemic immunotherapy with 
cytokines such as IFN-a and IL-2 in renal carcinoma 12061·12071 and melanoma'2081 have 
yielded modest responses rates with low complete remission rates. IFNs have shown 
disappointing results in solid tumours but unexpected results in hairy cell leukaemia, 
Kaposi's sarcoma and as a maintenance treatment for multiple myeloma. TNF has shown to 
be inactive and toxic /31. These studies indicated that cytokine therapy alone was susceptible 
to immunosuppression by the tumour and was best used in combination with other 
treatments ' 2091. 
In transforming growth factor-P (TGF-P) insensitive tumours, i.e. ones which do not 
have a growth response to TGF-p, neutralising TGF-P by antisense in vitro and in vivo 
inhibited the growth of malignant cells 12101. Jn·adiated tumour cells were vaccinated into a 
rat glioma model and found to be moderately effective. However, when the tumour cells 
were also modified genetically to secrete low levels of TGF-p, effector cells were generated 
with much higher lytic ability (2/1}. Antibodies neutralising TGF-P showed an increase in 
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NK activity in a mouse/human breast cancer model '2121 . The positive efrect of IL-2 on the 
stimulation of CTLs coupled with anti-TGF-P antibodies has shown promising results 12131 . 
In order to ensure presentation of tumour associated antigens in the context of MHC 
class I molecules, vaccinia virus, fowlpox virus and adenovirus have been used as viral 
vectors to encode tumour associated antigen genes. Vaccinia virus encoding CEA antigen 
has generated antibody and cellular responses in colorectal cancer patients ' 2141 • Anti-
tumour responses have been observed after vaccination with tumour cells that have been 
adenovirally transduced with cytokines such as GM-CSF fll.lf_ DNA vaccination has also 
been used as a vaccination method for ensuring tumour antigen entrance into the cell ' 2161. 
In B-cell lymphomas idiotype specific DNA sequences have been used to immunise 
patients ' 2171. Cytokines such as LL-12 have been combined with DNA vaccines and show 
enhanced responses fltRJ_ Tumour cell loss of MHC class I antigen expression is thought to 
be an escape from tumour surveillance ' 2191. Gene transfer of tumours with HLA class I 
molecules has been shown to elicit clinical responses /220J_ 
The recent marked growth in our understanding of the immune system and its 
interaction with malignant disease includes the mechanism by which antigen is presented to 
T lymphocytes [22 1.2221. Dendritic cells are now known to be essential for the initiation of 
primary immune responses and are particularly efficient at capturing and presenting 
. . T 11 f221 224 22>1 B . . h . . . h . h ant1gens to na1ve -ce s · · · · . y pmmng t em 111 v11ro w1t tumour antigens, t ese 
"professional" antigen-presenting cells (APCs) may bypass the state of inertia in which the 
immune system appears to co-exist with most tumours ' 2261 . Studies of dendritic cell 
vaccines in both animal models and man have demonstrated the generation of anti-tumour 
· f271 227 2281 R 1· bl h d f . . DC f 1mmune responses · · · . e 1a e met o s or generatmg Immature s rom 
peripheral blood mononuclear cells have facilitated their use in immunotherapy ' 229·2301. In 
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vitro studies in man have demonstrated that DCs loaded with tumour antigens can induce 
CTL . I'll 'I' 'Ill . . . J'l~ Jll Jl(lj responses agm nst melanoma •· ·-· -·-· · , chrome myelo1d leukaemm· -· ·-· · ·-· , acute 
myeloid leukaemia 12371 and pancreatic cancer 12381 . In vivo studies using DC loaded with 
tumour antigens have demonstrated encouraging clinical anti-tumour responses against; B-
cell lymphoma 12391, melanoma 12401, myeloma 12411, parathyroid carcinoma 12421, prostate 
1'4l 744 ' 411 d I · 1' 461 T . f"l . b DC h b h cancer - · · - ·- · an rena carcmoma - . umour 111 1 trat1on y s as een s own to 
be a good prognostic factor in colorectal adenocarcinomas 12471, human gastric cancer 12481 
and papillary thyroid carcinomas 12491. 
2.18 Rationale for this study 
It seems unlikely that an intrinsic "malignant" transformation of the COS+ B cell is 
solely responsible for the pathogenesis of B-CLL. The rapid death of these cells by 
apoptosis in vitro and partial reversal of this by some cytokines 12501 implies that the 
development of this disease must be dependent upon co-operative interaction between the 
malignant cells and other normal components of the immune system. More recently these 
investigations have intensified along with the growth in understanding of the relationship 
between different cell types in the normal immune response, both by direct cell-cell 
. . d . . 11· . flil 2121 F h 1· d . . f T 11 mteract1ons an v1a s1gna 1ng prote1ns · · · . rom t e ear 1est escnpt10ns o ce 
numbers and phenotype 1253· 2541 to recent findings of highly specific abnormalities of 
intrinsic T cell function and T cell-COS+ B-cell interactions 1255· 256· 2571, T cell dysfunction 
has thought to play a role in B-CLL. Hence although conventional therapies for B-CLL do 
offer temporary relief, the disease persists. B-CLL is essentially a malignancy of a cell of 
the immune system (B-cells). It seems logical that the final correction of such a disease will 
be held in the manipulation of the immune system. In vivo the interactions of B cells, T 
cells and APCs are so complex that we need a much greater understanding of them before 
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we c:an; fully understand a. disease such· as 8-GI!..E, Receni leaps forward in; dendf:itic cell 
!knowledge opened: 1llpi 1the possibility of being able lo cn.idely alter .the' ibalmlce betWeen 
anergy arid' anli"Lumour responses. Tihis study evaluated whether,in vitro.1B-CLL specific Tic 
cell responses couldi be' generatedi using autologous tumourcelllysate~pulsed deiJdritic:ceiJi. 
:By:manipulation .in vitro. :of the 1presentation .of possible B~CLJ[L, specific antigens .and I thei~ 
subsequerll :identification we' sought· lt() further, ,the: understahdi ng ofthe complex !hattire. of 
1this malignancy:.11his :study, aimedi to ;define some parameters· in viit:o 1thai would: provide 
valuable insights into the correctiimmunotherapy approath1using'DCs. 
Sl 
2. MATERIALS AND METHODS 
2.1 Patients 
Local Research Ethics Committee permission and individual informed consent were 
obtained for these studies. A group of thirty-two patients, who were either untreated or who 
had not received treatment in the last 6 months, were selected for the study. Patient details 
are given in Table I. Another group of ten healthy volunteers were used as a control. 
Protocols for isolation of cells from the blood of patients and healthy volunteers were 
identical. Selection of patients for specific experiments was at random. 
Table 1: Patient profile 
Patient IWCLL Stage WBC count Previous treatment 
X 109/L 
I A/0 25 NONE 
2 A/0 61.7 NONE 
3 A/0 18 NONE 
4 A/0 14.9 NONE 
5 A/0 23.2 NONE 
6 A/0 previously A/1 9.8 Chlorambucil 
7 A/0 previously cm 13.5 Chlorambucil 
8 A/0 previously CIII 15 Ch lorambuci I 
9 All 57 NONE 
10 Bill 119.2 NONE 
11 CfiV 118 NONE 
12 C/IV 122 Chlorambucil and 
Fludarabine 
13 C/IV 167 Chlorambucil and 
Splenic radiotherapy 
14 A/0 20 NONE 
15 All 26.4 NONE 
16 8/I 16 Chlorambucil and 
Cyclophosphamide 
17 A/0 12.1 I course 
Chlorambucil 
18 C/Hl 162 NONE 
19 A/0 previously Alii 8.6 Splenic radiotherapy 
and Chlorambucil 
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Patient IWCLL stage WBC count Previous treatment 
X 109/L 
20 C/111 163 2 courses 
Chlorambucil 
21 NO 45 NONE 
22 NO 12.7 NONE 
23 C/III 163 Splenic radiotherapy 
and Chlorambucil 
24 NO 27.7 NONE 
25 C/III 90.5 Ch lorambuci I 
26 8!1 223 Prednisolone 
27 8!11 74.1 Chlorambucil and 
prednisolone 
28 8/1 56.4 2 courses of 
Fludarabine, I x 
CHOP, I x Campath 
+chlorambucil + 
prednisolone 
29 NI 25.5 Ch lorambuci I 
30 C/IV 98.7 Chlorambucil 
31 NO 15.6 NONE 
32 A/11 26.6 NONE 
2.2 lmmunophenotyping. 
The Following monoclonal antibodies were used for immunophenotyping studies of 
DC and effector cells in the cytotoxic assays. CD4-FITC (Serotec, Oxford, UK), CD8-PE 
(Serotec), CD3-FITC (Serotec), CD 16-FITC (Serotec), CD56-FITC (Serotec), HLA-DR-PE 
(Serotec), CD83-FITC (lmmunotech, Coulter, Luton, UK), CD40-PE (Serotec), CD86-
FITC (Serotec), CDI4-PE!CD45-FITC (Becton Dickenson, Oxford, UK), CDIIc-PE 
(Serotec), CD20-PE (Serotec), CD5-PE (Serotec), CD 19-FITC (Serotec), CD I a-FITC 
(Serotec), anti-IgG I-PE and anti-IgG 1-FITC (Serotec). Cells were washed twice in 
Phosphate buffered saline (PBS) and then twice in PBS + 0.05% Bovine se111m albumin 
(BSA) (Sigma). Directly conjugated antibodies were added at I 0111 per I 0'' cells and 
incubated for 15 minutes at room temperature. Cells were washed twice in PBS and twice 
in PBS + 0.05% BSA. Positive antibody binding was assessed in terms of gates set at 2% of 
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relative isotype controls using an Epics Elite flow cytometer (Coulter). 
2.3 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
PBMC were isolated using a well established single step centrifugal technique1258· 
2592601
. Equal amounts of blood and RPMJ 1640 + 2mM Glutamine (Sigma, Dorset, UK) + 
500U/ml Penicillin (Sigma) + 500 Jlg/ml Streptomycin (Sigma) were diluted. I Oml of 
Lymphoprep (9.1% w/v Sodium Diatrizoate and 5.7% w/v polysaccharide) (Nycomed, 
Robbins Scientific, UK) was added to fresh 20 ml universal (Grenier). I Oml of diluted 
blood was layered onto the top of the Lymphoprep. Cells were separated by centrifugation 
in Hereaus Labofuge 200R (Hereaus, UK) swing out rotor for 20 minutes, 2200 rev/min 
(540g) at 22°C. On removal a middle whitish layer was observed with red blood cells at 
bottom of universal and yellow serum on top. Cells in the middle whitish layer were 
removed into a fresh sterile universal. Cells were washed twice in 20ml RPMJ 1640 + 2mM 
Glutamine + 500U/ml Penicillin + 500 Jlg/ml Streptomycin by centrifugation at 1500 
rev/min (252g) for I 0 minutes. Cells were resuspended in whatever medium required for 
culture or further separation procedures. Cells were counted in a 1110 dilution of 0.04% 
Trypan blue in a Haemocytometer (Sigma) using light microscopy. 
2.4 Depletion of CDI9 positive cells from PBMCs 
Peripheral blood mononuclear cells (PBMC) were isolated under Class lJ conditions 
by density gradient centrifugation from peripheral blood. PBMC's were counted on a 
haemocytometer in a I: 10 dilution of Trypan Blue (Sigma). Pan B Dynabeads (Dynal, 
Merseyside, UK) at 4 x I 08/ml were aliquoted into a conical centrifuge tube so that there 
was a 4: I bead to cell ratio. PBMCs were resuspended in cold PBS so that the Pan B 
Dynabead concentration never fell below I x I 08 beads/m I. Pan B Dynabeads were washed 
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using magnetic separation on a MP-I magnet (Dynal) for 2 minutes in cold PBS to remove 
Sodium Azide preservative. Washed Dynabeads and PBMC's were mixed and incubated 
whilst rotated for 45 minutes at 4°C. CD 19 positive cells were selected by adherence to the 
tube in closest proximity to the magnet for 3 minutes. CD 19 depleted cells were carefully 
removed with a pipette and used for the isolation of DCs. 
Separation of cell populations by Dynabeads was validated by analysis of cell 
fractions by flow cytometry (Figure 9). Of particular note is that PBMC from B-CLL 
patients consist of mainly of B lymphocytes (CD20+) with small percentages of T cells 
(CD3+) and monocytes (CD 14+) (Figure 9A). Depletion of CD 19 positive cells with 
Dynabeads was shown to result in a mixture of cells not containing B cells (CD20+) but 
consisting mainly of T cells (CD3+) and HLA-DR positive monocyte progenitor cells 
(Figure 98). The cells from the first wash on the magnet of the CD 19 positive cells 
contained a mixture of B cells (CD20+) and T cells (CD3+) and so were always discarded 
(Figure 9C). The cells removed from CD 19 positive Dynabeads using Detachabeads were 
over 99% cos• B cells (Figure 9D). 
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Figure 9: Flow cytometry to illustrate purity of cell separation methods. 
(A) Peripheral Blood Mononuclear Cells isolated using Lymphoprep. 
I! 6J.m 0.1% 0. /% 
... 
(B) Peripheral Blood Mononuclear Cells not bound to CD19 Dynabead 
~ 0.1" o.?M ~ 1.m "" ~ l!l 
.. 
• 1 rgG-Frrc 1eee 
.I lg('r-FITf' 1888 • 1 CDJ-FITC 1990 .1 fg('.t-FITC 1998 
(C) Peripheral Blood Mononuclear Cells collected from first wash of CD 19 Dynabeads 
- .· 
'"' • 1 lgG-FITC 1000 
.1 lgG-fiTC 1998 . I CDJ.fJTC 1900 .1 lgG-ffiC 
Figure 9: Cells isolated from l B-CLL patient (Patient 25) were stained with 
antibodies and analysed by flow cytometry as stated in Section 2.2. 
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2.5 Dendritic cell isolation and culture. 
PBMC from patients with B-CLL and healthy volunteers were depleted of CD19' 
cells using Pan B Dynabeads (Dynal) as stated in Section 2.4. The CD19-depleted PBMC 
were cultured in a 24 well tissue culture plate (Gibco, Life Technologies, Paisley, UK) at 
37"C in 5% C02 for 2 hours at a density of Ix I06/well. Culture medium consisted ofRPMI 
1640 (Gibco) + 10% human AB serum+ 2mM Glutamine (Sigma, Dorset, UK) + 500U/ml 
Penicillin (Sigma) + 500 f.1g/ml Streptomycin (Sigma). Non-adherent cells were removed 
by 4 rounds of vigorous washing that involved agitation and replacement of the culture 
medium with a sterile plastic Pasteur pipette. Adherent cells were then cultured in 
0.5ml/well culture medium + 800 U/ml GM-CSF (Cambridge Bioscience, Cambridge, UK) 
+ 1000 U/ml JL-4 (Cambridge Bioscience) at 37"C in 5% C02 for 6 days. The cultures were 
fed every 2 days by addition of 0.5mllwell culture medium containing IL-4 and GM-CSF. 
On day 6, the culture medium was removed and centrifuged. The non-adherent dendritic 
like-cells were resuspended in fresh culture medium with 800 U/ml GM-CSF and I 00 
f.1g/ml IL-12 (Cambridge Bioscience) replaced into the plate and cultured for 16 hours. 
2.6 Removal of CD 19 positive cells from Dynabeads 
The Dynabeads attached to the centrifuge tube described in Section 2.4 were 
resuspended in 1 Oml RPMI + 10% AB serum. After 3 minutes incubation on MP-1 magnet 
weakly positive CDJ9 cells (first wash) were removed from supematant with a Pasteur 
pipette and retained in a universal container (Greinier, UK). CD19 positive B cells 
attached to Pan B Dynabeads were resuspended in I ml/4 x I 08 Dynabeads RPMI I640 + 
10% AB serum. Pan B Detachabeads were added at IOOml/4 x 108 Dynabeads. Cells and 
beads were incubated for 1 hour at room temperature whilst undergoing rotary mixing. 
After 3 minutes incubation upon MP-I magnet CDI9 positive cells were removed with a 
57 
Pasteur pipette and retained in a universal container. Dynabeads were washed in this 
manner with 20 ml RPMI 1640 + 10% AB serum. CD19 strong and weak positive cells 
were centrifuged twice at 600 rpm for 3 minutes to remove any Dynabeads or 
Detachabeads that formed as a pellet. The resulting tissue culture supematant was 
centrifuged at 1500 rev/min (252g) for 5 minutes to reveal CD19 positive cells as an 
opaque white pellet. 
2. 7 Separation of Granulocytes 
Blood was separated using Lymphoprep as stated in Section 2.3. Granulocytes are 
found in the bottom layer with the red blood cells. This layer was decanted. Red blood cells 
underwent flash lysis. Cells were centrifuged at 1500 rev/min (252g) for 5 minutes to 
remove the intact cells in the form of a pellet. Cells remaining were classified as 
Granulocyte cells, resuspended in RPMI 1640 +Penicillin+ Streptomycin+ Glutamine+ 
I 0% AB Serum and counted using Trypan Blue. 
2.8 Preparation of soluble cell lysate. 
The CD19' B-cells from the PBMC fraction were removed from Dynabeads using 
Pan B Detachabeads (Dynal) as stated in section 2.4. On average B-CLL B-cells were 97% 
CD5 1 and 92% CD20'. B-cells were resuspended in 2 ml of lysis buffer (IOmM 
bicarbonate buffer pH 7.1 and 0.5mM Phenyl Methyl Sulphonyl Fluoride) (Sigma) on ice. 
The cells were homogenised on ice using a Dounce Homogeniser (Jencons, Leighton 
Buzzard, UK) and then ultrasonicated on ice using two 10 second bursts with a 15 second 
rest from a 50W-Vibracell (Sonics and Materials Inc, Jencons). Soluble protein was 
collected after ultracentrifugation at 55,000 rpm (1 OO,OOOg) for 1 hour at 4°C. The protein 
concentration was quantified as stated in section 2.9. Soluble protein lysates were sterile 
filtered using 0.41J. filters (Nalgene, Marathon Laboratory Supplies, London, UK) and 
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stored at -70°C. AJJ celllysates were exposed to CD19+ Dynabeads. Lysates were defined 
as allogeneic if they originated from a different individual to the effector T -cells. Lysates 
were defined as non-B-CLL if they were made from B-cells or T-cells from healthy 
volunteers or cell types unaffected by B-CLL such as granulocytes. 
2.9 Protein determination assay 
Protein concentration was quantified by the Bradford protein assay method using a 
protein determination kit (Biorad, Hertfordshire, UK). Duplicate BSA standards or lysate 
protein samples were diluted 100 J.LI to lOO 1-11 in the weJis of 96 well plate. Standards 
supplied from Biorad were diluted to 2.9mg/ml. 25 1-11 of Biorad colour reagent was added 
to each weJI. After a 10 minute incubation at room temperature the plate was mixed and 
read on a Dias spectrophotometer (Dynatech laboratories, UK). A standard curve was 
generated usingEIA Calc software an example ofwhich is shown in Figure 10. 
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Figure 10: Protein determination standard curve 
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Prolein SIDndllrd Concenlralion (pg/ml) 
Figure I 0: An example of a 1ypical slandard curve generaled by dilulion or BSA 
slanrlanls. 
The software programme fits a line by regression analysis. From the equation of that 
line the optical density measurement of the test lysate wells is used to calculate the 
concentration in pg/ml. Several dilutions for each lysate were tested to ensure lhat the 
protein concenlration measured in the lysate was within the optical density range of the 
standard curve. The calculated concentration was multiplied by its di I ut ion factor to give a 
total protein concentration for the lysate. When several of the lysate dilutions were within 
the optical density range of the standard curve, the calculated value was multiplied by its 
dilution factor and an average lysate total protein concentration was determined. 
2.10 Pulsing DCs with Tetanus Toxin and Tuberculin PPD 
The known antigens Tetanus Toxin and Tuberculin Purified Protein Derivative 
(PPD) were used as positive controls to validate the proliferation and ELISA assays. 
Tetanus Toxin and Tuberculin PPD were added to dendritic cell culture medium at 0.4Uiml 
and 900U/ml respectively on day 6 of culture and incubated for a further 4 hours at room 
temperature. 
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2.11 Pulsing DCs with soluble B-cell lysate. 
Dendritic cells were pulsed by the addition of soluble lysate to the culture medium 
at I OOng/ml per I 06 cells and incubated for 4 hours at room temperature. Control unpulsed 
DCs were incubated at this time with lysis buffer except in Patient's 5,7,9,1 0 and 13. 
2.12 T-cell isolation and T-cell cultures. 
T-cells were isolated indirectly from the PBMC fraction by depleting adherent and 
CD 19+ cells as stated in Section 2.4 and 2.5. The purity of the T -cells was on average 60% 
when assessed by flow cytometry using anti-CD3-ffiC conjugated antibodies. Lysate-
pulsed or unpulsed DCs were aliquoted at a concentration of I 01 cells per well to 96 well 
roundbottom tissue culture plates. T-cells were then added to give aT-cell: Dendritic cell 
ratio of at least 20: I. Cultures destined for cytotoxicity assays were fed with 5 U/ml of IL-2 
(Cambridge Bioscience) on days 3,7,1 0,14 and 17. Dendritic cells in cultures destined for 
cytotoxicity assays were restimulated by the addition of I 00 ng/ml soluble B-cell lysate or 
lysis buffer on days 7 and 14. Cultures were continued for a total of 21 days or 28 days at 
37°C in 5% C02 in culture medium + 5% AB serum. Cultures used to assess cytokine 
secretion or T-cell activation were not fed IL-2 or restimulated with soluble lysate. 
2.13 Mixed Lymphocyte Reaction 
PBMC were isolated from two mismatched normal healthy volunteers as stated in 
Section 2.3. Stimulator cells were irradiated with a Caesium source at 30Gy. Stimulators 
were added to 24 well plates at 3 x 105/ well in RPMI 1640 + I 0% human AB serum + 
2mM Glutamine + 500U/ml Penicillin + 500 j.lg/ml Streptomycin. Stimulators to act as 
targets in the final cytotoxicity assay were cultured at I x I 06/ well with RPMI 1640 + 10% 
AB serum + 2mM Glutamine + 500U/ml Penicillin + 500 11g/ml Streptomycin + 
Phytohemagglutinin from Plwseolus vulgaris (PHA) at I mg/ml (Sigma,UK). Responders 
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were resuspended in RPM! 1640 + 10% human AB serum+ 2mM Glutamine+ 500U/ml 
Penicillin+ 500 11g/ml Streptomycin at I x 106/well and added to equal number of wells 
containing stimulators or not as the case may be. Wells not containing Stimulators were 
made up to the same volume as those that did, by the addition of appropriate volumes of 
RPM! 1640 + 10% human AB serum+ 2mM Glutamine+ 500U/ml Penicillin+ 500 !lg/ml 
Streptomycin. Responders and stimulator cells were cultured for 7 days at 37°C in 5% C02 • 
On day 3 of culture IL-2 at 5U/ml was added to the MLR. Evidence of clumps of stimulated 
cells within the MLR but not in wells with responders alone were observed under I Ox 
objective of Hund Wetzlar phase contrast inverted microscope (Wilovert, Jencons) after 7 
days. 
2.14 Measurement ofT cell proliferation CIL-2 Receptor expression). 
T-cell activation was measured quantifying cells eo-expressing CD3 and CD25 (IL-
2 receptor) by double-labelled flow cytometry using the same protocol as 2.2. Flow 
cytometry was employed using anti-CD3-FITC/anti-CD25-PE conjugated monoclonal 
antibody (lmmuno Quality Products, Mast Diagnostics, Merseyside, UK). Positive antibody 
binding was assessed in terms of gates set at 2% of anti-IgG I-PE and anti-IgG 1-FITC 
labelled cells. Anti-CD3-FITC (Serotec) and anti-CD25-PE (Serotec) conjugated 
monoclonal antibodies were added individually to controls to allow for adjustment of 
compensation. 
2.15 Quantitation of cytokine secretion. 
Cell-free tissue culture supernatants were harvested on days I to 5 and stored at 
-70"C until required. When convenient, the supernatants were thawed and the 
concentrations of IFN-y and IL-4 measured in duplicate by ELISA (Pelkline, Eurogenetics, 
Hampton, UK). 96 well plates were coated overnight at room temperature by adding I 00111 
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of monoclonal anti-human IFN-y antibody diluted I: I 00 in carbonate/bicarbonate buffer pH 
9.6. Plates were washed with 0.2M PBS to remove unbound antibody. Non-specific binding 
was blocked by 200 Jll kit blocking reagent added for I hour at room temperature. The 96 
well plate was washed with kit washing buffer. I 00 Jll of IFN-y standards and test 
supernatants were diluted in kit dilution buffer and incubated for I hour at room 
temperature. IFN-y antibody-biotin conjugate was diluted I: I 00 and I OOJll added for I hour 
at room temperature. The 96 well plate was washed with kit washing buffer. Strepavidin-
Horseradish Peroxidase conjugate was diluted I: I 0,000 and I 00111 and was incubated for 30 
minutes at room temperature. The 96 well plate was washed with kit washing buffer. I 00111 
of Substrate solution containing O.IIM acetate buffer pH 5.5 + 0.5 mg/ml 3,5,3'5'-
tetramethylbenzidine (TMB) (Sigma, UK) + 0.003 % Hydrogen peroxide was added for 30 
minutes in the absence of light at room temperature. The colour change reaction was 
stopped by addition of I 00111 of 1.8 M Sulphuric acid solution. The plate was mixed and 
read on a Dias spectrophotometer (Dynatech laboratories, UK). A standard curve was 
generated using El A Calc software from lFN-y standards provided. Unknown sample values 
were calculated from that standard curve. Sensitivity limits for the assays were 2-6 pg/ml 
for IFN-y and 0.2-0.4 pg/ml for lL-4. 
2.16 Quantification of cell mediated cytotoxicity. 
Cytotoxicity was measured by a flow cytometric method, LIVE/DEAD cell 
mediated cytotoxicity (Molecular Probes, Cambridge Bioscience) ' 261 1. Target cells were 
labelled with 4Jll per 5 x I 05 cells of di0C 18 for 2 hours at 37"C in 5% C02 and then washed 
twice in culture medium. Effector cells were harvested from the tissue culture and placed in 
flow cytometry tubes (Falcon, Marathon Laboratory Supplies) at the appropriate effector: 
target ratios. A minimum of I o~ labelled targets was added. Propidium iodide was added to 
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each tube. Targets and effectors were gently mi xed and centrifuged at I 000 rev/mi n ( 11 2g) 
for 30 seconds. Targets and effectors were incubated together for 4 hours at Jr c in 59'o 
C0 2• Flow cytometry standard gates were set on unlabelled targets stai ned with propidium 
iodide and di0C 18 1abelled targets without propidium iodide as shown in Figure 11. 
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Figure 11 : (A) d iOC1R labelled targets with no propidiurn iod ide se t gates for PMT4, (B) unlabelled 
targets with propidium iod ide set gates fo r PMT2 and (C) targets wi th no effectors show non-
specific cell death. 
Non-specific cell death (spontaneous apoptosis) was measured by the cytotoxicity of 
di0C 18 labelled targets stained with propidium iodide without effectors ( 11 C). Cytotox icity 
was expressed as the number of dead targets (cells staining posi ti ve for propidium iodide 
and di0C18) di vided by the total number of targets (cells staining positive for di0C18). 
Percentage specific cytotoxicity was measured as fo llows: 
% specific cytotoxicity = (total cytotoxicity- spontaneous cytotoxicity) x I 00 
A Mixed Lymphocyte Reaction (MLR) was used to validate this system shown in Figure 
12. 
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Figure 12: Mixed Lymphocyte Reaction (MLR) cytotoxicity test 
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Figure 12: A MLR was cultured belween 2 mismmchcd normal heahhy volumeers as 
slaled in Seclion 2.13. Cells were assessed for cytoloxicily using melhod outlined in 
Section 2.16. Resuhs show triplicalcs for each eflcclor: large! ralio. Non-specific 
cyloiOxicily was 22%. 
As a control, effectors consisting of unpulsed DCs were used to detect any non-
specific uptake of the di0C 18 dye from target cells by DCs. The B-CLL B-cell targets were 
97% CD5+and 92% CD20+. The B-CLL T-cell targets showed binding for CD20-PE < 2%. 
Allogeneic targets were defined as those originating from another individual to the effector 
T-cells. Targets were defined as non-B-CLL if they were made from B-cells and T-cells 
from a healthy volunteer or granulocytes and T-cells from B-CLL patients. 
2.16 Antibody blocking studies. 
Antibody blocking experiments involved the addition of anti-HLA class I (Serotec), anti-
HLA class II (OR, DP, DQ) (Serotec), anti-Pan TCR a~ (Serotec), anti-CD4 (Serotec) and 
anti-CD8 (Serotec) monoclonal antibodies at I OO!Jg/ml at the commencement of the 4 hour 
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incubation of effectors and targets. 
2.17 Electrofusion 
Monocyte derived DCs were isolated as previously described. Electrofusion method 
was based upon findings of Scott-Taylor et al ' 2621. B-CLL B-cells and DCs were 
resuspended in 0.3M sodium sucrose solution at a cell density of 5 x I 05/ml. 0.4ml of B-
CLL B-cells and DCs were added to a 0.8ml electro-plated cuvette (Bio-Rad). An 
exponential pulse of 250V at 25 11Fd with a time constant averaging between 3.4 and 4 
milliseconds was delivered using Gene Pulser Transfection Apparatus (Bio-Rad). 
Additional B-CLL B-cells and DCs were pulsed with an exponential pulse of 500V at 
25!1Fd with a time constant of 8.7 milliseconds. B-CLL B-cells and DCs were mixed in 
electro-plated cuvette but not pulsed as a control for non-specific uptake of membrane 
fragments. Cells were washed once in Hepes buffered saline solution. Fused cells were 
separated on 10% w.v. dextran solution 2100 rev/min (500g) for 5 minutes whilst some 
remained non-separated as a control. The layer containing hybrid cells was washed in 
Hanks Balanced salt solution (HBSS). Cells in the process of "round-up" were observed in 
the separated cultures using x20 objective of a Hund Wetzlar phase contrast inverted 
microscope (Wilovert, Jencons). Cells were resuspended and cultured in culture medium + 
I 0% AB Serum + IL-4 + rL-12 and GM-CSF overnight at 37"C in 5% C02• The total viable 
cell yield was established from the count of cells in an aliquot mixed I: I 0 with 0.4% 
Trypan Blue using a haemocytometer after 16 hours in culture. This was a more accurate 
estimate of long term survival of the cells as electroporation can make live cells permeable 
to exclusion dyes such as Trypan Blue 12631. Comparison of the total cell yield in separated 
and non-separated cultures gave a crude estimation of fusion efficiency. Cell yields and 
fusion efficiencies can be seen in Table 4. Cells were assessed for the presence of CD86 
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and CD20 upon the cell surface by flow cytometry after 16 hours in culture as shown in 
Figure 41. Due to the low yield, fused separated cells exposed to the 2 different voltages 
were combined and added toT-cell eo-cultures. 
2.18 Reducing Sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SOS-PAGE) 
analysis 
SOS-PAGE analysis was carried out based upon previous methods as stated by 
Sambrook, Fritsch and Maniatis ' 2641. Cell lysates were diluted with equal quantities of 
SDS-gel loading buffer containing 0.05M Tris(hydroxymethyl)aminomethane 
(Tris),Hydrochloric acid buffered (HCL) pH 6.8 (Sigma) + I% v/v Glycerol (Sigma) + 
2%w/v SOS (Sigma) + 0.1 o/ow/v Bromophenol Blue (Sigma) + freshly added 0.05%v/v ~-
Mercaptoethanol (Sigma) and boiled for 5 minutes. Cell lysates were loaded onto Tris-HCL 
Ready gel containing a gradient of 4-15% polyacrylamide (Biorad, Hertfordshire, UK) with 
Broad Range Molecular Weight Markers (Biorad) details of which can be seen in Table 3. 
Electrophoresis was carried out in Protean System 11 Apparatus (Biorad, Hertfordshire, UK) 
in electrophoresis buffer containing 25mM Tris + 250mM glycine pH 8.3 + 0.1 o/ow/v SOS 
at I OY for 2-3 hours supplied by an APS powerpack (Holm-Nielson). Gels were stained 
with 90% Methanol (BDH): disti lied H20. I: I v/v + I Oo/ov/v Glacial Acetic Acid (Sigma)+ 
Coomassie Brilliant Blue R250 (Biorad) overnight on a lateral shaker and destained with 
two changes of destain solution (90% Methanol:distilled H20. I: I v/v + I Oo/ov/v Glacial 
Acetic Acid) each after 30 minutes. Gels were placed in distilled water and kept at 4 °C for 
I hour. Gels were photographed using digital camera electrophoresis documentation and 
analysis system 120 (Kodak, Newhaven,USA). and analysed by ID image analysis software 
(Kodak). 
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Table 2: Details of Broad Range Molecular Weight Standards 
Name of protein of marker Molecular Weight of marker Reference for marker 
(Dalton) 
Myosin 200,000 Woods EF, Himmelfarb s and 
Harring10n WF. J.Biol. Chem. 
196:1; 238: 2:174. 
~-galactosidase 116,250 Fowler AV and Zabin I. Proc. 
Narl. Acad. Sci. USA. 1977; 74: 
1507. 
phosphorylate b 97,400 Tilani K er al. Proc. Narl. Acad. 
Sci. USA. 1977; 74: 4762. 
Bovine Serum Albumin 66,200 Brown JR. Fed Proc. 1975;34: 
591. 
Ovalbumin 45,000 Warner RC., "Egg Proteins," in: 
The Proteins, Vol. IIA, p.435 
(Neuralh H. and Bailey K., eds.), 
Academic Press, New York 
(1954). 
Carbonic anhydrase 31,000 Davis R.P., "Carbonic 
Anhydrase," m: The Enzymes, 
Vol. V, p.545, (Boyer, P. D.,ed.) 
Academic Press, New York 
( 1971 ). 
Soybean trypsin inhibitor 21,500 Wu Y.V. and Scheragc 
H.A .. Biochemistry. 1962: 1:698. 
Lysozyme 14,400 Jollcs P .. Angcw. Chem lnrl. 
Edit. 1969; 8: 227 
Aprotinin 6,500 Kassell B. and Laskowski M. 
Biochem. Biopllys. Res. Com. 
1965: 20:46:1. 
2.19 Native PAGE analysis 
Cell lysates were diluted with I :5 in gel loading buffer 30%w/v glycerol (Sigma) + 
0.25%w/v Bromophenol Blue (Sigma). Cell lysates were loaded onto Tris-HCL Ready gel 
containing a gradient of 4-15% polyacrylamide (Biorad, Hertfordshire, UK) with Broad 
Range Molecular Weight Markers (Biorad) details of which can be seen in Table 3. 
Electrophoresis was carried out in Protean System 11 Apparatus (Biorad, Hertfordshire, UK) 
in electrophoresis buffer containing 45mM Tris-borate + I mM EDTA at I OV for 2-3 hours. 
Gels were stained with 90% Methanol (BDH): distilled H20. I: I v/v + I O%v/v Glacial 
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Acetic Acid (Sigma) + Coomassie Brilliant Blue R250 (Biorad) overnight on a lateral 
shaker and destained with two changes of destain solution (90% Methanol:distilled H20. 
l: l v/v + I O%v/v Glacial Acetic Acid) each after 30 minutes. Gels were placed in distilled 
water and kept at 4 °C for l hour. Gels were photographed using digital camera 
electrophoresis documentation and analysis system 120 (Kodak, Newhaven.,USA) and 
analysed by ID image analysis software (Kodak). 
2.20 Electro-blotting of proteins onto membranes 
Gels were not stained with Coomassie Blue if they were to be transferred onto 
either a nitro-cellulose membrane or PVDF. 
2.20.1 Transfer to Nitro-cellulose for Western Blotting 
Transfer buffer (Towbin Buffer/1651) containing 25mM Tris, pH 8.3 + 192mM 
glycine + 20% v/v Methanol was chilled Filter paper (Biorad), Fibre pads (Biorad}, 
0.45J.1m nitro-cellulose membrane (Biorad) and gels were allowed to equilibrate in 
transfer buffer for at least l hour at 4°C. Gels were already marked for orientation and 
a corresponding mark placed on the nitro-cellulose membrane. The cassettes of Mini 
Trans-Blot Electropheretic Transfer Cell (Biorad) were assembled as shown in Figure 
13. Air bubbles were carefully removed to ensure good transfer. Ice blocks were 
placed around the apparatus to reduce heat transfer. Transfer occurred overnight at 
30V, 90mA using APS powerpack. 
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Figure 13: Arrangement of layers in blotting apparatus 
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2.20.2 Transfer to PolyVinylidene DiFiuoride CPVDF) for protein sequencing 
PVDF membrane is thought to be the best support for proteins as it has high 
protein binding capacilf66 and is resistant to acidic and organic solvents used in 
amino-terminal protein sequencin!(67.268. Transfer was carried out as previously 
stated in Section 2.20.1. 
2.21 Electro-Elution of protein bands 
B-CLL lysates were separated by reducing PAGE, as outlined in section 2.18. 
Protein bands were visualised by staining with Coomassie Blue. After equilibration in 
distiJled water for 1 hour 65K.Da, 42K.Da, 31KDa and 25KDa bands were excised with a 
razor blade. Membrane caps containing dialysis membrane with 10,000 Dalton (Da) 
exclusion pore size were soaked at 60°C in elution buffer (25mM Tris, 192mM Glycine and 
0.1% SDS) for 1 hour prior to use. The model 422 Electro-EJuter was assembled as shown 
in Figure 14. The gel slices were chopped and placed in individual labelled glass tubes on 
the E lectro-Eluter. The glass tubes were filled with elution buffer. Elution took place 
70 
overnight with 8- 1 OmA/glass tube. The eluted protein was found in the membrane cap. 
Approx imately 400f..ll of protein solution was decanted. The membrane cap was rinsed with 
a further 200f..ll of fresh elution buffer. The protein olution was d ialysed overnight at 4°C 
against PBS using I O,OOODa Slid-A -Lyzer dialysis cas ettes (Pierce, Perbio Science, 
Che ter, UK). Protein content was estimated as outlined in section 2.9. 
Figure 14: Arrangement of tubes for electro-elution. 
2.22 Western blot analysis 
------ Glass tube 
Silicone adaptor 
Gel slice 
Frit 
Membrane cap 
Reducing SOS-PAGE was carried out on celllysates from both B-CLL patients and 
normal healthy volunteers as stated in section 2.18. The gels were not stained with 
Coomassie Blue. The resulting gel wa blotted onto nitro-cellulose a described in ection 
2.20. 1. Protein bands were stained wi th 2% Ponceau S stain solution (Sigma) and destained 
in distilled water. All bands were marked in pencil at this stage. Non-specific binding was 
blocked in Bovine Lacto Transfer Technique Optimiser B (BLOTTO B) for I hour at room 
temperature with gentle shak.ing. BLOTTO B consisted of I OmM Tri HCL (S igma) pH8 + 
150mM Sodium Chloride (Sigma) + I o/o skimmed milk powder (Safeway, UK) + I% 
Bovine Serum albumin (BSA) (S igma) + 0.05% Tween 20 (Sigma). Goat anti -Human 
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CD5, Goat anti-Human CDI9, Goat anti-Human CD23, Rabbit anti-Human CD72, Mouse 
anti-Human CD38 monoclonal antibodies (Santa Cruz, USA) were incubated with the 
nitro-cellulose blot diluted at I :500 in BLOTIO B for I hour at room temperature with 
gentle shaking. The blot was washed 3 times in IOmM Tris buffered 150mM saline pH8 
(TBS) + 0.02% Tween 20. A secondary polyclonal Donkey anti-Goat lg alkaline-
phosphatase conjugate, polyclonal Rabbit anti-Mouse lg alkaline-phosphatase conjugate or 
polyclonal Mouse anti-rabbit lg alkaline-phosphatase conjugate (Santa Cruz) diluted I: I 000 
in BLOTIO B respectively were incubated for I hour at room temperature with gentle 
shaking. The blot was washed 3 times in TBS + 0.02% Tween 20 and once in TBS alone. 
The Western blot was developed using an Alkaline-Phosphatase development kit (Biorad) 
for 2 -4 minutes, washed in distilled water and air-dried. 
2.23 Protein Sequencing 
Protein bands of interest were sequenced. B-CLL lysates were concentrated using a 
freeze drier and then separated using reducing SOS-PAGE as stated in section 2.18. Gels 
were blolled onto PVDF as stated in section 2.20.2. Bands were sent for automated N-
terminal sequencing to 2 commercial services either Proseq ( Box ford, USA) or PNACL 
(Leicester, UK). 
2.24 Statistics. 
Effects of treatment upon groups of 5 patients or more were analysed by one-way 
analysis of variance (ANOV A). Direct comparisons between treatment groups with smaller 
sample groups were analysed using the Student's /-lest. Differences between median values 
were compared using the Kruskal-Wallis test. Statistics were generated using Statsgraphics 
Plus software. 
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3. RESULTS-DENDRITIC CELLS 
3.1 Characterisation of dendritic cell immunophenotypes. 
The results of immunophenotyping studies of DCs derived from normal volunteers 
and patients with B-CLL are summarised in Table 3. 
Table 3: Dendritic cell surface markers 
Cell surface Normal DCs BCLL patient DCs 
marker (Mean%+ sd) (Mean%+ sd) 
HLA-DR 56.8 ± 17.1 54.0 ± 8.4 
CD83 1.4 ± 0.9 1.2 ± 0.8 
CD40 12.9 ± 5.9 26.7 ± 8.4 p=0.02 
CD86 27.8 ± 1.8 15.7±3.8 P=0.003 
CD16 2.2 + 1.2 19.2 ± 6.9 
CD 56 0.3 ± 0.3 0.2±0.1 
CD3 10.7 ± 5.2 9.2 ±5.6 
CD14 19.3 ± 18.2 11.2 ± 7.0 
CDllc 4.2 ± 4.5 10.1 ± 6.0 
CD20 4.1 + 2.7 4.7 + 3.0 
CD la 9.6± 7.3 9.6± 8.3 
CD45 92.5 ± 3.5 89.0 ± 4.0 
Table 3. Analysis of markers for CDI9 depleted PBMC cultured in RPMI 1640 + 
I 0% AB serum + IL-4 (I OOOU/ml) + GM-CSF (800 U/ml) for 6 days at 37"C, 5% C02 from 
3 normal volunteers and 5 B-CLL patients. p-values were calculated using single-tailed 
unpaired Student's Hest. 
There were no significant differences in mean cell surface marker expression of HLA-
DR, COla, CD3, CD4, COlic, CDI4, CDI6, CD20, CD45, CD56, and CD83 between 
patients and healthy volunteers. However, CD40 was found to be significantly increased in 
patients compared to healthy volunteers (p=0.02), and CD86 was found to be significantly 
decreased in B-CLL patients compared to healthy volunteers (p=0.003). 
3.2 Photographs of monocyte DCs 
Dendritic cells from I B-CLL patient were isolated according to the method in 
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section 2.5 and photographed using a Diavert microscope (Leitz) using x20 objective and 
automatic MPS 45 camera (Wild). It can be observed from Figure 15 that monocyte derived 
DCs change from rounded monocyte like cells to cells with dendrite protrusions over the 6 
day incubation. Numbers of monocyte cells with in the culture did not increase. Dendritic 
cells were thus a consequence of cell differentiation from the common granulocyte-
macrophage precursor monocyte cells observed after I day of culture. The DCs on day 7 
had been incubated at 37°C, 5% C02 overnight with IL-12 (I OOng/ml) and then 
subsequently pulsed with autologous B-CLL lysate for 4 hours at room temperature. Larger 
numbers of dead cells were seen after the overnight incubation with IL-12 than without. 
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Figure 15: Monocyte derived dendritic cell cultures 
Day I Day 2 
Day6 
Figure 15: Dendritic cells from Patient 25 were isolated as stated previously and cultured for the indicated 
period at 37"C, 5% C0 2 in RPMl 1640 + Penicillin + Streptomycin + Glutamine+ I 0% AB erum. Cells in 24 
well plates were photographed using Diavert microscope (Leitz) with x20 objecti ve and automatic MPS 45 
camera (Wild ). 
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3.3 Validation of system using autologous DCs pulsed with Tetanus Toxin and Tuberculin 
T cells were eo-cultured with commonly used antigens to assess the efficacy of DCs 
to stimulate T cell activation (lL-2 receptor expression). IL-2 production is initiated by 
antigenic stimulation and the IL-2 receptor is constitutively expressed after approximately 
48 hours 1269·2701. T cell activation was observed when autologous DCs, pulsed with either 
Tetanus Toxin or Tuberculin PPD, were cultured with autologous T cells from a single 
healthy volunteer (Figure 16a). However, when the Tetanus Toxin and Tuberculin PPD 
antigens were added to T cells without DCs there was an increase in T cell after 6 and 7 
days eo-culture. The T-cells were responding to the Tetanus Toxin and Tuberculin PPD as a 
recall antigen after in vivo vaccination. The activation ofT-cells by autologous DCs pulsed 
with tetanus toxin occurred much quicker after 3 days of eo-culture. The activation ofT 
cells by DCs pulsed with Tuberculin PPD occurred after 5 days eo-culture. 
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Figure 16a: T cell proliferation to autologous DCs pulsed with Tetanus 
Toxin and Tuberculin PPD in a normal healthy volunteer. 
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Figure 16a: T -cells from I normal healthy volunteer were cultured alone, with Tetanus 
Toxin (0.4U/ml) and Tubercu lin PPD (900U/ml) or with DCs pulsed with Tetanus Toxin 
(0.4U/ml) and Tuberculin PPD (900U/ml) for 4 hours at room temperature. Cells were 
harvested on day 3-7 of culture and assessed by now cytometry for CD3/CD25 eo-
expression. 
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T cells from B-CLL Patient 26 showed an increase in T cell activation when 
stimulated by autologous DCs pulsed with Tetanus Toxin or Tuberculin PPD (Figure 16b). 
However, when Tetanus toxin and Tuberculin PPD were added to T-cells without DCs 
increased T-cell activation was observed after 5 days. The response to antigen alone 
without being pulsed onto DCs was greater in the B-CLL patient. This may be because the 
individuals recall antigen response is stronger due to recent vaccination or increased 
exposure to the antigens. However, B-CLL patients have been shown to express increased 
levels of CD25 as the disease progresses f271/. Pulsing Tuberculin PPD onto DCs stimulated 
more T cells to express the [L-2 receptor than administration of the Tuberculin antigen 
directly to T-cells. These experiments validated that specific antigens pulsed onto DCs 
could stimulate T cell activation, using markers such as the IL-2 receptor (CD25). 
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Figure 16b: T cell proliferation to autologous DCs pulsed with stimulated 
by Tetanus Toxin and Tuberculin PPD in a B-CLL patient. 
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Figure 16b: T -cells from I B-CLL Patient 26 were cuhured alone, with 
Tetanus Toxin (0.4U/ml) and T uberculin PPD (900U/ml) or with DCs pulsed 
with Tetanus Tox in (0.4U/ml ) and T uberculin PPD (900U/ml) for 4 hours at 
room temperature. Cells were harvested on day 3-7 of culture and assessed by 
flow cytometry for CD3/CD25 eo-expression. 
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Cytokine production by T cells was also assessed by ELISA to show T helper cell 
activity. IFN-y was measured from the same patients and healthy volunteer that had shown 
an increase in IL-2 receptor. T-cells from the healthy volunteer secreted increased amounts 
of IFN-y when cultured with autologous DCs pulsed with either Tetanus Toxin or 
Tuberculin PPD (Figure 17a). IFN-y secretion in response to the administration of 
Tuberculin PPD toT-cells without DCs after 5 days was the same as that when using pulsed 
DCs. However, IFN-y secretion followed the same pattern as IL-2 receptor expression. 
T-cells ·from the B-CLL Patient 26 secreted increased amounts of IFN-y when 
cultured with autologous DCs pulsed with either Tetanus Toxin or Tuberculin PPD (Figure 
17b). When comparing the T-cell responses from the normal healthy volunteer (Figure 16a 
and 17a) and B-CLL Patient 26 (Figure 16b and 17b) it was observed that although the peak 
response was weaker in the B-CLL patient the responses followed similar overall patterns. 
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Figure 17a: IFN-ysecretion by T cells to autologous DCs pulsed with 
Tetanus Toxin and Tuberculin PPD in a normal healthy volunteer. 
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Figure 17a: T-cells from I normal healthy volunteer were cultured with Tetanus 
Toxin (0.4U/ml) and Tuberculin PPD (900U/ml) alone or with DCs pulsed with 
Tetanus Toxin (0.4U/ml ) and Tuberculin PPD (900U/ml) for 4 hours at room 
temperature. Tissue culture supernatanL was assessed by ELlS A. Each treatment 
group was measured in duplicate per time point. 
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Figure 17b: IFN-y secretion by T cells to autologous DCs pulsed with 
Tetanus Toxin and Tuberculin PPD in a B-CLL patient 
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Figure 17b: T-cells from I B-CLL Patient 26 were cultured with Tetanus Toxin 
(0.4U/ml) and Tuberculin PPD (900U/ml) alone or with DCs pulsed with Tetanus 
Toxin (0.4U/ml) and T uberculin PPD (900U/ml) for 4 hours at room temperature. 
Tissue culture supernatant was assessed by ELISA. Each treatment group was 
measured in duplicate per time point. 
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3.3 Allogeneic dendritic cell: T cell interactions 
In order to test the ability of DCs to stimulate cytotoxicity cell-cell allogeneic 
reactions between Des and T cells were investigated by mixed cultures. Figure 18 shows 
the resu1ts from 3 B-CLL patients and 3 healthy normal volunteers. It should be noted that 
Des from B-CLL patients cultured with allogeneic T cells from healthy volunteers 
stimulated cytotoxicity towards allogeneic B-CLL B cell targets (*). The converse was true 
in that DCs from normal healthy volunteers stimulated allogeneic B-CLL T cells to kill 
allogeneic normal healthy B cells (/\). However, the cytotoxicity generated by B-CLL T 
cells was of a lower percentage than normal T -cells. T -cells from B-CLL patients showed 
higher background cytotoxicity when not stimulated. These two phenomenon were 
probably due to the fact the T -cells from B-CLL patients have shown dysfunctional 
characteristics. Collectively the antigen presentation data suggests that DCs can be used as 
efficient antigen presenting cells. 
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Figure 18: Cytotoxicity generated in mixed lympbocyte culture between T 
cells and DCs from B-CLL patients and healthy normal volunteers. 
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OeOOritic eels from Patiem 2, 7 and 8 and 3 healhy volunteers were ~IXed for 21 days in 
RPMI1640 + 5% AB serum+ GUamine + Penicilin + Streptomycin+ IL-2 (5U/ml) at 3t>C, 
5% C02 v.flh autologous T cells or allogeneic normal T eels and tested for cytotoxicity against 
allogeneic or autologous targets. 
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4. RESULTS- T CELL RESPONSES 
4.1 Measurement of T cell proliferation (fL-2R expression) in B-CLL patients. 
T-cells derived from patients with B-CLL were cul tured alone or with autologous B-
CLL lysate-pulsed or unpulsed DCs. T-cells were assessed for eo-expression of CD3 and 
CD25 (IL-2R). Figure 19 illustrates typical now cytometric profiles generated from eo-
cultures of B-CLL Patient 22. It can clearl y be seen that the proportion of T cells eo-
expressing CD3 cells and CD25 increased when T-cells were stimulated by B-CLL B-cell 
lysate pulsed DCs. 
Figure 19: Typical example of flow cytometry profiles assessing T cell 
proliferation (IL-2R expression) in a B-CLL patient 
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Figure 19: T-cells from B-CLL Patient 22 were eo-cultured alone, with lysis buffer 
pulsed DCs or 8-CLL lysate pulsed DCs for 7 days in RPM1+5% AB Serum+ 
Penicill in+ Streptomycin + Glutamine at 37''C, 5%C02. Cells were harvested and 
assessed for CD3/CD25 eo-expression by flow cytometry. Gates were set at 2% of 
FITC-Ig and RPE-Ig negative controls. 
85 
Activation markers were assessed in the eo-cultures of 5 patients and analysed as a 
sample group. A significant increase in T-cell activation was found after 4 days of culture 
by T-cells cultured with autologous lysate-pulsed DCs compared to T-cells cultured with 
DCs pulsed with lysis buffer (p=0.03) (*)(Figure 20a). 
A lysate from a normal healthy volunteer was used as a control and pulsed onto 
DCs from B-CLL patients. It was important to see whether an allogeneic lysate from a 
normal healthy volunteer could also stimulate T-cells from B-CLL patients. Although there 
was an increase in the percentage of activated B-CLL T cells after eo-culture with 
autologous B-CLL DCs pulsed with an allogeneic B-cell lysate from a healthy volunteer, 
this was not significant (Figure 20a). 
4.2 Mea~urement ofT-cell proliferation {IL-2R expression) in healthy volunteers 
Dendritic cells from 5 normal healthy volunteers were pulsed with autologous 
normal lysate and then eo-cultured with autologous normal T-cells. This allowed a direct 
comparison between the autologous system in normal healthy volunteers and B-CLL 
patients. When an autologous non-B-CLL B-cell lysate from healthy volunteers was pulsed 
onto autologous DCs, there was no increase in T cell activation (Figure 20b). Interestingly, 
when an allogeneic non-B-CLL B-cell lysate from healthy volunteers was pulsed onto 
autologous DCs, the percentage of activated autologous T cells was increased at day 3 and 6 
but not significantly (Figure 20b). A strong allogeneic response would have been expected 
when using an allogeneic B cell lysate from normal healthy volunteers. 
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Figure 20a: T cell proliferation (IL-2R expression) to autologous lysate 
pulsed DCs from B-CLL patients 
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Numbers of CD3/CD25 positive T-cell from 5 B-CLL were measured 
(Figure 20a). Median values expressed were tested using the Kruskal-Wall is 
test. (*) Indicates a significant increase in double positive cells with p=O.OJ 
when eo-cultures of pulsed DC were compared with unpulsed DCs. 
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Figure 20b: T cell proliferation (IL-2R expression) to autologous lysate 
pulsed DCs from normal healthy volunteers 
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Numbers of CDJ/CD25 positive T-cells from 5 healthy volunteers' (Figure 20b) were 
measured . Median values expressed were tested using the Kruskal-Wallis test. No significant 
increases were found. 
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4.3 Quantitation of cytokine secretion in B-CLL patients. 
T-cells derived from patients with B-CLL were cultured alone or with lysate-pulsed 
or unpulsed (lysis buffer added in 5 patients) DCs. The supernatant from these cultures was 
harvested and tested for IFN-y protein levels by ELISA. IFN-y was chosen as it is an 
important T helper cell type I (Th I) cytokine. A significant increase of IFN-y secretion in 
culture supernatant was found after 72 hours by T-cells cultured with B-CLL lysate-pulsed 
autologous DCs compared to both T-cells cultured with unpulsed DCs and T-cells cultured 
alone (p=0.0004) (Figure 21 a). In addition there was no secretion of IFN-y by T -cells 
cultured with autologous DCs pulsed with soluble allogeneic B-cell lysate derived from 
healthy volunteers (non-B-CLL) (Figure 21 a). 
4.4 Quantitation of cytokine secretion in healthy volunteers 
Secretion of IFN-y by T-cells derived from healthy volunteers and cultured with 
autologous DCs pulsed with autologous B-cell lysate from healthy volunteers (non-B-CLL) 
was measured. Normal T-cells, stimulated using the same system as that for B-CLL 
patients, did not secrete significant amounts of IFN-y (Figure 21 b). Dendritic cells from a 
normal healthy volunteer that had been pulsed with allogeneic B-CLL lysate could not 
stimulate autologous normal healthy T-cells to secrete IFN-y. Even background levels, ofT 
cells alone or T-cells with DCs pulsed with lysis buffer, of IFN-y secretion in the group of 5 
healthy volunteers was lower than the I 0 B-CLL patients (Figure 21 b compared with 21 a). 
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Figure 21a: IFN-ysecretion by T-cells cultured with autologous lysate 
pulsed DCs from B-CLL patients. 
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ELISA. Data was analysed by one-way ANOY A. Where(*) indicates an overall significant effect of treatment 
with p=0.0004. Each treatment group per patient was measured in duplicate. 
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Figure 2lb: IFN-y secretion by T -cells cultured with autologous lysate 
pulsed DCs from normal healthy volunteers 
-~ 
UJ 
(/) 
.± 
E 
e;, 
0. 
'"F 
z 
u. 
0 
c: 
0 
:0::: 
cu 
... 
... 
c: 
Cl) 
0 
c: 
0 
0 
c: 
cu 
Cl) 
~ 
5000 
4000 
3000 
2000 
1000 
0 
24 48 72 96 120 
Time (Hours) 
DT cells 
• dendritic cells + T cells 
• dendritic cells+ allogeneic normal lysate+ T cells 
• dendritic cells+ autologous lysate+ T cells 
Tissue culture supematants from cultures of 5 normal healthy volunteers (Figure 2 1 b) were measured for IFN-
y by ELISA. Each treatment group per patient was measured in duplicate. 
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4.5 Secretion of IL-4 
To establish the nature of the cytokine profile generated by the stimulated T-cell 
cultures a typical T Helper cell type 2 (Th 2) cytokine was measured. Concentrations of IL-
4 in tissue culture supernatants were measured in 2 patients with B-CLL and found to be 
less than 50 pg/ml. 
4.6 Measurement of cytotoxic T-cell activity in B-CLL patients. 
T-cells were cultured with DCs for 21 days with IL-2 fed on days 3,7,10,14, and 17. 
Soluble lysate was added to the pulsed DCs on day 7 and 14. T-cell effectors were then 
tested in a flow cytometric cytotoxicity assay. A typical example of the flow cytometric 
profiles at a 40: I effector: target ratio from Patient 13 are shown below in Figure 22. It can 
be seen that cytotoxicity to B-CLL B cell targets is greater by T-cells cultured with 
autologous DCs pulsed with B-cell lysate from B-CLL patient than that seen by T cell 
effectors stimulated by DCs pulsed with lysis buffer or T-cells cultured alone. 
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Figure 22: Typical Flow cytometric profiles of cytotoxicity to B-CLL B 
cells 
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Figure 22: T -cells from Patient 13 were cultured and are sho wn here after incubation at 40: I 
effector rat io in RPM! 1640 + I 0 % AB Serum + Penic ill in+ Streptomycin+ Glutamine fo r 4 
hours at 37oC, 5%C02. Gates were set as illustrated in Figure 11 . Non-specific cytotox ic ity to 
B-CLL B-cell targets was measured at 29%. 
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T-cells derived from I 0 patients with B-CLL were cultured alone or with lysate-
pulsed or unpulsed (lysis buffer added in 8 patients) DCs and then tested for cytotoxicity 
against B-CLL B-cell targets. At the 40: I effector: target ratio, a significant increase in 
cytotoxicity against B-CLL targets was generated by T-cells cultured with B-CLL lysate-
pulsed autologous DCs compared with both T-cells cultured with unpulsed DCs and with 
T-cells cultured alone (p=0.0008) (Figure 23a). In order to check the speciticity of this cell 
mediated cytotoxicity other control targets were tested. To test whether the cell-mediated 
cytotoxicity.was directed towards a Pan B-cell antigen, such as CDI9, control B cell targets 
from normal healthy volunteers were used. Significant cytotoxicity was not demonstrated 
against allogeneic B-cell targets from healthy volunteers (non B-CLL targets) (Figure 23b). 
Secondly to test for any autoimmune reactivity that may have a detrimental effect upon the 
immune system of the patient, autologous T-cells from B-CLL patients were used as targets. 
Significant cytotoxicity against autologous T-cells derived from B-CLL patients (non-B-cell 
targets) was not stimulated by eo-culture T cell effectors with a B-CLL B cell lysate pulsed 
DCs (Figure 23c). T-cells derived from patients with B-CLL cultured with soluble B-CLL 
lysate in the absence of DCs did not show significant cytotoxicity against B-CLL or B-cell 
targets from healthy volunteers. Presentation of the B-CLL B cell lysate by DCs was 
required in order to stimulate T-cell responses. 
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Figure 23a, 23b and 23c : Cytotoxicity ofT cell effectors from B-CLL 
patients 
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Effec tors fro m I 0 8 -CLL patients were cultured for 2 1 days (see Chapter 2) and cytotoxicity against 
auto logous 8 -CLL B-cell targets (Figure 23a), allogeneic B-cell targets fro m healthy volunteers (non-8 -CLL) 
(Figure 23b) and auto logous 8 -CLL T-cel l targets (Figure 23c) was measured. T-cells had been cultured 
a lone L:, or with auto logous DCs pulsed with auto logous 8 -C LL lysate+ , allogem: ic lysate fro m healthy 
volunteers (non 8 -CLL) e or lys is buffer • (except in patient 7 and 13 no lysate). Data was analysed by 
one-way ANOV A. Where(*) indicates an overa ll significant effect of treatment with p=O.OOOB. 
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Figure 24: Cytotoxicity against HLA matched normal B-cells by T -cell 
effectors from B-CLL patient stimulated by lysate pulsed DCs 
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Figure 24: T-cells from B-CLL Patient 26 were eo-cultured alone, with lysis huffer pulsed 
autologous DCs or lysate pulsed autologous DCs for 28 days at 37"C, 5tKC01. Cultur~s were fed fL-
2 and restimulated as stated in Section 2. 12. Cytotoxicity was measured against HLA-matched 
PBMC' . T cells and B cells. Duplicates per treatment per target were measured . 
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Many anti-tumour responses have been shown to be HLA restricted. Therefore, it 
was important to test B-CLL targets of the same HLA type as control targets. In Patient 26, 
effectors were tested against B cells, PBMC's and T cells from 2 HLA class I and Il 
matched healthy volunteers and I HLA class Il matched healthy volunteer. No cytotoxicity 
to these targets was demonstrated as shown in Figure 24. 
4.7 Measurement of cytotoxic T-cell responses in healthy volunteers 
As a direct comparison with the B-CLL autologous system, T-cells from normal 
healthy volunteers were stimulated by autologous DCs pulsed with B-cell lysate from 
normal healthy volunteers. T-cells derived from healthy volunteers showed no specific 
cytotoxicity to autologous B-cell targets from healthy volunteers (non-B-CLL targets) 
(Figure 25a). T-cells were also cultured with autologous DCs pulsed with allogeneic B-CLL 
lysate. Effector from normal healthy volunteers after stimulation by normal DCs pulsed 
with an allogeneic B-CLL B-cell lysate did not demonstrate significant cytotoxicity against 
autologous B-cell targets from B-CLL patients (Figure 25b). 
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Figure 25. Cytotoxicity ofT cell effectors from normal individuals. 
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Efkclors from 5 normal healchy volunceers were cultured for 21 days (see Chapter 2) and cytotoxicity againsl 
autologous B-cell targecs from healthy volunu:ers (non-B-CLL) (Figure 25a) and allogeneic B-CLL B-cell 
targels (Figure 25h) was measured. T -cells had been cultured alonc6 or wilh autologous DCs pulsed wich 
aulologous normal B-ccll lysalc • , allogeneic lysale from B-CLL patien+ or lysis buffer. . Data was 
analysed by one-way ANOV A. 
98 
4.8 Stimulation of cytotoxicity by Granulocyte lysate from B-CLL patient 
In addition, it was thought necessary to demonstrate that a lysate from a cell type 
other than B-cells could not stimulate similar anti-8-CLL responses. A cell not shown to be 
involved in the disease of 8-CLL was chosen. Granulocytes have shown limited 
involvement in the pathology of B-CLL 12721. Granulocytes were isolated as described in 
Section 2.7. Lysate generation, pulsing of DCs and culture conditions for the granulocyte 
lysate were the same as those as 8-cells. T-cells cultured with autologous DCs pulsed with 
an autologous granulocyte lysate from B-CLL Patient I showed no significant increase in 
cytotoxicity against autologous granulocytes or autologous 8-CLL cells as shown in Figure 
26. Although the cytotoxicity ofT-cell effectors cultured alone or with DCs pulsed with 
lysis buffer was higher against granulocyte targets than 8-CLL cells this was thought to be 
due to the fragility of the granulocyte cells. 
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Figure 26: Cytotoxicity stimulated by granulocyte lysate from a B-CLL 
patient 
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Figure 26: Granulocytes and 8 -CLL 8 cells were separated from 8 -CLL Patien t I and cell lysatcs were 
prepared by identical methods according to Chapter 2. A single batch of DCs was pulsed with the 2 
different Iysates under the same conditions. T -cell effectors were cultured without o r with pulsed DCs 
under the same conditions for 2 1 days as stated in Chapter 2. All targets were auto logous. 
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4.9 Stimulation of cytotoxicity using allogeneic B-cell lysates from B-CLL patients 
In order to further characterise the specificity of the stimulatory ability of the B-CLL 
B-cell lysates, allogeneic B-cell lysates from B-CLL patients were pulsed onto DCs from 
another B-CLL patient and cultured with T-cells from that B-CLL patient. Mixed results 
were obtained. T-cells derived from Patient 14 and cultured with autologous DCs pulsed 
with an allogeneic B-CLL lysate from Patient IS did not demonstrate cytotoxicity to B-CLL 
targets from Patient 14 (Figure 27a). However, T-cells derived from Patient 6 and cultured 
with autologous DCs pulsed with allogeneic B-CLL lysates from Patients 2 and 13 
demonstrated significant cytotoxicity to B-CLL targets from Patient 6 (p=0.003 and 
p=0.009). Allogeneic B-CLL lysates from B-CLL Patient 7 did not stimulate cytotoxicity to 
B-CLL targets from Patient 6 (Figure 27b ). The lysates from Patient 7 and IS had 
previously generated specific cytotoxicity when used as autologous lysate, pulsed onto 
autologous DCs, cultured with autologous effectors and tested against autologous targets. 
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Figure 27: Cytotoxicity generated by allogeneic-8-CLL-Iysate pulsed DCs 
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Effectors from 8 -CLL patients were cultured alone 0 , with autologous DCs pulsed with autologous 
B-CLL lysate , 8 -CLL a llogeneic lysate from patienLS 15. 2. 13 and "[] and lysis buffll for 
2 1 days. Cytotoxicity shown was performed at a target: effector ratio of 40: I . Where (*) indicated a 
significant increa e in mean ~peci fic cytotoxicity compared with auto logous DCs with lys is buffer with 
p<O.OI when analysed by Students Hest. Each treatment group was measured in duplicate per patient. 
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4.10 Characterisation of effector cell immunophenotypes. 
Effector cells from B-CLL patients 14 and 16 where immunophenotyped after 21 
days in culture. The mean cell surface expression was found to be 47% CD4+ cells and 13% 
CD8+ cells, the remaining cells being CD3-. CD 16 and CD56 expression was absent. 
4. 11 Antibody blocking studies. 
Although Natural Killer cells were not found by flow cytometry in the effector cell 
population, they could still be responsible for the killing of B-CLL cells. In order to 
characterise the mechanism of cytotoxicity, antibodies were used to inhibit the cytotoxic T-
cells. Antibody blocking experiments were performed at the effector stage of the 
cytotoxicity assay on 3 patients chosen at random. Significant inhibition of cytotoxicity was 
demonstrated with anti-class II but not with anti-class I monoclonal antibodies in Patient 2 
(Figure 28a) p=0.006 and 12 p=0.031 (Figure 28b). Significant inhibition of cytotoxicity 
was demonstrated in Patient 4 with anti-pan TCR a~ and anti-CD4 but not with anti-CD8 
monoclonal antibodies (p=0.03 and p=0.046) (Figure 28c). This confirmed that the 
cytotoxicity induced by B-CLL lysate pulsed DCs was reliant upon a HLA class-II restricted 
mechanism. 
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Figure 28: Antibody blocking of cytotoxicity generated from B-CLL 
patient T -cell effectors. 
Figure 20: Antibody Blocking. T-cell effectors from B-CLL patient 2 (Figure 20a) and B-CLL patient 
12 (Figure 20b) and patient 4 (Figure 20c) were cultured alone 0 . with autologous B-CLL DCs pulsed with 
B-CLL lysate or lysis buffer• for 21 day . Anti-human HLA-class I and anti-human HLA-class 11 
antibodies were present whilst effectors were incubated at a 40: I effector :target ratio with autologous 8 -CLL 
8 -cell targets (Figure 20a and Figure 20b). Anti-Pan TCR ap , Anti -CD8 and Anti-CD4 anti bodies were 
incubated with autologous 8 -CLL 8 -cell targets at a target: effector ratio of 40: I (Figure 20c). Where(*) and 
(**) indicate a significant inhibition of specific cytotoxicity in the pre cnce of antibody compared with none 
with p<0.05 and p<O.O/ when analysed by Student 's Hest. Each treatment group was measured in duplicate 
per patient. 
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5. RESULTS- FURTHER OPTIMISATION 
5.1 Maturation of DCs with IFN-a 
The low levels of cytotoxicity may be due to the relatively immature state of the 
monocyte derived DCs (CD83.) used to present lysate antigens to the T-cells in our 
experimental system. After loading of antigen onto the dendritic cell surface a further 
'danger signal' is required to achieve maximal presentation of that antigen to the T-cell 
12731
. Type I Interferon's (IFN) have shown maturation effects upon CD34+ derived DCs 
12741
. IFN-a (2jlg/ml) (Cambridge Bioscience) was added to monocyte derived DCs after 
pre-treatment with IL-12 and pulsing with either B-CLL lysate or lysis buffer on 7 days of 
culture. After 24 hours incubation the DCs were washed by centrifugation and added toT-
cells as stated in Section 2.11. Cytotoxicity against B-CLL B-cell targets was assessed after 
a further 21 days ofT-cell effectors in eo-culture. In Patient 17, autologous T-cells cultured 
with lysate pulsed DCs matured by IFN-a showed decreased specific cytotoxicity to B-CLL 
targets (Figure 29). The addition of IFN-a to lysate pulsed monocyte derived DCs from 
Patient 17 or 27 did not stimulate cell surface expression of CD83. In Patient 27, a decrease 
in the number of cells positive for HLA-DR antibody staining was observed when the 
maturation agent was added to DCs after lysate pulsing. However, when IFN-a was added 
before lysate pulsing during the same experiment there was an increase in HLA-DR 
expression (Figure 30). 
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Figure 29: Effect of maturation by IFN-a on dendritic cell maturation as 
measured by cytotoxicity by T cells to autologous B-CLL targets. 
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Figure 29: T-cell efft!ctors generated from DCs treated or untreated with IFN-a (2J..lg/ml ) for 24 hours were 
tested against autologous 8 -CLL B-cells fro m Patient 17. Mean !.J1Cc ific cy totoxicity was gt!ne rated from 
duplicates for each treatment point. (* ) lndicat t!s a significant decrea~e in cyiOtoxicity (p=0. 0/8) when IFN-a 
was added to lysate pu lsed DCs compared with no IFN-a. 
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Figure 30: Cell surface expression of HLA-DR on DCs with maturation 
agent IFN-a. 
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Figure 30: Dendritic cells from 8-CLL Patient 27 were treated with fFN-a (2 !-lg/ml) with and without previous 
exposure to autologous lysate and were stained with anti- Human HLA-DR-RPE conjugated antibodies as 
stated in Section 2.2. 
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5.2 Maturation of DCs with Poly (I:C) 
Polyriboinosinic Polyribocytidylic Acid (Poly(l:C)) induces stable mature DCs 
capable of stimulation in a primary allogeneic MLR 12751. Therefore, it was another possible 
dendritic cell maturation agent that should be investigated. Poly (I:C) at 50Jlg/ml was added 
For 3 days after pulsing with B-CLL B-cell lysate to monocyte DCs. Although 50Jlg/ml was 
not the optimal concentration to achieve maximal effect, it did increase the cell surface 
expression of CD83 on immature monocyte DCs (Figure 31 ). T-cell effectors, from Patient 
18, stimulated by Poly(I:C) matured and immature autologous DCs were tested for 
cytotoxicity against autologous B-CLL B-cell targets. At the 40: I effector target ratio, 
autologous effector T-cells cultured with Poly (I:C) treated DCs exhibited decreased 
specific cytotoxicity to B-CLL B-cells. However, at the target: effector ratio of 20: I specific 
anti-B-CLL B-cell cytotoxicity was increased when T-cell effectors had been cultured with 
autologous lysate pulsed DCs matured with Poly (I:C) (Figure 31 ). 
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Figure 31: The effect of maturation agents on CD83 expression by 
dendritic ceUs. 
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Figure 31 : Dendritic cells from Patient 21 were isolated and cultured for 6 days as stated in Section 2.5. IL-12 
pre-treatment and lysate were administered as previously stated in Section 2.1 0. Maturation agents were added 
to duplicate wells of 24 well plate at various concentrations. After 3 days incubation at 37"C, S%C02 cells 
were removed using EDT A and stained for CD83-FITC staining as stated in Section 2 .2 . 
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Figure 32: Effect of Poly (I:C) on dendritic cell maturation as measured 
by cytotoxicity by T cells to autologous B-CLL B-cells 
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Figure 32: T-cell effectors generated from DCs treated or untreated with Poly (I:C) (50!-lg/ml) for 3 days were 
tested against autologous 8 -CLL 8-cell s from Patient 18 after eo-culture for 21 days at 37"C. 5lh-CO!. Mean 
specific cytotoxicity was generated from duplicates for each treatment point. (*) Indicates an increase due to 
use of Poly (I :C). 
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5.3 Maturation of DCs with LPS 
Lipopolysaccharide (LPS) has been shown to induce maturation of DCs in 1•ivo 11091 
and in vitro 1276·2771 . Therefore, LPS was another good candidate to increase the maturation 
of monocyte derived DCs from B-CLL patients. LPS was added to autologous DCs after 
pulsing with a B-CLL B cell lysate at I OOng/ml for 24 hours before eo-culture with 
autologous T cells. Although this was not optimal for Patient 21 and so did not show peak 
expression in the concentration curve (Figure 31 ), the addition of LPS as a maturation agent 
resulted in 12% CD83 cell surface expression in Patient 19. A decrease in the numbers of 
double positive CD86/CD40 cells was also observed. There was no significant difference in 
IFN-y secreted by T cells eo-cultured with DCs matured with LPS after pulsing with B-CLL 
B cell lysate. There was no increase in specific cytotoxicity to B-CLL B-cell targets by 
effectors that had been cultured with lysate pulsed DCs matured with LPS. However, the 
autologous T cells eo-cultured with DCs pulsed with lysis buffer and then treated with LPS 
showed increased levels of non-specific cytotoxicity (Figure 33). 
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Figure 33: Effect of LPS on dendritic cell maturation as measured by 
cytotoxicity by T cells to autologous B-CLL B-cell targets 
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Figure 33: T-cell effectors from Patient 19 were generated from DCs treated or untreated with LPS 
( IOOng/ml) for 24 hours and tested against autologous B-CLL B-cclls after eo-culture for 21 days at 
37"C, 5%C01. 
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5.4 Maturation of DCs with TNF-a 
Tumour Necrosis Factor-alpha (TNF-a) administration to monocyte derived DCs 
produced COla+, CD83+ DCs capable of maximal stimulation in an allogeneic Mixed 
Lymphocyte Reaction (MLR) 11101. Therefore TNF-a was used as a potential maturation 
agent. The addition of TNF-a as a maturation agent resulted in an increase in CD83 cell 
surface expression (Figure 31 ). TNF-a was added to DCs, from Patient 20, at lOng/m I for 
48 hours after pulsing with autologous B-CLL B-cell lysate and then eo-cultured with 
autologous T cells. There was no difference in the numbers of double positive CD86/CD40 
cells. At effector: target ratios of I 0: I and 20: I there was increased levels of specific 
cytotoxicity to B-CLL B-cells by effector T-cells which had been stimulated by TNF-
a treated autologous lysate pulsed DCs. However, at the higher effector: ratio of 40: I there 
was no significant difference in cytotoxicity against B-CLL B cells by T-cells cultured with 
TNF-a matured lysate pulsed DCs (Figure 34). 
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Figure 34: Effect of TNF-a. on denddtic cell maturation as measured by 
cytotoxicity by T cells to autologous B-CLL B-cell targets 
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Figure 34: T -cell effectors from Patient 20 were generated from DCs treated or untreated with TNF-cx 
( I Ong/ml) for 48 hour and tc ted again t autologous B-CLL B-cells after eo-culture for 21 days at 37"C, 
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5.5 Use of Heal Shock to improve antigen presentation 
Antigenic peptides have been coupled with tumour cell derived proteins to enhance 
macrophage responses against a wide range of tumours ' 278·2791. Therefore, it was thought 
that if the B-cells from B-CLL patients" experienced heat shock and that when they were 
used to prepare the lysate, these lysates would prove more antigenic. After isolation as 
outlined in Sections 2.4 and 2.6, the B-CLL B-cells were placed at a 45°C water bath for 90 
minutes. This treatment has shown to induce heat-shock protein-70 (HSP-70) ' 2801, heat-
shock protein-72 (HSP-72) ' 2811 and used in many studies involving heat shock protein ' 282· 
283. 284/ B-cell lysate generated from heat-shocked B-CLL B-cells was compared with B-
cell lysate from untreated B-CLL cells by pulsing onto autologous DCs and eo-culture with 
autologous T cells from Patient 11. T cell effectors generated were then tested for 
cytotoxicity against autologous B-CLL B-cell targets. Heat-shock treatment of the B-cells 
used to prepare B-CLL lysate when pulsed onto DCs, increased observed cytotoxicity by 
autologous T-cell effectors at 40: I and 20: I effector: target ratios (Figure 35a). However, 
the increase in cytotoxicity was not significant when compared with that observed from T-
cell effectors stimulated by DCs pulsed with lysate from B-cells not receiving heat-shock 
treatment. Interestingly, T-cell effectors cultured without DCs but with soluble heat shock 
lysate showed increased cytotoxicity to autologous B-cell targets. When the lysate was 
analysed by SDS-PAGE it was observed that the lysate from B-CLL B-cells were different 
to the lysate from heat-shock treated B-CLL B-cells in the same patient (Figure 35b). 
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Figure 35a: Effect of heat-shock treatment of B-CLL B-cells before lysate 
preparation on cytotoxicity against autologous B-CLL B-ceU targets. 
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Figure 35a: B-cells from Patient 11 were heat-shocked at 45°C for 90 minutes prior to lysate preparation. 
Heat-shocked and untreated lysates were pulsed onto DCs which were eo-cultured with autologous T-cells for 
21 days at 37oC, 5%C02. Cytotoxicity was measured against autologous B-ce\ls. 
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Figure 35b: SDS-PAGE of heat shock treated B-celllysate from B-CLL 
patient 
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Figure 35b: B cells from Patient 11 were isolated. Lysate was prepared from half and the remaining 
half was heat shock treated in a 45°C water bath for 90 minutes. Lysate was prepared from the heat 
shock treated cells. Both lysates were assayed for total protein content and analysed by SDS-
PAGE. Italic numbers in brackets indicate total net intensity of each lane. 
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5.6 Pre-treatment ofT cells with IL-15 
T-cells from patients with B-CLL may have been exposed in vivo to possible 
immunosuppressive factors secreted by the B-CLL cells. T-cells of B-CLL patients show 
dysfunctional cell surface molecule expression12551. Treatment with cytokines in 
conjunction with B-CLL B-cell lysates presented by monocyte derived DCs may be 
necessary to stimulate dysfunctional T cells. CD4+ T-cells treated with IL-15 have shown 
enhanced antigen specific proliferation in vitro 121151• Since IL-15 can maintain T -cell 
activation normally suppressed by multiple myeloma cells 12861, another late B lineage 
tumour, this effect was tested on T-cells from B-CLL patients. T-cells were plated at 8 x 
105/ml in 24 well plates (Life Technologies, lnvitrogen) in culture medium + I 0% AB 
Serum+ IOng/miiL-15 (Cambridge Bioscience). Cells were incubated for 16 hours at 37"C 
in 5% C02• T cells were washed in culture medium twice to remove any residual IL-15 
before eo-culture with DCs as stated in Section 2.12. 
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5.6.1 Proliferation (IL-2R expression) by IL-15 treated T-cells 
A typical flow cytometric profile from Patient 21 after 7 days incubation can be seen 
in Figure 36. T-cells were stimulated by DCs pulsed with autologous B-CLL B-cell lysate 
as previously observed in Section 4.1. However, the percentage of activated T-cells was 
further increased by the T-cells being pre-treated with IL-15 before stimulation by lysate 
pulsed DCs (Figure 36). The experiment was repeated in B-CLL patient 22. There was an 
observable increase in the numbers of activated T-cells after 5 days (in patient 22) and 7 
days (in patient 21) eo-culture with autologous B-CLL lysate pulsed DCs than T cells eo-
cultured with autologous DCs pulsed with lysis buffer (Figure 37). T-cells treated with IL-
15 prior to culture with autologous DCs pulsed with B-cell lysate showed an observable 
increase in activation after 7 days than IL-15 pre-treated T-cells eo-cultured with autologous 
DCs pulsed with lysis buffer in both Patients 21 and 22 (Figure 37). T-cells that had 
received prior treatment with IL-15 showed greater activation levels after 7 days of 
stimulation by B-CLL lysate pulsed DCs than those not pre-treated with IL-15 in both 
patients (Figure 37). 
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Figure 36: Comparison ofT cell proliferation (IL-2R expression) after 
IL-15 treatment from a B-CLL patient 
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Figure J6: Pulsed or unpulsed DCs from Patient 21 were eo-cultured wi th T-cells alone or T -cells treated wi th 
lL-15 ( I Ong/ml) for 16 hours. Typical examples shown were incubated for 7 days at JrC. 5~ CO~ in RPM I 
1640+ 5%AB serum + Penicill in + Glutamine+ Streptomyc in. Cells were harvested and stained for activation 
markers as stated in Section 2. 14. 
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Figure 37a: Effect of IL-15 pre-treatment upon T cell proliferation (IL-
2R expression) after stimulation by B-CLL lysate pulsed DC 
6 0 
5 0 
8 • 0 0 
~ 3 0 0 
8 
0 2 0 
.,. 
1 0 
Tlm • (day a) 
CJ T c ell s 
o r cells tiL -15 
• d a n d r I tic c e lis +- l c e li s 
CJ dendrll lc ce ll a • IL - 15 T cells 
• de n dr i ! IC ce lls .. BC Ll lysate ... T cells 
Cl dendr l t lc c ells + BCLL lysate • IL 15 T cells 
Figure 37b: Effect of IL-15 pre-treatment upon T -cell proliferation (IL-
2R expression) after stimulation by B-CLL lysate pulsed DC 
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Figun: 37a and b: Numbers of CDJ/CD25 positive T-cells were measured from Patient 21 (Figure 37a) and 
Patient 22 (Figure 37b ). T -cells were cultured alone or pre-incubated with IL-15 ( I Ong/ml) for 16 hour and 
then cultured alone or with autologous 8 -CLL DCs pulsed with a soluble 8 -CLL lysate or lysis buffer. 
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5.6.2 IFN-y secretion by IL-15 pre-treated T cells 
A significant increase of IFN-y secretion in culture supernatant was found after 4 
days by T-cells cultured with B-CLL lysate-pulsed autologous DCs compared to both T-
cells cultured with lysis buffer-pulsed DCs and T-cells cultured alone (p=0.038) (Figure 
38). T-cells derived, from the same B-CLL patients, treated with IL-15 prior to culture with 
autologous DCs pulsed with B-cell lysate showed a significant increase in IFN-y secretion 
after I day (p=0.0/8)(Figure 38). More IFN-y was secreted by T-cells which had been IL-
15 treated and then cultured with B-CLL lysate-pulsed autologous DCs (p=0.030 )(Figure 
38). 
5.6.3 Cytotoxicity to B-CLL targets generated by T-cell effectors pre-treated with 
IL-15 
T-cells eo-cultured with B-CLL lysate pulsed DCs showed significantly higher 
levels of specific cytotoxicity to autologous B-CLL B cell targets when compared with DCs 
pulsed with lysis buffer (p=0.019)(Figure 39). T-cells, from the same B-CLL patients, pre-
treated with IL-15 prior to culture with autologous DCs pulsed with B-cell lysate also 
showed significantly higher levels of specific cytotoxicity to B-CLL B-cell targets 
(p=0.002)(Figure 39). T cells eo-cultured with autologous B-CLL lysate pulsed DCs 
showed significantly greater specific cytotoxicity against B-CLL B-cell targets when pre-
treated with IL-15 (p=0.006) (Figure 39). 
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Figure 38: Effect of IL-15 pre-treatment on IFN-y secretion by T-cell 
effectors stimulated by autologous B-CLL B-cell lysate pulsed DCs . 
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Figure 38: Tissue culture supematants from patient 21 and 23 were measured for secreted IFN-y by ELISA. 
T -cell s were cultured alone or pre-incubated with IL-15 ( I Ong/ml) for 16 hours and then eo-cultured for 21 
days. Mean values were <ested using unpaired Students' t-test. # indicates a significant (p=0.038) di fference 
between { (DC+Lysate)+ T} and I DC+ T }. * indicates a significant (p=0.0/8) di fference between 
I(DC+Lysate)+(T+fL-1 5)} and IDC+(T+IL-15)}." indicates a signi ficant (p=O.OJO) difference between 
I (DC+Lysate)+(T +IL-15)} and I (DC+Lysate)+ T } . Each treatment group per patient was measured in 
duplicate. 
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Figure 39: Effect of IL-15 pre-treatment on cytotoxicity ofT -cell effectors 
from B-CLL patients 
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Figure 39: Effectors from patients 5,6,and 7 were prc-incubated with IL-15 ( I Ong/ml) for 16 hours and then 
eo-cultured for 28 days and tested for cytotoxicity against autologous B-CLL B-cell targets. One measurement 
was made per patient per treatment. Data was analysed by one-way ANOV A. Overall significant effect of 
stimulation by lysate pulsed DCs (p=O.O 19). Overall significant effect of stimulation of fL-1 5 pre-incubated 
T -cells by lysate pulsed DCs (p=0.002). Overall significant effect of pre- incubation with IL-15 (p =0.006). 
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5.6.4. Effect of IL-15 pre-treatment on cytotoxicity to K562 cells 
IL-15 can induce Natural Killer (NK) cell development 12'~ 71 and increase cytotoxic 
activity of NK cells 12881. K562, an erythroleukemia cell line, are sensitive to NK cell 
mediated cytotoxic activity 12891. It was possible that the increase in cytotoxicity observed in 
Figure 39 was due to NK activity and not T-cell effectors. Therefore, pre-treated T-cell 
effectors were also tested for cytotoxicity against K562 cells. K562 T cells eo-cultured with 
B-CLL lysate pulsed DCs showed no specific cytotoxicity to K562 cell targets (Fig 40). IL-
15 pre-treated T cells eo-cultured with autologous B-CLL lysate pulsed DCs did not show 
significant cytotoxicity to K562 cell targets (Figure 40). T cells eo-cultured with autologous 
DCs pulsed with B-CLL B-cell lysate showed similar levels of cytotoxicity to K562 cell 
targets whether pre-treated with IL-15 or without cytokine (Figure 40). 
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Figure 40: Effect of IL-15 pre-treatment on cytotoxicity ofT -cell effectors 
from B-CLL patients against K562 ceUs. 
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Figure 40: Effectors from patient 7 were pre-incubated with ll.rl5 {IOng/ml) for 16 hours and then eo-cultured 
for 28 days and tested for cytotoxicity against KS62 cell targets. One measurement was made per treatment 
group 
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5.7 Fusion of DCs and B-CLL B cells 
5.7.1 Introduction 
The majority of effective anti-tumour responses generated are MHC class-I-
restricted, but data presented in this thesis suggests a predominant MHC class-II-restricted 
anti-tumour response in B-CLL. The generation of CD8+ cytolytic T-lymphocytes (CTL) as 
well as a CD4+ cytokine and cytotoxic anti-tumour response would be necessary for 
effective vaccination in patients with B-CLL. Priming of CTL by native antigens requires 
introduction into the cytoplasm 1290· 2911. A strategy that assures that antigens will be 
delivered and processed efficiently in a MHC class-I -restricted manner is to fuse APCs 
with tumour cells. Whole cell vaccines have been produced in this manner for several 
different tumours 1292· 293· 2941. Therefore fusion of monocyte derived DCs with autologous 
B-CLL B cells was attempted by electroporation in an effort to generate CD8+ CTL. 
Table 4: Summary of electrofusion efficiencies and yields 
Fusion method Number of viable Percentage fused Total fused cell 
cells cells yield 
Mixed not fused 4.3x 105 6.6% 2.8 X 104 
(control) 
250 V non- 3 X 10' 10.4 3.1 X 104 
separated 
250V separated on I X 104 50.5 5 X IO.i 
10% Dextran 
500V non- I X 105 45.0 4.5 X 104 
separated 
500V separated on 5 X 104 83.1 4.1 X 104 
10% Dextran 
Table 4: B-CLL B-cells from Patient 8 were electrofused using Gene Pulser Transfection Apparatus (Biorad). 
Viability counts were estimated by counting cells excluding Trypan Blue dye using haemocytometer 16 hours 
after voltage application. Percentage of cells fused were calculated from flow cytometry labelling with CD20-
RPE and CD86-FITC antibodies under stated conditions 16 hours after voltage application. 
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Figure 41: Flow cytometl'ic analysis of fused B-CLL and DCs 
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Figure 24 : Fused cells were labelled with CD20- RPE and CD86-FITC antibodies, as stated 
in Section 2.2, 16 hours after voltage application. 
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5.7.2. Results 
T-cell effectors from the same B-CLL patient were generated via two different 
approaches. Some were generated by eo-culture ofT-cells with B-CLL lysate pulsed DCs 
and others were generated by eo-culture ofT-cells with B-CLL dendritic ceii-B-cell fusion 
cells. T-cell effectors generated in these two different ways were then tested for cytotoxicity 
against autologous B-CLL B-cell targets as a direct comparison. As previously observed 
(Section 4.6), T -cell effectors cultured with lysate pulsed autologous DCs showed a 
significantly higher percentage specific cytotoxicity against B-CLL B-cell targets than T-
cell effectors cultured with autologous DCs pulsed with lysis buffer (p=0.037) (Figure 42). 
T-cell effectors cultured with autologous fused dendritic-ceii-B-cell hybrids showed a 
significantly higher percentage specific cytotoxicity against B-CLL B-cells than other T-cell 
effectors (p=0.0/6)(Figure 42). A direct comparison in the same B-CLL patient showed 
that autologous fused dendritic-ceii-B-cell hybrids were more effective at stimulating T-cell 
effectors with specific cytotoxicity against B-CLL B-cells than autologous DCs pulsed with 
B-CLL B-cell lysate (p=O.O 13) (Figure 42). 
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Figure 42: Cytotoxicity to B-CLL B-cells by T -cells generated by eo-
culture with fusion hybrids 
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Figure 42: Effectors from Patient 8 were cuJtured for 28 days and cytotoxicity against autologous B-CLL B 
cell targets at a 40: l ratio was measured. Data were analysed by unpaired Students' t-test. Where # indicates 
significant (p=0.037) increase in cytotoxicity due to puJsing DCs with lysate. Where " indicates significant 
(p=0.0/6) increase in cytotoxicity due to electrofusion of DCs with B-CLL B-cells rather than mixing the 2 
cell types. Where • indicates significant (p =O.OJ3) increase in cytotoxicity due to electrofusion ofDCs with B-
CLL cells rather than puJsing with lysate. Each treatment group was measured in duplicate. 
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Figure 43: Effect of monoclonal antibodies on cytotoxicity ofT -cell 
effectors stimulated by eo-culture with fusion hybrids. 
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Figure 43 : Effectors from Patient 8 were cultured for 28 days and cytotoxicity against autologous B-CLL B-
cell targets at a 40: 1 ratio was measured. Anti-human CD4 and anti-human CD8 antibodies ( 1 OOmg/ml) were 
added to effectors for 4 hours when incubated with targets. Data were analysed by unpaired Students' t-test, 
where • indicates significant (p=0.039) inhibition with anti-human CD4 antibodies of cytotoxicity stimulated 
by lysate pulsed DCs and # indicates significant (p=O.OJ8) inhibition with anti-human CD8 antibodies of 
cytotoxicity stimulated by electrofused DCs. Each treatment group was measured in duplicate. 
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Monoclonal antibodies against Human CD4 and CD8 were incubated with all the T 
cell effectors during the cytotoxicity assay incubation period. T-cell effectors stimulated by 
lysate pulsed autologous DCs showed a significant inhibition of specific cytotoxicity 
against B-CLL B-cell targets by human anti-CD4 antibodies (p=0.039) (Figure 43). T-cell 
effectors stimulated by autologous dendritic-ceii-B-cell hybrids showed a decrease in 
cytotoxicity against B-CLL B-cells of 14% when incubated with anti-human CD4 
antibodies (p=0.062)(Figure 43). Most importantly, T-cell effectors stimulated by 
autologous dendritic-ceii-B-cell hybrids showed a significant inhibition of cytotoxicity 
against B-CLL B-cells by anti-human CD8 antibodies (p=0.0/8) (Figure 43). 
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6. Results-Properties of Lysates 
At present there are no documented peptide sequences that could be responsible for 
the anti-tumour responses demonstrated. However, differences between B-cell lysates of 
normal healthy volunteers and B cells from B-CLL patients have previously been detected 
by 2-D electrophoresis 12951 . However, no functional tests have ever been performed to 
assess the importance of these B-CLL specific proteins. A quick method for identification 
of possible proteins within the lysate that could act as target anti-tumour antigens was 
required in order to perform functional tests using the in vitro dendritic cell system. 
6.1 Native PAGE 
A typical example of the native gel containing B-cell lysates from both B-CLL 
patients and normal healthy volunteers is illu~trated in Figure 44. A single dominant band at 
between 116 kDa and 97 kDa were observed 1n all the lysates. Additional fainter bands 
were seen in both lysates from B-CLL patients and 'lormal healthy volunteers. There was 
not a clearly visible difference between lysates generated from B-CLL patients and normal 
healthy volunteers. Any differences observed using non-reduced geb was dependant upon 
the amount of protein contained within the lysate loaded onto each gel. 
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Figure 44: Native gel of B-celllysates from B-CLL patients and normal 
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Figure 44: Lysates were assayed for protein content as stated in section 2.9. Samples were loaded onto a 
nati ve gel and stained according to section 2. 19. 
6.2 SOS-PAGE 
It should be noted from Figure 45a that all the B cell lysate had an obvious protein 
visible at the 65 kDa molecular weight. Many more protein bands were observed in the 
protein lysates from B-CLL patients where the same total protein had been loaded onto the 
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reducing gel as the B cell lysate from a control healthy volunteer (Lanes 3, 4, 13, 14 vs. 
Lane 9, 16, 18). Proteins were detected in some patients that were not observed in all of 
them (Lanes 5 and 7). We have not correlated these patient specific bands with stage or 
cyto-genetics. 
Figure 45a: SDS-PAGE ofB-celllysates from B-CLL patients and normal bealtby volunteers 
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Figure 45a: Lysates were assayed for protein content as stated in section 2.9. Samples were loaded onto a 
reducing gel and stained according to section 2.18. 
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Figure 45b: SOS-PAGE of 8-celllysates from 8-CLL patients and 
normal healthy volunteers 
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Figure 45b: Lysate were a sayed for protein content a stated in section 2.9. Samples were 
loaded onto a non-reducing gel and stained according to section 2. 18. 
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When 50 J.1g ofB-celllysate from B-CLL patients was loaded onto the gel a 42 kDa 
band not seen in the B cell lysate from a healthy volunteer was observed. This observation 
was made in I 0 B-CLL patients and 5 normal controls as summarised in Figure 46a. 
However, when I OOug was loaded onto the gels a faint 42 kDa protein could be observed in 
the lysate from l healthy volunteer's B-cells (Figure 45b). Therefore the lysates loaded at 
lOOJ.1g were analysed separately as summarised in Figure 46b. In order to draw a direct 
comparison between these lysates a series of dilutions of both lysates from B-CLL patients 
and normal healthy controls was performed (Figure 47). This was because the protein 
estimates may have been incorrect. The difference in expression of this B-CLL specific 
band may have been due to less total protein being added in the B-cell lysates from healthy 
volunteers. Figure 47 illustrates that at comparable total protein concentrations the 42 kDa 
protein band is clearly more highly expressed within the B-cell lysate from a B-CLL patient 
than a healthy volunteer. A band of less intensity was also observed at 25 kDa in most B-
CLL patients (Figure 46a and 46b ). We chose to test the functional capability of the 65 
kDa, 42kDa and 25kDa bands present in all the B-CLL lysates by pulsing these separated 
bands onto DCs. 
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Figure 46a: Comparison of digital optical densimetry profiles of B-cell 
lysates from B-CLL patients and healthy volunteers 
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Figure 46a: Cellly ates from I 0 8-CLL patients and 5 normal healthy vo lunteers were prepared as stated in 
Section 2.7. 501Jg was loaded into each well and analysed by SOS-PAGE as described in Section 2. 18. Gel. 
were scanned using Kodak image proces ing oftware and net band inten ity was measured. 
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Figure 46b: Comparison of digital optical densimetry profiles of B-cell 
lysates from B-CLL patients and healthy volunteers 
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Figure 46a: Cell lysates from 6 B-CLL patients and I normal healthy volunteers were prepared as stated in 
Section 2.7. IOO~g was loaded into each well and analysed by SOS-PAGE as de cri bed in Section 2. 18. Gels 
were canned using Kodak image processing software and net band intensity was measured. 
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Figure 47: SOS-PAGE of various dilutions of B-celllysate from healthy 
volunteer and B-CLL patient 
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1- I OO!Jg Molecular weight tandard 
2-751Jg normal 8-celllysate (3 17.250) 
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Figure 47: Lysate. were assayed for protein content as stated in sec tion 2.9. Samples were loaJed onto a non-
reducing gel and stained accordi ng to cction 2. 18. Italic numbers in brackets depi<.: t total net imcn ity 
read ing for each lane. 
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6.3 lmmunogenicity of individual protein bands. 
In 5 B-CLL patients, B-celllysates were isolated as stated in Section 2.8 whilst DCs 
were cultured according to Section 2.5. Individual protein bands were extracted from the 
polyacrylamide gel by electro-elution as stated in Section 2.21. Proteins were pulsed onto 
DCs and then eo-cultured with T-cclls as the lysates had done previously. IFN-y secretion 
and cytotoxicity against autologous B-cell targets were compared for the 65kD, 42kD, 
25kD and whole lysate. 
As previously illustrated in Figure 21 a, whole B-cell lysate from B-CLL patients 
when pulsed onto autologous DCs after 3 days eo-culture with autologous T-cells produced 
a significant increase in IFN-y secretion (p=0.0/98) (Figure 48). Both 65kD (p=0.0025) and 
42kD (p=0.0/25) band, when pulsed onto autologous DCs, stimulated autologous T-cells to 
produce increased levels of IFN-y. The 65 kDa protein band was more effective at 
stimulating the secretion of IFN-y than the 42kD band or whole B-cell lysate. 
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Figure 48: Effect of individual protein bands upon IFN-y secretion by T-
cells from B-CLL patients. 
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Figure 48: lFN"'Y was measured by ELlS A from Patients' 25,29,30,31 ,32. Overall effect of 
treatment was measured by on~way ANOV A(*) indicates significant increase (p=0.0/98) in IFN-r 
secretion by T -cells cultured with DCs pulsed with whole lysate compared with those cultured with 
DCs pulsed with lysis buffer. (") indicates significant (p=0.0025) increase in IFN-y secretion by T-
cells cultured with DCs pulsed with 65k.D band compared with those cultured with DCs pulsed with 
lysis buffer. ($)indicates significant (p=O. 0 I 25) increase in IFN-y secretion by T -cells cultured with 
DCs pulsed with 42kD band compared with those cultured with DCs pulsed with lysis buffer. 
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As previously illustrated in Figure 23a, whole B-cell lysate from B-CLL patients 
when pulsed onto autologous DCs and eo-cultured with autologous T-cells generated T-ccll 
effectors with increased cytotoxicity, at the effector: target ratio of 40: I, against autologous 
B-cells (p=0.008). Dendritic cells pulsed with the purified 65kDa (p=0.0/4) or 42 kDa 
(p=0.005) protein band generated T-cell effectors with significantly increased cytotoxicity 
at the 40: I effector: target ratio against autologous B-cells (Figure 49). At the lower 
effector: target ratio's of 10: I and 20: I the 42kDa band pulsed onto autologous DCs 
generated T-cell effectors with greater cytotoxicity against autologous B-CLL B-cell 
targets. Therefore, it was possible that the 42 kDa band contained the antigen responsible 
for stimulating a cytotoxic T-cell response. The purified protein band of molecular weight 
25 kDa did not stimulate significant increases in either IFN-y secretion or cytotoxicity 
against autologous B-CLL B-cell targets. The 25 kDa protein band was not sent to be 
sequenced in order to save valuable resources. 
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Figure 49: Stimulation of cytotoxicity against B-cells by T -cell effectors 
fr·om B-CLL patients by different protein bands pulsed onto DCs 
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Figure 49: T -cell effectors were generated by 28 day!> culture from Patient ' 25,29,30.3 1 ,32. 
Overall effect of treatment was mea ured by one-way ANOVA. (*)indicates significant (p=0.008) 
increa e in cytotoxicity by T-cells cultured with DCs pul ed with whole ly ate compared with those 
cultured wi th DCs pu lsed with lysis buffer. (") indicates significant (p=0.0 /4)increase in 
cytotoxicity by T -cells cultured with DCs pulsed with 65kD band compared with those cultu red 
with DC pul ed with lysis buffer. (S)indicate · significant (p=0.005) increase in cytotoxici ty by T-
ce lls cultured with DCs pulsed with 42kD band compared with tho e cultured wi th DCs pul. ed 
wi th ly i buffer. 
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6.4 Western blot analysis of SOS-PAGE 
There were two protein bands of particular interest that needed identification. One 
approach was to choose proteins with corresponding molecular weights of 65kDa and 42 
kDa that were known to be over-expressed in B-CLL patients. Western blot analysis would 
then confirm whether these proteins were a possible target antigen. 
6.4.1 CDI9 
CD 19 is a 95 kDa transmembrane glycoprotein that contains two extracellular 
immunoglobulin domains 1296· 2971. CD 19 is selectively expressed on the cell surface of B-
lymphocytes, where it activates intracellular signalling cascades 129x1. Expression of CD 19 
is continuous throughout B-cell development and through terminal differentiation of B-cells 
into plasma cells 12991. CD 19 forms functional complexes with B-lymphocytes surface 
proteins, including Integrin pI, CD21 and CD81. As such it would provide a good control 
marker to differentiate B-lyrnphocytes from T-lyrnphocytes. CD 19-dynabeads had been 
used in all the purification steps and so it was a good idea to investigate whether either of 
the two bands were merely an artefact due to the method of B-cell separation. Decreased 
CD 19 expression on the cell surface of B-cells from B-CLL patients has been reported 13001 . 
Figure 50 shows that in Lanes 5 and 8 two protein bands reactive to anti-human CD 19 at 
approximately 64kDa and 31 kDa were detected. No reactive bands were detected in Lane 7 
(containing T-cell lysate) despite plenty of protein bands being detected by Ponceau S 
staining. There was a decreased detection signal from B-CLL B cells than those from 
healthy volunteers. 
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Figure 50: Western blot of various cell lysate using affinity-purified 
polyclonal goat anti-human CD19 
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5- I OO~tg B-cell lysate rrom healthy volunteer I 
Figure 50: Lysates were run on a 4-15% Tris-HCL polyacrylamide gel under reducing conditions. Gel 
was lcfl unstained and elcctro-bloued onto nitro-cellulose. Protein hands were stained with Ponceau S 
and marked in pencil. Primary antibody goat-anti-human CD 19 (I :500) was added for I hour. 
Secondary antibody donkey anti-goat alkaline phosphatase conjugate (I: I 000) was added ror I hour. 
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6.4.2 cos 
COS is a 67k0a transmembrane glycoprotein expressed on virtually all T-
lymphocytes, some thymocytes and 8-cells 1' 1. lt resembles C06, as both share a common 
structure of 3 scavenger receptor cysteine-rich domains and similar tissue distribution 13011 . 
COS is associated with T-cell signalling through the TCR/C03 complex 13021. A B-cell 
antigen known as C072 is the ligand for COS 13031. COS expression has been found upon B-
cells from B-CLL patients 13041. Cross-linking of COS with antibodies has induced 
apoptosis of 8-cells from 8-CLL patients 13051. Therefore, it was considered a prime 
candidate as a protein not expressed in normal 8-cells but that may have attributed to the 
immunogenicity of the 65kDa and in the 8-cell lysate. Samples that showed the clearest 
detection of COS were those loaded with I OOJ..ig of total protein. COS was detected as 2 
bands of approximately 50k0a and 30k0a in lysates from 8-cells from both 8-CLL patients 
and normal healthy volunteers (Figure 51, Lanes 5 and 8). In T-cell lysates from both 
normal healthy volunteers and B-CLL patients (Figure 51, Lanes 2 and 7) the 31 kOa band 
was detected alone. This may well be a consequence of different glycosylation or different 
disulphide bonds of the protein subunits. 
147 
Figure 51: Western blot of various cell lysate using affinity-purified 
polyclonal goat anti-human CDS 
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Figure 51: Lysatcs were run on a 4-15'7t- Tris-HCL polyacrylamide gel under reducing conditions_ Gel 
was left unstained and clectro-blotted onto nitro-cellulose. Protein bands were stained with Ponceau S 
and marked in Pencil. Primary antibody goat-anti-human CD5 (I :500) was added for I hour_ 
Secondary antihody donkey anti-goat alkaline phosphatase conjugate (I: I 000) was added for I hour-
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46.4.3 C072 
C072 is the 45 kOa human homologue of murine Lyb-2 1·1061. C072 is a ligand for 
COS expressed upon both normal 8-cells and leukaemia 8-cells regardless of COS eo-
expression 13071. The COS-C072 ligand pair may be involved in an autostimulatory loop 
that may play a role in replenishment of all types of 8-cell13081. C072 was highlighted as a 
possible target antigen for cytotoxicity against B-CLL 8-cells 1·1091. Interestingly the rabbit 
anti- human, rat, mouse, C072 antibody only detected a protein band at approximately 
60k0a in T-cell lysates from normal healthy volunteers (Figure 52). This result was 
disappointing. Even when I OO~g of lysate was, added to another gel and, blotted with the 
same combination of antibodies, C072 was still not detected in B-cells. Primary and 
secondary antibody concentrations were increased and C072 was still not detected in 8 
cells from either normal healthy volunte~rs or 8-CLL patients. 
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Figure 52: Western blot of various cell lysate using affinity-purified 
polyclonal rabbit anti-human, rat, mouse CD72 
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Figure 52: Ly~ate~ v.ere run on a 4- 1 5 <;~ Tris-HCL polyacrylamide gel under reducing conditions. Gel wa\ left 
unstained and electro-blottcc.l onto nitro-ce ll ulose. Protein hand~ were stained with Ponceau S and markec.l in 
Pencil. Primary antibody rabbit-ant i-human, rat , mouse CD72 ( I :500) was adc.led for I hour. Secondary 
ant ibody mou~e anti-rabbit alkaline phosphata~c conjugate ( I : I 000) wa\ added for I hour. 
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6.4.4 CD23 
CD23 is a 45 k.Da type II integral membrane glycoprotein expressed on mature B-
cells, monocytes, eosinophils, platelets and DCs ' 3101. Soluble forms ofCD23 are increased 
in serum ofB-CLL patients ' 3111 and soluble CD23 may be an even stronger clinical marker 
than clinical stage ' 3 ' 21. However, CD23 expression on freshly isolated B-CLL cells was 
transient but was restored by cytokines secreted from activated T -cells such as IL-2, IFN-y, 
TNF-a and IL-4 ' 3131. CD23 was therefore an ideal candidate for our protein of interest seen 
at approximately 42k.Da. However, CD23 was only detected in T -cell lysates from a B-CLL 
patient (Figure 53). This result was disappointing. Even when IOOJ..lg of lysate, was added 
to another gel and, blotted with the same combination of antibodies, CD23 was still only 
detected in T -cell lysates from a B-CLL patient. Primary and secondary antibody 
concentrations were increased and CD23 was still only detected in T -cell lysates from 
normal healthy volunteers. 
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Figure 53: Western blot of various cell lysate using affinity-purified 
polyclonal goat anti-human CD23 
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Figure 45: Lysates were run on a 4-15% Tris-HCL polyacrylamide gel under reducing conditions. Gel was left 
unstained and electro-blotted onto nitro-cellulose. Protein bands were stained with Ponceau S and marked in 
Pencil. Primary antibody goat-anti-human CD23 (1 :SOO) was added for 1 hour. Secondary antibody donkey 
anti-goat alkaline phosphatase conjugate ( l : l 000) was added for l hour. 
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6.4.5 CD38 
CD38 is a 45kDa type 11 integral membrane glycoprotein expressed on early and activated T 
and B cells 13141. CD38 is also found on monocytes and thymocytes 13151 . Expression of 
CD38 by B-cells from B-CLL patients is co1Telated to poor survival and poor prognosis 
1
316
·
3171
. A strong protein band was detected at approximately 60 kDa by the mouse 
monoclonal anti-human CD38 antibody in the lanes loaded with I OOJ..lg of lysate from B 
and T-cells from B-CLL patient 26 and normal B-cells (Figure 54, Lanes 3,4 and 6). 
Interestingly, the detection of CD38 was strongest in the lane containing 50J..lg of B-cell 
lysate from B-CLL patient I 0. There was no band detected by the anti-human CD38 
antibody in the lane containing 50 J..lg B-cell lysate from B-CLL patient. This reflects the 
heterogeneity observed with CD38 expression in B-CLL patients. 
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Figure 54: Western blot of various cell lysate using mouse monoclonal 
anti-human CD38 
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Figure 54: Lysatcs were run on a 4- ISik Tri~-HCL polyacrylamide gel under reducing conditions. 
Gel was left unstained and e le~.:lro-blol!ed onlo nitro-cellulose. Protein bands were stained with 
Ponccau S and marked in Pencil. Primary antibody mouse monoclonal ami-human CD38 ( I :500) 
was added for I hour. Secondary antibody rabbit anti-mouse alkaline phosphata~c conjugate 
( I : I 000) was added for I hour. 
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6.5 Protein seguencing 
The 65kDa band and the 42 kDa band from the B-cell lysate of B-CLL patient and 
65 kDa band from a normal healthy volunteer were separated by reducing SOS-PAGE 
and electro-blotted onto PVDF membrane. Proteins immobilised on the membrane were 
sent to Protein and Nucleic Acid Chemistry, University of Leicester, UK, and Proseq, 
Boxford, Massachusettes, USA, for sequencing. Results were generated from the 42kDa 
band from B-CLL patient and 65 kDa from normal healthy volunteers. However, the 
65kDa from B-CLL patients did not yield any sequence data. The 65kDa band from 
normal healthy individuals yielded a sequence 35 amino acids long as shown in Figure 55 
by N-terminal sequencing using an ABI 476 protein sequencer. A BLAST protein 
database search was carried out using the NCBI website 13181. The 35 amino acid peptide 
showed a strong homology to Human Serum Albumin as shown in Figure 55. The 42kDa 
band from B-CLL patients was an N-blocked protein. An in situ CNBr digestion revealed 
2 strong signals and 4 weaker signals. 0-phthalaldehyde (OPA) was added to the digest. 
This chemically selected the proline residue from the peptide mixture 11191. Peptides were 
then sequenced. Two strong peptide signals of 20 amino acids and 19 and one weaker 
peptide signal of 19 amino acids showed homology with Human actin (Figure 56). 
However, the remaining weak signal revealed a peptide of 13 amino acids to which no 
match could be found in the databases. Even when protein amino acid data was translated 
to nucleic acid sequence a corresponding match could not be found. 
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Figure 55: Sequence data from 65kDa band of B-celllysate from 
normal healthy volunteer 
Normal healthy volunteer 65kDa band.- 14 matches 
I) Human Serum albumin precursor 97% 
2) Bovine Serum albumin precursor 82% 
3) Sheep Serum albumin precursor 80% 
4) macmu Serum albumin precursor 82% 
5) Rat Serum albumin precursor 77% 
6) Horse Serum albumin precursor 74% 
7) Felca Serum albumin precursor 7 1% 
8) Pig Serum albumin precursor 77% 
9) Canfa Serum albumin precursor 68% 
I 0) Mouse Serum albumin precursor 70% 
I I) Rabbit Serum albumin precursor 68% 
12) Merun Serum albumin precursor 69% 
13) Chick Serum albumin precursor 65% 
14)TRASC 67 KD Serum albumin (alb-1 ) 60% 
I) Aligned with HUMAN Serum alburnin precursor 
DAHKSEVAHRFKDLGEENFKALYLIAFAQILQQCP 
25 DAHKSEVAHRFKDLGEENFKALVLIAFAQILQQCP "tJ 
4) Aligned with MACMU Serum albumin precursor 
DIHKSEYAHRFKDLGEENFKI LVt.IAFIQ LQQCP 
I/ DIHKSEVAHRFKDLGEEHFKILVtiAFIQ QQCP 'i l 
8) Aligned with PIG Serum albumin precursor 
LQQCP 
LQQCP "'' 
Figure 55: Li ted above are sequences showing homology from blast search of non-redundant 
Swissprot sequences. Percentages represent identical amino acids to tc~ t sequence. Below arc 
shown examples of alignments . Sequence generated from blot is shown in blue. Red number~ 
give residue number from amino terminus. Green highlights amino acids not matching sequence 
data. 
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Figure 56: Sequence data from 42kDa band of B-celllysate B-CLL 
patient 
42 kDa from B-CLL patient aligned with Human Actin 
I) Strong signal (52%) 
E I L 11 APPERKTYSVVPEIVR 
320 I I I APPE~YS 3-+2 
2) Weak signal (30%, 79%) 
GTKDSYVDDEPXXXRGMLT 
11 
42 
3) Strong signal (53%) 
K TERGYSFY 
I X5 K RGYS 
4)Weak signal 
ARGGQV fXQLTXXXE IXXH 
20'1 
Figure 56: Above arc shown examples of alignments for 4 peptides generated by dige tion. 
Alignmem of sequence data and Genbank search (NCBI). Sequence genera1ed from blot is shown in 
blue. Red numbers give residue number from amino terminus. Green highlight amino acids not 
matching sequence data. Percentages represent identical residues. Unidentilied residue. are 
symbolised by (X). 
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7. Discussion 
7.1 Anti-Idiotype responses 
Chronic B-cell malignancies represent a potential target for immunotherapy by virtue 
of the fact that they are derived from immune cells and thus have the capacity for 
interaction with T lymphocytes. In addition, each tumour is derived from a clonal 
expansion of one malignant B-cell, and thus each cell in the clone will share specific 
determinants, for example those encoded by variable region sequences of rearranged 
immunoglobulin genes. Clinical studies in which patients with lymphoma and myeloma 
were vaccinated with idiotype protein have demonstrated the generation of anti-idiotypic 
T-cell responses and a degree of clinical response f3}(}.m. 139• 322.3131. An alternative 
approach has been to load DCs with idiotype protein and subsequently use the pulsed DCs 
as a form of immunotherapy. Such an approach has also been shown to induce anti-
idiotypic immune responses in lymphoma, rm. 325• 3261 and myeloma, fU/,3271 with some 
encouraging clinical results. Over-expression of surface IgM has been shown to possess 
possible prognostic significance in B-CLL patients£3281. A similar rationale can therefore be 
proposed for immunotherapy in B-CLL, and this study was designed to determine whether 
DCs loaded with B-CLL tumour protein could stimulate anti-B-CLL cell responses. 
7.2. Phenotype ofDCs 
Initial problems of generation of adequate numbers of DCs from patients with B-
CLL were overcome once the malignant B-cells were removed. These DCs were 
morphologically and numerically similar to those from healthy individuals. 
Immunophenotyping DCs generated from healthy individuals and patients with B-CLL 
demonstrated similar levels of expression of cell surface molecules, with the notable 
exception of CD40, which was increased, and CD86, which was decreased. A previous 
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study has demonstrated that dendritic cell generated from healthy individuals and patients 
with myeloma are phcnotypically and functionally similar. however this did not include 
CD40 1-'291. Although the significance of this tinding is unclear at present, CD40+ DCs have 
been found to be vital for the generation of anti-tumour responses in mice13301• 
Establishment ofT cell help via the CD40-CD40L interaction is essential for generation of 
antigen specific CD8+ T-cells 115~ 1 . Ligation with anti-CD40 antibodies can replace the 
need forT cell help f.IJII_ Stimulation of CD40 by increased expression of CD40-Iigand has 
been shown to stimulate immune recognition of B-CLL B-cells in l'il'o 1·1321 and in l'itro 
133
-'
1
. The decreased levels of cell surface CD86 in B-CLL patients differ significantly from 
the findings in myeloma patients and may be linked to the disease. Soluble CD86 
expression has been shown to be increased in serum from patients with AML and B-CLL 
Both normal DCs and B-CLL B-cells express an alternatively spliced form of CD86 that 
encoded for the soluble form 133-l/. Since CD86 has been shown to be a key eo-stimulatory 
molecule 13351 its decreased expression upon the DCs may well be related to the increase in 
soluble CD86 levels seen in B-CLL patients. 
7.3 Defect in B-CLL is T-cell dysfunction 
The functional capabilities of DCs from B-CLL patients' were compared with those 
of normal healthy volunteers. Firstly, Tuberculin PPD and Tetanus Toxin were pulsed onto 
DCs and the number of activated T-cells and IFN-y secretion was assessed. Numbers of 
activated T-cells were similar in both B-CLL patients' and normal healthy volunteers 
(Figure 16a and 16b). However, secretion of IFN-y in response to antigen pulsed DCs was 
decreased in the B-CLL patient compared with the normal healthy volunteer (Figure 17a 
and 17b). The intracellular expression of IFN-y by antigen activated T-cells in B-CLL 
patients has been shown to be significantly reduced and correlated to disease stage 13361• 
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However, IFN-y secretion from un-stimulated T-cells from B-CLL patients has been shown 
to be significantly higher (S.Scrivener unpublished observation) This may have a complex 
role, as changes in the proteasome are triggered by IFN-y 12·~ 1 . It is therefore possible that 
the presentation of tumour related MHC class I antigens has been altered in B-CLL 
patients. However, untreated T lymphocytes from B-CLL patients still release IFN-y in 
response to exogenous IL-2 13371. When the DCs ability to stimulate normal T-cells in the 
allogeneic culture system (Figure 18) was investigated, it was seen that the lower T-cell 
cytotoxicity levels were due toT-cell dysfunction in B-CLL patients. B-CLL patients have 
long been known to exhibit reduced T-cell helper function 13381 and increased suppressor 
function 13391. The use of adoptive transfer has demonstrated that T-cells from early stage 
B-CLL patients inhibit the accumulation of malignant cells whereas in patients with late 
stage disease the T-cells could enhance the effects of the malignant B-ceiJ 1·NuJ. 
7.4 Activation ofT-cells by lysate pulsed DCs 
There is a sub-population of peripheral human CD4+, CD25+ known to have 
regulatory properties 13411. However, these cells do not produce IL-2, IL-4 or IFN-y. It is 
possible that the appearance of CD25+ CD3+ cells in our cultures in response to lysate 
pulsed DCs represent the stimulation of this regulatory subset. It seems unlikely as the 
same cultures secrete IFN-y and the appearance of CD3+, CD25+ cells was validated by 
recall responses to Tetanus Toxin and Tuberculin PPD in both healthy volunteers and B-
CLL patients. This regulatory T-cell sub-population also express CD45RO, HLA-DR and 
CTLA-4 (CD 152). T-cells isolated from the blood of B-CLL patients and stimulated with 
OKT3 showed reduced expression of CD25 and CTLA-4 (CD 152) 12551. It seems unlikely 
therefore that the regulatory sub-population of CD4+ cells is the same population of 
dysfunctional T-cells observed in B-CLL patients. 
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7.5 T helper I response 
Resulls from Chapter 3 demonstrate that patient derived DC~, when pulsed with 
soluble 8-CLL lysate, stimulate autologous T-cells to secrete IFN-y but not IL-4. This 
suggests that our culture system has primed aT helper I. Antigen presenting cells, such as 
DCs, have the capacity to generate either a T helper I or a T helper 2 immune response 
13
.n1. T helper I responses are associated with the secretion of particular cytokines such as 
IFN-y and IL-12 /J431, and induce cell-mediated immunity, all of which are particularly 
important in the response against tumours. The levels of IFN-y observed in this study are 
similar to those generated by superantigen-pulsed DCs cultured with T-cells 13441 but are 
higher than those generated by CD40L-stimulated 8-CLL 8-cells cultured with autologous 
T-cells 13451 However, we have no evidence to suggest which cell type within the pulsed 
dendritic ceii-T-cell eo-culture is responsible for the production of IFN-y. Immature resting 
DCs express relatively few CD80 and CD86 molecules. These molecules are up-regulated 
after contact with T-cells 13461. Contact with T-cells allows the establishment of CD40-
CD40L interaction 1111· 3471 • CD40 up-regulates CD80 and CD86 and induces the p75 
component of IL-12 1· 34111 . fL-12 has been shown to be a stimulator of IFN-y production in 
T-cells 13491 . However, IL-12 can also stimulate macrophages and DCs to produce IFN-
y f.UOJ_ T -cells of CD 57+ /CD28. phenotype have been observed to be significantly 
increased in 8-CLL patients and responsible for the secretion of IL-2, IFN-y and TNF-a in 
response to anti-CD3 stimulation '3511. lt is equally possible therefore that either 
CD 57' /CD28. T-cells or DCs or both are responsible for the increase in IFN-y secretion in 
response to stimulation by lysate pulsed DCs. 
7.6 Role of IL-12 in preparation of DCs 
Studies have shown that IL-12 polarises DCs towards the induction of T helper 
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responses 1351· 353· 3541. Pre-treatment of munne DCs with IL-12 was shown to elicit 
responses to relatively un-reactive tumour/self peptides, 13·'51 . In view of this, we pre-
incubated the DC with IL-12 just prior to the addition of antigen. Recently IL-12 
responsiveness has been demonstrated in human monocyte derived DCs 13561. One 
preliminary experiment showed that without pre-treatment with IL-12, monocyte derived 
DCs pulsed with B-CLL lysate could not stimulate significant T cell responses. Therefore, 
all the experiments were carried out with an IL-12 pre-treatment before lysate was pulsed 
onto DCs. IL-12 could possibly reverse the effects of cytokines such as IL-l 0 and TGF-P 
which may have been encountered by the DCs from B-CLL patients. Dendritic cells do 
respond differently to the same stimuli because of previous exposure to cytokines and 
• (?52/ 
maturatiOn agents · · . 
7.7 Immunosuppression in leukaemia 
T helper type 2 responses are associated with the secretion of cytokines such as IL-4 
and IL-l 0 13571. Tumours have been shown to secrete factors such as IL-l 0 1358·359· 360· 361 · 362· 
3631
, transforming growth factor-P (TGF-P) 13MJ and vascular endothelial growth factor 
(VEGF) 13651, which suppress dendritic cell and/or T-cell function. Immature DCs treated 
with IL-l 0 have been shown to induce anergy in melanoma antigen specific CD8+ cytotoxic 
T-cells in vitro f.l.illl_ IL-l 0 may modulate immune escape by two different mechanisms; 
anti-tumour antigens presented by IL-10 modulated immature DCs, with low eo-
stimulation markers, induce anergic anti-tumour specific T-cells and immature IL-l 0 
modulated DCs induce regulatory T-cells which maintain the anergic nature of the anti-
tumour specific T-cells 13M 1. However, the effect of IL-10 may be more complex as in vitro 
IL-10 can inhibit the proliferation of B-cells from B-CLL patients 13671 . Clinical responses 
to dendritic cell vaccines have been affected by the cytokine profile of the individual 
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patient 13681. TGF-~ is perhaps the most potent immunosuppressive factor f.I(JY/. TGF-~ can 
inhibit the production of lL- 12 by monocytes 13711 3711 . TGF-~ may also inhibit important 
cell surface receptors important for ce ll acti vation and growth 13721. TGF-~ is a potent 
inh ibitor of cytotoxic T-ce ll differentiation 1370·3731. Admin istration of TGF-~ in vi i'O can 
inhibit T-cell responses to vi ruses and allogeneic antigens 13731. However, TGF-~ is also a 
potent inhibitor of proli feration of neoplastic cell s i11 vitro, its effects in vivo may depend 
upon microenvironment 137-11. In the majority of B-CLL patients TGF-~ inhibits in vitro B-
cell proliferation but loss of responsiveness i demonstrated in a ubset of patient 13751. 
VEGF is mainly recognised by its angiogenic propertie . VEGF inhibits the differenti ation 
of CD34+ cells into DCs '3651. B-cells from B-CLL patients have shown to secrete both 
TGF-~ r3761 and VEGF f377J. The T-cells used in our experiments were derived from 
patients with B-CLL and thus were exposed in vivo to immunosuppressive factors secreted 
by the B-CLL cells. 
7.8 Role of IL-15 and reversal of T cell anergy 
TGF- ~ secreted from tumour cell s has been shown to suppress T-cells response to 
IL-2 fJ781 by blocking Signal Tran ducers and Acti vators of Transcription (STAT3) and 
STAT5 phosphorylation 1379·3801. IL-15 has been shown to maintain STAT3 and STAT5 
phosphorylation despite TGF-~ secreted by multiple myeloma cell s 12861. [L-15 may restore 
signalling of T cell. , affected by ill vivo exposure to inhibitory fac tors such as TGF-
~ . through STAT3 and STAT5 phosphorylation. T-cells isolated from B-CLL patients may 
be exposed to B-CLL specific antigens without eo-stimulatory signals and induced into an 
anergic phenotype in vivo. Analysis of T-cell receptor B vari able (TCRBV) genes, in 
patients' with B-CLL, has showed skewing of the T-cell population 1255·381 1. IL-1 5 may 
revert T-cells from an anergic phenotype and result in an increased response to tumour 
163 
revert T-cells from an anergic phenotype and result in an increased response to tumour 
antigens presented by autologous DCs. IL-15 is capable of selectively activating primed T-
cells and naive CD8+ cells but not naive CD4+ cells ' 3821. IL-15 has also been shown to 
enhance responses of yo T -cells to non-peptide antigens ' 3831. Therefore, the administration 
of IL-15, to T-cells from B-CLL patients, may enhance the survival of an adilitional 
population ofT -cells responsive to the same or other antigens presented by the autologous 
tumour cell lysate-pulsed DCs. Further characterisation of the responding T -cell phenotype 
in IL-15 treated and untreated T -cells from B-CLL patients is required. 
As well as its effects upon T -cells, IL-15 promotes differentiation and growth of B 
cells ' 3841. lL-15 has been shown to promote growth of B-CLL cells via the IL-2 receptor f3 
and y chain ' 3851. However, it is not likely that activated B-CLL cells are responsible for the 
increased T -cell responses observed, as separation methods sought to remove all CD 19+ 
cells from the dendritic cell-T-cell eo-culture. IL-15 can also induce monocyte derived 
DCs to become mature cells resembling those generated with TNF-a. '3861. The pre-
treatment ofT cells with IL-15 and subsequent culture with autologous immature DCs may 
increase measurable T-cell responses by an indirect effect upon dendritic cell maturation. 
Treatment ofT-cells with IL-15 can stimulate IL-5 ' 3871, IFN-y and TNF-a. '3881 secretion 
that induces dendritic cell maturation. An increase in the stimulatory capacity of the DCs 
would then increase the magnitude ofT-cell responses. However, in this study induction of 
CD83 expression within the dendritic cell population did not increase total specific 
cytotoxicity levels to the same extent as that seen with T-cell pre-treatment with IL-15. 
7.9 Class ll restricted killing ofB-CLL cells 
An abnormally high number of CD8 positive T cells with a cytotoxic cell surface 
164 
demonstrated fNI!J. Triggering B-CLL B-cells wi th a CD40L-tran. fected 3T6 cell line 
stimulated allogeneic T-celb from B-CLL patients to make proliferative and cytotox ic 
responses 13331. However, untreated B-CLL ce lls are not capable of stimulati ng similar 
results '3911. B-CLL B cells stimulated by CD40L when cultured with allogeneic T ce lls 
from B-CLL patients demonstrated CD8+ cytolytic T cell responses. Whereas, when B-
CLL B cell s stimulated by CD40L were cultured with autologous T cells from B-CLL 
patients CD4+ medi ated release of IFN-y was observed 13" 51 . The capacity for B-CLL B 
cells to appear more antigenic to B-CLL patient T-cells was linked to an upregulation of 
CD80 and CD86 on the B-CLL B cell surface. T-cel l abnormalities such as the oligoclonal 
I monoclonal expansions of CD4+ TCRBY subsets that have been observed '392·2561 may 
reflect previous attempts in vivo ofT cells to recognise tumour cells {3931. Antigen-non-
specific act ivated CD4+ T cells have the potential to inhibit the proli ferative response of B-
CLL B-cells JJ941. Spontaneously occu1Ting T lymphocytes in B-CLL patients have been 
iso lated that were capable of responding to CD40L acti vated B-CLL B cell s "'291. However, 
in al l of these experiments increased T cell signalling via CD80 and CD86 is required to 
generate an adequate measurable T cell response. Therefore, presentation of B-CLL 
antigens in the correct contex t of eo-stimulatory molecules is required by T-cells from B-
CLL patients in order to make an anti -tumour response. 
Although the levels of specific cytotoxicity (24%), generated in our cultures at an 
effector: target rati o of 40: I, seem low when compared to those of other in vitro studies 
{ 'P 2 1' 'l'i 216 IO 'i J I'll 19~ 2 17 2 1~ 197 198 
-· • • • ~ . - · • • • • • 7 • , they are comparable to levels shown by other -· · · ''· · · ·' · · · · · 
399
' . These di ffere nces could be due in part to the fact that different diseases were studied. 
However, in a study of B-CLL, similar levels of specific cytotoxicity were generated when 
CD40L stimulated B-CLL cells were cultured with allogeneic T-cells but not autologous T-
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cells 13-151 . Of particular interest was the nature of the re~ponding ce ll popu lation. The 
responding ce lb in two patients were predominantly CD4"'. Anti body blocking experimcnb 
in the three patients tested demonstrated significant. inhibition of cytotoxicity wi th anti-
clas 11, anti-pan TCR a~ and anti-CD4 but not with anti-class I or anti-COS monoclonal 
an tibod ies. Overall thi s sugge ts that CD4+ HLA class n restric ted cytotox ic T-cells are 
responsible for the majori ty of lysis of B-CLL cell s in our culture system. MHC Class Il-
restricted cytotox icity results from exogenous antigen processed and presented by DC via 
the classical MHC class 11 pathway (Figure 7). HLA class rr molecules are only expressed 
on antigen presenting cells such a B ce lls. 14001. Some tumour cells such as metastatic 
melanoma express MHC class Il. Hyper-expression of MHC class n molecules can be a 
triggering factor for autoimmune diseases 1401/. Class II restricted cytotox ic T cells form a 
major part of anti-viral responses to herpes simplex vi rus and measles f-IO:!. 4031. As B-CLL 
is a malignancy of B cells it may be that the MHC class ll molecule. are highly expressed 
on the B-CLL B cell surface and thi s is why a MHC class 11-rest.ricted response is 
generated. However, if thi s were the sole reason, other B cell malignancies would show 
similar MHC cla ll-restriction. 
In general, it is thought that CD8+; classes I restricted T-cells are responsible for 
anti-tumour immunity 1236· 238· 39/i. <~0-1/. However, CD4+ cytotoxic T-cell have been reported 
in hepatocellular carcinoma f-I05J and p21-ras ( 12Val) mutated cells 14061. CD4+ T ce lls 
which secreted IFN-y were shown to eliminate UV light-induced tumour 6 132A-PRO by 
indirect cell killing mechanisms in a mou ·e model. In an imal tumour systems, transfection 
of MHC class U molecules into the tumour cell resulted in rejecti on whereas transfection 
with MHC class I had no effect f-IOl/. MHC class IT-restricted CD4 + T cells have been 
isolated against tumour antigens such as tyrosinase, MART- 1/Melan-A, gpiOO, MAGE-3, 
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YESO-I/CAG3 which have all prev iously been presented by MHC c las~ I molecules 140"~. 
1 ormally cytotoxic CD4+ T-cells represent 1-6% of the CD4+ T-cell population f-IIJYf. CD4T 
T -cel ls wi th an anergic cytotox ic phenotype have been expanded from PBMC of B-CLL 
patients 14111· mr. Therefore, the stimulation of cytotox icity against auto logous B-CLL B-
cel ls by ly ate pulsed DCs may be a result of the acti vation of thi s anergic population ofT-
cells. However, B-CLL patients with decreased the numbers of CD4+ T-cells due to recem 
therapy w ith fludarabine 14121, may not exhibit a specific cytotox ic response in our culture 
system. 
7. I 0 Maturity of DCs 
However, the levels of cytotox icity (Figure 23a) may have been because of the 
relatively immature state of the monocyte derived DC (CD83 negative) used to present 
lysate antigens ro the T-cells. CD83 shares its homology with the member of the IgG 
superfamil / 4 ' 31. CD83+ cel ls possess a distinct cel lular phenotype, cytokine gene 
expression profi le f.JI.JJ and greater stimulatory capacity 1"'' 51 compared wi th COST cel ls. 
After loading of antigen onto the dendritic cell surface a further 'danger signal' is required 
to achieve maximal presentation of that antigen to the T -cell 12731. M aturation agent 
therefore have been cytokine or bactetial products associated with infection such as LPS 
ft09.:!76 2771, IFN-a fll-1/' TNF-a fiiOI, Poly(I :C) /2751' CpG DNA f.Jt6f . 
Results in Chapter 5 i llustrate that the addition of TNF-a, Poly(I :C) and LPS to 
autologous DCs after pu lsi ng with B-CLL lysate does result in the emergence of CD83+ 
DC . However, the highest percentage of CD83+ DCs after addition of any maturation 
agent wa merely 12%. Higher CD83+ expression levels have been observed where the 
cel ls were cultured w ith 10% Fetal cal f serum 11101 or under serum free conditions f-1! 51 but 
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not when ce ll were cultured in medium containing 5% human AB ·erum f -li T/. Hence our 
leveb of CD83 expre. sion \ere probably limited by the presence of human AB serum in 
the culture. It could be argued that LPS and TNF-a. are required for longer incubation 
periods in order to induce CD83. This i. un l ikely, however, as the effects of TNF-a. 
( I Ong/ml), such as increased MHC class I and 11, ICAM-1, B7 and CD40 expression and 
down regulated Ii and FcyRll expression, have been observed after 24 hours f-Il l /. In 
contrast to LPS, TNF-a. and Poly (I:C), IFN-a. did not stimulate CD83 expression in our 
system . This is probably because maturation effects with IFN a. and ~require the presence 
of TNF-a. !2741 . 
The addition of TNF-a. ( I Ong/ml) or Poly(I :C) to monocyte derived DCs after 
pulsing with B-CLL lysate did not increase the level of specif ic cytotoxi city at the highest 
effector: target ratio. However, at lower effector: target ratios the addition of maturation 
agents to DCs stimulated effectors to exhibit maximal specific cytotoxici ty levels. This 
indicated that although the absolute number of targets kil led by specific cytotoxicity did not 
increase with maturation agents, the frequency of specific cytotoxic cel ls within the 
effector ce ll population was increased. The absolute levels of specific cytotoxicity may be 
l imited by the expression of antigen/s upon the targets in the contex t of MHC Class-IT 
molecules. In vivo TNF-a. matured lysate-pulse-DCs were able to generate clinical 
respon es in patients' with medullary thyroid carcinoma whereas immature DCs did 
not/4181. 
LPS maturation of monocyte derived DC in serum free conditions acts through 
inducing secretion of high levels of TNF-a. !4131. Whether LPS induced maturation of 
monocyte derived DCs is entirely due to TNF-a. is unclear. Although Chapter 5 showed a 
difference in the degree of specificity ofT-cell responses generated using LPS or TNF-a. 
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this rnay be due to differe nces between individual B-CLL patients. LPS , T F-a and Poly 
I C) · NF ·-D f.J/I.JJ<J 4 ' 01 E · r 1 · h · · · ( : acti vate -IU) · · - • xpress10n o many genes w 11 c are Important 111 ant1gen 
presentation by DCs in volves NF-KB, such as CD86.~2 1 and CD83 f -ll .ll_ Other genes contain 
a NF-ld3 binding site in their regul atory regions such as CD80, MHC class I (H-2Kb), 
MHC class n (HLA-87), CCRS, IL-12, macrophage inflammatory protein (MIP)- Ia, MfP-
I~ ' fL-1 a , IL- l~, IL-6, IL-8, CD54, Fas, Fas Ligand, RANTES and TNF-a 1411· 4.!.11. 
Dendritic cells, induced to maturation by LPS or TNF-a, exhibit increased stimulatory 
capacity because of the accumulation and persistence of antigen MHC class-11 complexes 
upon the cell surfacef4:?.J/. Matured DCs also exhibit MHC class-1 up-regulation that 
stimulates additional subsets of T-cells14251, hence increasing the magnitude of the overall 
T -cell response. 
7.1 1 Natural Killer cell s 
Although there is evidence that DCs can directly trigger anti -tumour responses by 
Natural Killer (NK) cells f -1261, the effector cel ls in our assay did not express the NK 
markers CD 16 and CD 56. Although our work demonstrated that NK cells were not present 
within the responding T cell population; a better way to demonstrate that NK ce lls were not 
respon ible for the killing of B-CLL targets was to use a cell line K562. K562 cells are 
lysed by NK cell ac ti vity f 2891. No specific killing of K562 cell line was demonstrated by T-
cell effector generated by eo-culture with B-CLL lysate-pulsed autologous DCs (Figure 
40). In add ition, B-CLL B-cell targets have been shown to be resistant to anti-FAS 
mediated cytotoxici ty f-127/ and to lysis by normal or autologous LAK cell s 14281. IL-15 can 
also induce NK cell development f.?Xll and increase cytotoxic acti vity of NK cells flXXI _ 
K562 cell s are sensiti ve to NK cell mediated cytotoxic acti vity and in thi s study [L-15 did 
not increase the amount of NK cell activity. 
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K562 cells are sensitive to NK ceJJ mediated cytotoxic activity and in this study IL-15 did 
not increase the amount ofNK cell activity. 
7.11/n vivo priming ofT-cells and deletion 
Perhaps the modest level of tumour specific cytotoxicity observed is due to the 
relatively low frequency ofB-CLL-reactive cells within the patients' T-cell repertoire. The 
lack of a specific response by T -ceJJs from healthy volunteers presented B-CLL lysate 
antigens by their own DCs suggests the presence of a pre-existing pool of reactive T-cells 
in B-CLL patients not found in healthy volunteers. Recently the existence of autologous T 
lymphocytes capable of spontaneous specific recognition of B cells from B-CLL patients 
has been demonstrated '4291. However, there is also evidence that there are considerable 
decreases in the ratio of TH I to TH2 helper T cell phenotypes !3361. FasL expression has 
been found on melanoma ' 4301, lymphoma ' 4311, glioma !4321 , lung tumour cells, colon 
cancer !4331 and breast adenocarcinoma. The expression of FasL by some tumours may 
confer immune-privileged status by inducing deletion by apoptosis of autologous tumour-
specific effector lymphocytes f4341. 
7.12 Antigen processing and cell fusion 
One of the main aims of the optimisation experiments was to generate MHC class I 
restricted responses by the stimulation of CD8 positive T cells. Most of the studies that 
have previously been able to generate CD8 responses have used peptides to pulse onto 
DCs. Many of the properties of intrinsic to peptides (the size and method of production) 
may result in the DCs processing them via the MHC class I pathway. In general it is 
thought that DCs process and present exogenous proteins by the HLA class II pathway and 
that endogenously synthesised protein generate MHC class I restricted cytotoxic T 
lymphocytes !4351• However, this is not to say that DCs cannot present exogenous protein 
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I molecule~ '' 381 . However. the method of entry into the dendritic cell has been . hown to 
influence the mo~t common pathv ay by which rhe protei m. are proce ~eel through f 1·1" 1. 
Fusion of B-cells and monocyte derived DCs from a B-CLL patient was sti ll attempted to 
try and overcome any problems related to ·cross-priming' such a ; lack of appropriate 
bone-marrow derived APC, limiting nature of the antigen, inadequate CD4+ help and 
inadequate le els of transport or associated with antigen processing (TAP). 
Dendritic cel ls transfected with full -length cDNA have resu lted in MHC etas I 
restri cted T cel l responses being generated f.J.JOJ. However, the fusion of DCs and carcinoma 
cells has been shown to generate both MHC class I and class 11 respon e f.J4! . .J.J:!f. 
Although initial attempts with in vivo vaccination did not result in clinically significant 
outcomes f.J.JJJ. Use of human allogeneic DCs fu eel with tumour cells in metastatic renal 
cell carcinoma has shown more promising results ill vivo 14441. When compared ill vitro, 
either allogeneic or autologous DCs fused to ovarian carcinoma cells cou ld generate 
cytotox ic T cell acti vi ty but allogeneic DCs fused to tumour cells produced higher 
proliferative responses f.J.J51. 
lembrane fragmentation and amalgamation are common effect of applying electric 
pulses to cells. Membrane resealing occurs rapidly and pontaneou ly after ce ation of the 
electric pttlse' 4461. There i · a ·ignificant difference between 'membrane mixing' and the 
estab li shment of a stable growing hybrid cell f .J-171. True fusion between human tumour cells 
and CD34+ cells have resulted in hybrid cells capable of efficient growth ' 2621. However, 
attempts to produce hybrids with monocyte derived DCs have been unsuccessful in 
producing table hybrid populations because of their low replicati ve potential ' 229· ·I.Jiil . 
Analysis of fusion rates, by flow cytometric dyes and antibody staining, overestimates 
hybrid efficiencies f .J.J91 but, for the purposes of this study it provided relevant information 
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Analysis of fusion rates, by flow cytometric dyes and antibody staining, overestimates 
hybrid efficiencies '""91 but, for the purposes of this study it provided relevant information 
about ' membrane mixing' between two specific cell types in a heterogeneous mix of cells. 
Fusion rates for B-CLL cells were low but this was probably due to the well-known 
spontaneous apoptosis of B-CLL cells in vitro. Dendritic cells mixed with B-CLL B-cells 
without an electric current showed a 50% decrease in cell viabili ty. Flow cytometric 
analysis showed this cell death to be located in the CD20+ cell population. Perhaps the 
addition of cytokines such as IL-2, IL-4 and IL-15, known to increase in vitro viability ' 3851 
of B-CLL B-cells, may increase fusion yields. It was not possible to bring the cells into 
preliminary alignment before applying the membrane destabilising voltage, due to the 
limitation of the gene pulser apparatus. This has been shown to increase fusion yields by 
the formation of 'pearl-chained' cells 14461. By increasing the voltage and pulse duration 
higher fusion rates and higher purity were achieved in separated, fused dendritic-B-eLL B-
cells. However, voltages and current duration were not increased greatly as irreversible 
membrane breakdown results in cell death due to electric pulses of excessive strength and 
duration ' 4461. Further optimisation of the voltage and current duration could possibly 
increase yields of fused dendritic-B-CLL B-cells. For these experimental purposes, 
introduction of antigens into the cytosol of the DCs by 'membrane mixing' was the main 
objective rather than the establishment of a proliferating hybrid cell. It has been 
demonstrated that short-term fusion or eo-culture can result in the generation of anti-
tumour T -cell responses 14501. 
Despite sub-optimal electrofusion conditions, it was possible to generate hybrid 
monocyte derived DCs that could stimulate both MHC class I and IT-restricted effector T-
cells. This is in contrast to previous findings where only HLA class-II restricted T-cell 
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and ineffecti ve stimulation of anergic dy functional T-ce l l ~ , were overcome by 
elcctrofusion of monocyte derived DC w ith B-CLL B-cell 
7. 13 Autoimmunity versus anti - leukaemia effect 
One concern that has been rai sed with regard to dendriti c cell vaccination is the possibility 
o f inducing autoreacti vity. In our culture system, reacti vity was not demonstrated against 
autologous B-CLL T-cell and granulocytes or HLA matched and allogeneic B-cell from 
healthy individual ·. Ideally we would wi h to test for cytotox icity against autologous non-
malignant B-cells from B-CLL patients but due to the overabundance of the malignant B-
cells in these patients we found thi s impossible. A lthough T-cells make poor targets we did 
not wish to introduce anti -viral epitopes into our system in the form of EBY-transfected 
targets. Recently, T cells generated by stimulation with CML pu lsed DCs showed 
pro liferation against autologou CML cell s but not an HLA-identical sibling 14511. Clinical 
studies with dendritic ce ll vaccination have so far not reported evidence of allloimmune 
I. 1124 ~4o 241 ' 41 ' 4fll A · · h b . d cl b DC I d . h ·c1 c 1sease. · · - · · - · ·- . utoJmmunJty a een m uce y s pu se w1t pept1 es 
eluted from tumour cells in mice 1452· 4531. One report states that blast cell lysates pulsed 
onto human DCs mediate inhibitory effects 14541. However, it seems more likely that 
immature DC were generated and that these were able to induce tolerance as thi s has been 
demonstrated 1 105-"55· 45fJ!_ 
7. 14 Possible B-CLL antigen(s) 
Our experiment have demon trated specific T-cell response to 8 -CLL. Although 
cytotoxicity was induced with some allogeneic B-CLL ly ates th is was not the case with 
other . Thi s suggests that, although a common antigen may be present in a proportion of B-
CLL patients, other B-CLL patient may have unique antigens. Thi should not be 
surprising, as B-CLL is not a homogenous disease. 2-D analysis of proteins from B-cells of 
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CLL patients, other B-CLL patients may have uruque antigens. This should not be 
surprising, as B-CLL is not a homogenous disease. 2-D analysis of proteins from B-cells of 
B-CLL patients revealed a group of proteins between 50-60k:D that were not found in B 
cells from normal individuals !2951. Analysis of the B-cell lysates from B-CLL patients 
confirmed the presence of a B-CLL common antigen and patient specific antigens (Figure 
45a). 
Due to the use of CD19 Dynabeads during the production phase of the lysate it 
would also be useful to show that similar levels ofCD19 are present in the lysates from B-
CLL patients and B cells from healthy volunteers. CD 19 was detected at 64k:Da and 31 k:Da 
to varying degrees in B-cell lysates from both B-CLL patients and normal healthy 
volunteers (Figure 50). CD5 has been demonstrated on the cell surface of B cells from B-
CLL patients along with the expression of CD72 (a CD5L) !4571. CD5 and CD6 have been 
linked to Bcl-2/ Bax ratios in a role of apoptosis protective mechanisms !4581. CD5 was 
detected at in B-cell lysates from B-CLL and normal healthy volunteers (Figure 51). 
However, CD72 was only detected upon T -cell lysates from normal healthy volunteers 
(Figure 52). This was in disagreement with studies analysing cell surface expression of 
these molecules. CD5 expression in T -cell lysates from B-CLL patients correlated with the 
reduced cell surface expression previously demonstrated !2551. Molecules such as CD23 
!4591 and CD38 fJOOJ are increased upon the B-CLL B cell surface. CD23 was not detected in 
B-cell lysates from B-CLL patients but was detected in T -cell lysates from 1 B-CLL 
patient. CD38 was detected in some but not aJJ B-cell Jysates from B-CLL patients and in 1 
normal healthy volunteer. However, the normal healthy volunteer also showed detection of 
CD5. This may be for two JX>Ssible reasons; a lack of symptoms resulting in a no diagnosis 
or detection of protein by western blot cannot differentiate between constitutive expression 
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capacity. Bcl-2 is an intracell ular signal li ng molecule which has been reported to be greatly 
up-regu lated in B cells from B-CLL patients fJ5y1. Another inh ibitor of apoptosis protein , 
Survivin has recently been shown to be inducible in B-CLL ce lls f-1601. High CD20 
expression has been related low li fe expectancy f -161 1. However, none of these proteins are 
of a molecular weight corresponding to the 4 1 kDa or 65 kDa bands of interest. There is a 
relati vely uncharacterised B lymphocyte surface molecule (p42) wi th a molecular weight of 
42kDa that shows no reactivity to anti-CD23, CD40 or CD72 antibodies f-1621. 
Sequencing revealed the 65k0a band from normal healthy volunteers to have a 
close homology with human serum albumin . The 65kDa band from B-cell lysates of B-
CLL patients could not be sequenced probably because it was natural ly N-blocked. The 
42kDa band from B-cell lysates from B-CLL patients showed a homology with human 
actin. However, thi s was not a close homology and so may be a protein similar in structure 
to actin. The producti on of act in-contain ing and vimentin-contain ing intermediate 
filaments in response to 12-o-tetradecanoyl-phorbol- 13-acetate (TPA) have been observed 
in B-cells from B-CLL and hairy cell leukaemia (HCL) and not normal B cells ' 4631. There 
is also evidence of an atypical relationship between CD5-CD2 1 and actin in B-CLL B-cells 
14641
. A subset of genes have been isolated from B-CLL patients using DNA chip 
microatTays which are specifical ly expressed '4651. Analysis of the B-cell lysates ustng 
DNA chip microarrays would prove very interesting. 
7. 15 Impl ications for the clinic 
There are three possible sources of DCs for use in immunotherapy. Fi rstly, DCs can 
be directly purified from the peripheral blood. Their low density allows physical separation 
f -IM. " 671. Purity can easily be increased by depletion ofT-cells, B-cells, Natural Killer cells, 
and monocytes from the separated fractions of blood or the positive selection of HLA-DR++ 
1
"
611
' , CD83+, or CMRF-44+ 14691 cells using magnetic anti body coated beads or a cell sorter. 
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However, DCs from the peripheral blood are still at a relati vely low densi ty. Secondly, 
CD34+ puri f ied ce lls from peripheral blood f./7Uf or bone marrow rm . .J?]f can be cu ltured 
with GM-CSF and TNF-a. Larger numbers can be generated using this method although 
the DCs are often only 50% pure. It is di fficult to separate the antigen capture process from 
antigen presentati on. However, DCs grown from CD34+ precursors do have high cell rates 
which make them ideal candidates for gene transfers wi th retrov iruses and cel l fusions. 
Apheresis can be used to increase the number of CD34+ progenitor ce lls'4731 or CDI 4+ 
precursors ' 4741 by in vivo administration of G-CSF or GM-CSF followed by large scale 
isolati on of DCs by immunomagnetic bead separation. Thirdly, monocyte deri ved DCs can 
be generated from CDI4+ cells cultured w ith GM-CSF and rL-4. 90% of these DCs are 
immature and so at the optimal stage for antigen uptake. Maturation can be initiated by 
culture with TNF-a 11101(in a serum free envi ronment). 
Culture conditions are important for a product that will be returned to the patient ' s 
body. The use of fetal calf serum wou ld involve the ri sk of uptake and presentation of 
xenogeneic antigens by DCs. However, the use of xenogeneic antigens has shown that 
slight side-effects associated with cross-species interactions may be beneficial in breaking 
tolerance to self antigens f.Jn . Serum contains proteases that would alter the structure and 
therefore antigenicity of proteins and peptides added in vitro to DCs ' 4761. A utologous 
serum from patients with a malignancy could contain anti bodies which could interfere with 
loading of the tumour antigen onto the D Cs. This has been demonstrated with a anti -
Gala( I ,3)Gal antibodies that cross-react with MUC- 1 ' 4771. Serum from B-CLL patients 
has been shown to contain an undefined serum factor that may play a ro le in the 
pathogenesis of the disease ' 47111. Therefore, the use of serum free mediums such as AIM-V 
f 229· 479· 4801, X-VIVO 15 '48 1 I are favoured for the production of DCs of a clinical grade. 
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has been shown to contain an undefined serum factor that may play a role in the 
pathogenesis of the disease ' 4781. Therefore, the use of serum free mediums such as AIM-V 
f129• 479• 4801, X-VIVO 15 ' 4811 are favoured for the production ofDCs of a clinical grade. 
The nature of the antigen used to prime DCs has considerable implications for 
therapeutic studies. Many in vivo studies have used well-defined synthetic peptide 
sequences with some success ruo.uJ.u 4'406'480'482• 483• 4841. A previous study in melanoma had 
demonstrated the generation of equivalent anti-melanoma responses after vaccination with 
either melanoma peptide- or tumour lysate-pulsed DCs ru oJ_ Longer peptides or complete 
proteins in cell lysates may prove more effective as the DCs endocytose and process the 
antigen so that the optimal 9-mer peptide is presented ' 2361. A mix of peptides also guards 
against loss of 1 dominant tumour antigen and tumour escape. Where self-proteins are also 
tumour-associated proteins they can be modulated to become more antigenic with some 
success '
4851
. In many malignancies there is limited amount of autologous antigen. This is 
not the case in B-CLL as the malignant B-cells are commonly found in the periphery. Total 
RNA from tumour cells has been shown to be effective at generating anti-tumour 
responses ' 4861. Where antigen is limited, vaccination with RNA after amplification of 
RNA by PCR may provide an alternative ' 4871. DNA transduction of DCs as a strategy 
possesses several advantages; responses are not restricted by MHC haplotypes, unknown 
peptides can still be presented and presentation of antigens is more prolonged ' 4881. 
The site of injection for DCs may prove vital. Sub-cutaneous injection of dendritic 
cell vaccines was more effective than intra-venous injections in murine experiments !4891. 
lntralymphatic injection of DCs ensures contact between DCs and T-cells at the lymph 
node ' 4901 and has resulted in more effective responses ~'2401. 
In vitro generation of tumour-specific T -cells by DCs and injection ofT -cell clones 
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illustrated in a tudy of I melanoma patient f -1 911. T -cell clones and DCs have been 
combined with other therapies ·uch a~ cytokines i-N: J and bone marrow transplantation f-1911 . 
The data presented here would favour a manipulation of the T-cells of B-CLL 
patients by cytokine modification to overcome the anergic nature of the T-cells from B-
CLL patients. Fusion hybrids of autologous DCs and B-CLL B-cells were the most 
effective stimulus for both MHC class I and II restricted responses. Generation of 
auto logous reactive T-cell clones within the B-CLL patient would be subject to immuno-
suppres ion. De-bulking of the tumour prior to immunotherapy would be vital in order to 
prevent the large number of peripheral B cells interfering with dendritic cell homing and 
subsequent T-cell interaction . However. the choice of drug therapy or radiotherapy would 
have to avoid immunosuppression particularly of the CD4+ T-cells. The potential of the 
peptide sequences already isolated could be explored so that a defi ned protein (gene) could 
be targeted. Eventually thi s could lead to generation of new drug therapies. The reverse 
immunology approach has been succes ful in other malignancies at identi fy ing optimal 
antigens. Testing of tumour associated proteins using the DC system could lead to more 
effecti ve therapies for B-CLL patients particularly those with drug resistant disease. 
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cancer [21 ]. In vivo studies using DC loaded with tumour antigens 
have demonstrated encouraging clinical anti-tumour responses 
against B-cell lymphoma [22], melanoma (23], myeloma [24], 
parathyroid carcinoma [25], prostate cancer [26-28] and renal 
carcinoma [29]. In this study, we evaluated whether in vitro B-
CLL-specific T-cell responses could be generated using auto-
logous tumour cell lysate-pulsed DC. 
MATERIALS AND METHODS 
Volurrteer selection 
Local research ethics commillee pemuss10n and individual 
informed consent were obtained for these studies. A group of 16 
patients who were either untreated or who had not received 
treatment in the last 6 months were selected for the study. Patient 
details are given in Table I. Another group of five healthy 
volunteers was used as a control. Protocols for isolation of cells 
from the blood from patients and healthy volunteers were 
identical. Selection of patients for antibody blocking and mixed 
lysate experiments was random. 
Dendritic cell isolation and culture 
blood mononuclear cells (PBMC) were isolated by 
gradient centrifugation from peripheral blood. PBMC 
patients with B-CLL and healthy volunteers were depleted of 
9+ cells using Pan B Dynabeads (Dynal, Merseyside, UK). 
CD 19-depleted PBMC were cultured in a 24-well tissue 
lcult1ure plate (Gtsco, Life Technologies, Paisley, UK) at 37°C in 
C02 for 2 h. Culture medium consisted of RPM! 1640 
8:1GIItC01), I 0% human AB serum, 2 mM glutamine (Sigma, Dorset, 
K), 500 Ulml penicillin (Sigma) and 500 ,.,.gtml streptomycin 
igma). Non-adherent cells were removed by vigorous washing 
culture medium. Adherent cells were then cultured in culture 
m with 800 Ulml granulocyte macrophage colony stimulal-
faclor (GM-CSF) (Cambridge Bioscience, Cambridge, UK) 
1000 U/ml interleukin-4 (IL-4) (Cambridge Bioscience) at 
Table I. Patient profile 
WBC count 
IWCLL stoge xl09/l Previous treatment 
NO 25 None 
NO 61·7 None 
NO IS None 
NO 14·9 None 
NO 23·2 None 
NO previously All 9·8 CWorambucil 
NO previously Cm 13·5 Chlorambucil 
NO previously Cm IS Chlorambucil 
NI 57 None 
Bill 119·2 None 
C/IV 118 None 
C/IV 122 Chlorambucil and Fludarnbine 
C/IV 167 Chlorambucil and 
splenic radiolherapy 
NO 20 None 
All 26-4 None 
B/1 41·2 Chlorambucil and 
Cyclophosphamide 
37°C in 5% C02 for 6 days. The cultures were fed every 2 days 
with fresh culture medium containing IL-4 and GM-CSF. On day 
6, the culture medium was removed and the cells cultured in fresh 
cullure medium with 800 U/ml GM-CSF and 100 ,.,.gtml inter-
leukin-12 (IL-12) (Cambridge Bioscience) for 16 h, washed, and 
resuspended in culture medium. 
Preparation of soluble cell lysate 
The CDI9+ B-cells from the PBMC fraction were removed from 
Dynabeads using Pan B Delachabeads (Dynal). In the B-CLL 
patient, these cells were 97% CD5+ and 92% CD20+ B-cells 
were resuspended in 2 ml lysis buffer (10 mM bicarbonate buffer 
pH 7·1 and 0·5 mM phenyl methyl sulphonyl fluoride) (Sigma) on 
ice. The cells were homogenized on ice using a Dounce 
Homogeniser (Jencons, Lcighlon Buzzard, UK) and then ultra-
sonicated using two 10 s bursts with a 15 s rest from a 50 W 
Vibracell (Sanies and Materials Inc. Jencons). Soluble protein was 
collected after ultracentrifugation al 55 000 rev/min (100 000 g) 
for I h at 4°C. The protein concentration was quantified by the 
Bradford protein assay method using a protein determination kit 
(Biorad, Hemel Hempstead, UK). Soluble protein lysates were 
sterile-filtered using 0·4 ,.,.m fillers (Nalgene, Marathon Labora-
tory Supplies, London, UK) and stored al - 70°C. All cell lysates 
were exposed to CDI9+ Dynabeads. Lysales were defined as 
allogeneic if they originated from a different individual to the 
effector T cells. Lysates were defined as non-B-CLL if they were 
made from B-ee lis or T -eells from healthy volunteers, or cell types 
unaffected by B-CLL such as granulocytes. 
Pulsing dendritic cells with tetanus toxin and wberculin PPD 
The known antigens tetanus toxin and tuberculin purified protein 
derivative (PPD) were used as positive controls to validate the 
proliferation and ELISA assays. Tetanus toxin and tuberculin PPD 
were added to DC culture medium al 0·4 Ulml and 900 U/ml, 
respectively, and incubated for 4 h at room temperature. 
Pulsing dendritic cells with soluble B-celllysale 
DC were pulsed by the addition of soluble lysate to the DC culture 
Table 2. Dendritic cell surface markers. Analysis of markers for CDI9 
depleted PBMC cultured in RPM I 1640 + I 0% AB serum + IL-4 ( 1000 
U/ml) + GM-CSF (800 U/ml) for 6 days at 37"C. 5% C02 from two 
normal volunteers and four B-CLL patients. P-vaJues were caJculalcd 
using single-tailed unpaired Student's t-test 
Cell surface Nonnal dendritic cells BCLL patient dendritic cells 
marker (Mean percentage + s.d.) (Mean percenlage + s.d.) 
HLA-DR 56·8 + 17·1 54·0 + 8·4 
CD83 1·4 + 0·9 1·2 + 0·8 
CD40 12·9 + 5·9 26·7 + 8-4 p = 0·02 
CD86 27·8 + 1·8 15·7 + J.8 p = 0-003 
CDI6 2·2 + 1·2 12-4 + 16·0 
CD56 0·3 + 0-3 0·2 + 0·1 
CD3 10·7 + 5·2 9·2 + S-6 
CDI4 19·3 + 18·2 11·2 + 7·0 
CD! le 4·2 + 4·5 10·1 + 6·0 
CD20 4·1 + 2·7 4-7 + 3·0 
CD la 9·6 + 7-3 9·6 + 8·3 
CD45 92·5 + 3·5 89·0 + 4·0 
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Fig. l. Proliferation. Number of CD3/C025-positive T -cells from (a) five B-CLL patients and {b) five healthy volunteers were measured. 
T -cells were cultured alone <•>. with autologous dendritic cells pulsed with B-CLL lysate <• >. allogeneic lysate from healthy volunteers 
(non-B-CLL) (!ilil), autologous lysate from healthy volunteers (non-B-CLL) (1!1!), or no lysate (D) were measured. One measurement per 
patient was made. Positive controls of autologous dendritic cells pulsed with tetanus toxin (0) or tuberculin PPD (11!1) and cultured with 
autologous T-cells were measured in duplicate in one patient and one healthy volunteer. Median ranked values, calculated from duplicates. 
were tested using the Kruskal-Wall is test. (*) Indicates a significant increase in double positive cells, with P = 0·03 (**) with P = 0·0 I (a) 
and P = 0·001 (b). when eo-cultures of pulsed dendritic cells were compared with unpulsed dendritic cells. 
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medium at I 00 ng/ml per I 06 cells, and incubated for 4 h at room 
temperature. Control, unpulsed dendritic cells were incubated at 
this time with lysis buffer, except in Patient's 5, 7, 9, 10 and 13. 
T-ee// isolation and T-ee// cultures 
T -cells were isolated indirectly from the PBMC fraction by 
depleting adherent and CDI9+ cells. The purity of the T-cells 
was, on average, 60% when assessed by flow cytometry using 
anti-CD3-FITC-conjugated antibodies. Lysate-pulsed or unpulsed 
dendritic cells were aliquoted at a concentration of 103 cells per 
well to 96-well round-bottom tissue culture plates. T -cells were 
then added to give a T-cell:DC ratio of at least 20:1. Cultures 
destined for cytotoxicity assays were fed with S U/ml of 
interleukin-2 (IL-2) (Cambridge Bioscience) on days 3, 7, 10, 
14 and 17. DC in cultures destined for cytotoxicity assays were re-
stimulated by the addition of 100 ng/ml soluble B-cell lysate or 
lysis buffer on days 7 and 14. Cultures were continued for a total 
of 21 days at 37°C in S% C02 in culture medium + 5% AB 
serum. Cultures used to assess cytokine secretion were not fed IL-
2 or re-stimulated with soluble lysate. 
lmmwoophenotyping 
The following monoclonal antibodies were used for irnmunophe-
notyping studies of DC and effector cells in the cytotoxic assays: 
CD4-FITC (Serotec, Oxford, UK), CD8-PE (Serotec), CD3-FITC 
(Serotec), CDI6-FITC (Serotec), CDS6-FITC (Serotec), HLA-
DR-PE (Serotec), CD83-FITC (lnununotech, Coulter, Luton, 
UK), CD40-PE (Serotec), CD86-FITC (Serotec), CDI4-PFJ 
CD4S-FJTC (Becton Dickinson, Oxford, UK), CDilc-PE (Ser-
otec), CD20-PE (Serotec), COS-PE (Serotec), CD 19-FITC 
(Serotec), CDla-FITC (Serotec), anti-lgGI-PE and anti-lgGI-
FITC (Serotec). Cells were washed twice in PBS and then twice in 
PBS + 0·05% BSA (Sigma). Directly-conjugated antibodies were 
added at 10 p.l per 106 cells and incubated for 15 min at room 
temperature. Cells were washed twice in PBS and twice in 
PBS + 0·05% BSA. Positive antibody binding was assessed in 
terms of gates set at 2% of relative isotype controls using an Epics 
Elite flow cytometer (Coulter, Luton, UK). 
Proliferatioro assay 
T-cell activation was measured, quantifying cells eo-expressing 
CD3 and CD2S (IL-2 receptor) by double-labelled flow 
cytometry. The methodology outlined by Loken and Wells [30] 
was employed, using anti-CD3-FITC-/anli-CD25-PE-conjugated 
monoclonal antibody (lmmuno Quality Products, Mast Diagnos-
tics, Merseyside, UK). Positive antibody binding was assessed in 
terms of gates set at 2% of anti-lgGI-PE- and anti-lgGI-FITC-
labelled cells. Anti-CD3-FITC- (Serotec) and anti-CD2S-PE 
(Serotec)-conjugated monoclonal antibodies were added indivi-
dually to allow compensation. 
Qualllijication of cytokine secretion 
Cell-free tissue culture supernatant fluids were harvested on days 
1-S and stored at -70°C until required. When convenient, the 
supernatant fluids were thawed and the concentrations of IFN-y 
and IL-4 measured in duplicate by ELISA (Pelkline, Eurogenetics, 
Hampton, UK). Sensitivity limits for the assays were 2-6 pglml 
for IFN-y and 0-2-0·4 pglml for IL-4. 
Cytotoxicity assay 
Cytotoxicity was measured by a flow cytometric method, LIVE/ 
DEAD cell mediated cytotoxicity (Molecular Probes, Cambridge 
Bioscience) [31]. Target cells were labelled with 4 p.l per 5 x 105 
cells of diOC 18, for 2 hat 37°C in 5% C02, and then washed twice 
in culture medium. Effector cells were harvested from the tissue 
culture and placed in flow cytometry tubes (Falcon, Marathon 
Laboratory Supplies, London, UK) at the appropriate effector:-
target ratios. A minimum of I x 104 labelled targets was added. 
Propidium iodide was added to each tube. Targets and effectors 
were gently mixed and centrifuged at 1000 rev/min for 30 s. 
Targets and effectors were incubated together for 4 h at 37°C in 
S% C02 . Flow cytometry standard gates were set on unlabelled 
targets stained with propidium iodide, and di0C 18-labelled targets 
without propidium iodide. Non-specific cell death (spontaneous 
apoptosis) was measured by the cytotoxicity of di0C 18-Iabelled 
targets stained with propidium iodide without effectors. Cytotoxi-
city was expressed as the number of dead targets (cells staining 
positive for propidium iodide and diOC 18) divided by the total 
number of targets (cells staining positive for diOC 18). Percentage 
specific cytotoxicity was measured as follows: 
% specific cytotoxicity = (total cytotoxicity 
- spontaneous cytotoxicity) X 100 
As a control, effectors consisting of unpulsed dendritic cells were 
used to detect any non-specific uptake of the diOC 18 dye from 
target cells by dendritic cells. 
Target cells in cytotoxicity 
The B-CLL B cell targets were 97% COS+ and 92% CD20+. The 
B-CLL T cell targets showed binding for CD20-PE < 2%. 
Allogeneic targets were defined as those originating from another 
individual to the effector T cells. Targets were defined as non-B-
CLL if they were made from B cells and T cells from a healthy 
volunteer, or granulocytes and T cells from B-CLL patients. 
Antibody blocking studies 
Antibody blocking experiments involved the addition of anti-HLA 
class I (Serotec), anti-HLA class 11 (DR, DP, DQ) (Serotec), anti-
Pan TCR al3 (Serotec), anti-CD4 (Serotec) and anti-COS 
(Serotec) monoclonal antibodies at lOO p.g/ml at the commence-
ment of the 4 h incubation of effectors and targets. 
Statistics 
Effects of treaunent upon cytotoxicity and cytokine secretion 
analysed by one-way analysis of variance (ANOVA). 
comparisons between treatment groups were analysed using 
Student's 1-test. Differences between median values 
compared using the Kruskal-Wallis test. Statistics were gentera,ted 
using Statsgraphics Plus software (Manugistics, Maryland, 
RESULTS 
Characterization of dendritic cell immunophenotypes 
The results of irnmunophenotyping studies of DC derived 
normal volunteers and patients with B-CLL are shown in Table 
There were no significant differences in mean cell-surface 
expression of HLA-DR, CD la, CD3, CD4, CD lie, CDI4, 
CD20, CD45, CD56 and CD83, between patients and 
volunteers. However, CD40 was found to be nn;t.ronoh 
increased in patients compared with healthy 
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J. Cytotoxicity of B-CLL T -cells. Effectors from I 0 B-CLL patients 
cultured for 21 days (see Materials and Methods for conditions) and 
:ytc>tmticity against autologous B-CLL B·celltargets (a), allogeneic B·cell 
from healthy volunteers (non·B·CLL) (b) and autologous B-CLL 
targets (c) was measured. T cells had been cultured alone (.t.) or 
autologous dendritic cells pulsed with autologous B-CLL lysate(+), 
lysate from healthy volunteers (non B-CLL) (0) or lysis buffer 
in patients 7 and 13 no lysate) <•>· Data were analysed by one-way 
. (*) Indicates an overall significant effect of treatment with 
= 0·0008. Individual results can be seen in Table 3. 
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Fig. 4. Cytotoxicity of normal T cells. Effectors from five healthy 
volunteers were cultured for 21 days (see Materials and Methods for 
conditions) and cytotoxicity against autologous B-cell targets from healthy 
volunteers (non-B-CLL) (a) and allogeneic B·CLL B-cell targets (b) was 
measured. T -cells were cultured alone (.t.) or with autologous dendritic 
cells pulsed with allogeneic B·CLL lysate (fil). autologous lysate from 
healthy volunteers (non-B-CLL) (0) or lysis buffer(.). One measurement 
was made per patient and treatment group . 
(P = 0·02), and CD86 was found to be significantly decreased in 
B-CLL patients compared with healthy volunteers (P = 0·003). 
Proliferation assays 
T-cell activation was observed when autologous dendritic cells, 
pulsed with either tetanus toxin or tuberculin PPD, were cultured 
with autologous T cells in a B-CLL patient (P = 0·01) (Fig. la) 
and a healthy volunteer (P = 0·007) (Fig. I b). T-cclls derived 
from patients with B-CLL were cultured alone or with autologous 
B-CLL lysate-pulsed or unpulsed dendritic cells. A significant 
increase in T-cell activation was found after 4 days of culture by T 
cells cultured with lysate-pulsed dendritic cells, compared with T 
cells cultured with unpulscd dendritic cells (P = 0·03) (Fig. la). 
Although there was an increase in the percentage of activated B-
CLL T -cells after eo-culture with autologous B-CLL dendritic 
cells pulsed with an allogeneic non-B-CLL lysate from a healthy 
volunteer, this was not significant (Fig. la). Similarly, when an 
allogeneic lysate was pulsed onto dendritic cells from a healthy 
volunteer, the percentage of activated autologous T -cells was 
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Table 3. Individual specific cytotoxicty to B-CLL targets for 10 patients in Fig. 3(a) at 40: I effector:target ratio. Individual cytotoxicity results after 
effectors have been incubated for 4 h with B·CLL B-cclltargets at 37'C,5% CO, at a ratio of 40: I. Effectors had been cultured for 3 weeks with two rounds 
of restimulation 
Dendritic cells Dendritic cells Dendritic cells 
Patient T-cells + lysis buffer + B-CLL lysate + non·B·CLL lysate 
number (% + s.d.) +T-cells (% + s.d.) + T -cells (% + s.d.) + T-cells (% + s.d.) 
I • 4·2 1·1 21·7 6·9 
2 3·2 + 4·5 1·34 + 4·9 20·6 + 3·7 5·05 + 4·3 
3 6·3 6·6 22·30 n.d. 
4 0 11·09 + 0·13 30·76 + I n.d. 
5 4-40 2·90 21·52 n.d. 
7 t 9·70 9·70 28·60 n.d. 
8 0-00 2·50 18 0·17 
11 6·60 5·00 14·10 n.d. 
13 t 3-40 2·13 17·70 n.d. 
16 3·15 + 2·3 4·45 + 3 13·1 + 4·7 n.d. 
•Indicates non-B-CLL lysute is lysate from granulocytes. tlndicates patients' who did not receive lysis buffer as a control. Results showing no standard 
deviation were not perfonned in duplicate due to limited numbers of effectors. 
increased but not significantly (Fig. I b). There was no increase in 
activated T -cells cultured with autologous dendritic cells pulsed 
with an autologous non·B-CLL B cell lysate from healthy 
volunteers (Fig. I b). 
Qua11tijicatio11 of cytoki11e secretio11 
T cells from both B-CLL patients and healthy volunteers secreted 
increased amounts of IFN--y when cultured with autologous 
dendritic cells pulsed with either tetanus toxin or tuberculin PPD 
(Fig. 2a, b). T cells derived from patients with B-CLL were 
cultured alone or with lysate-pulsed or unpulsed (lysis buffer 
added in five patients) dendritic cells. A significant increase of 
IFN--y secretion in culture supematant fluid was found after 72 h 
by T cells cultured with B-CLL lysate-pulsed autologous dendritic 
cells compared with both T cells cultured with unpulsed dendritic 
cells and T cells cultured alone (P = 0·0004) (Fig. 2a). In 
addition, there was no secretion of IFN--y by T cells cultured 
with autologous dendritic cells pulsed with soluble allogeneic B-
cell lysate derived from healthy volunteers (non-B-CLL) 
(Fig. 2a). T cells derived from healthy volunteers and cultured 
with autologous dendritic cells pulsed with autologous B cell 
lysate from healthy volunteers (non-B-CLL) or with allogeneic 
B-CLL lysate did not secrete significant amounts of IFN--y 
(Fig. 2b). Concentrations of IL-4 in tissue culture supematant 
fluids were measured in two patients with B-CLL and found to be 
less than 50 pglml. 
Cytotoxicity assays 
T cells derived from patients with B-CLL were cultured alone, or 
with lysate-pulsed or unpulsed (lysis buffer added in eight 
patients) dendritic cells, and then tested for cytotoxicity against 
healthy and B-CLL-derived B- and T-cell targets. A significant 
increase in cytotoxicity against B-CLL targets was generated by T 
cells cultured with B-CLL lysate-pulsed autologous dendritic 
cells, compared with both T cells cultured with unpulsed dendritic 
cells and T cells cultured alone (P = 0·0008) (Fig. 3a). However, 
no significant cytotoxicity was demonstrated against allogeneic B-
cell targets from healthy volunteers (non-B-CLL targets) 
(Fig. 3b), or against autologous T cells derived from B-CLL 
patients (non-B-cell targets) (Fig. 3c). In one patient, effectors 
were tested against B-cells, PBMCs and T-cells from two HLA 
class 1- and II-matched healthy volunteers and one HLA class II-
matched healthy volunteer. No cytotoxicity to these targets was 
demonstrated. 
T-cells derived from healthy volunteers cultured with auto-
logous dendritic cells pulsed with autologous 8-cell lysate from 
healthy volunteers (non-B-CLL lysate), or with allogeneic 8-CLL 
lysate, did not demonstrate significant cytotoxicity against 8-cell 
targets from healthy volunteers (non-B-CLL targets) (Fig. 4a) or 
B-CLL targets (Fig. 4b ). 
T-cells derived from patients with B-CLL cultured with 
soluble B-CLL lysate in the absence of dendritic cells did not 
show significant cytotoxicity against B-CLL or B-celltargets from 
healthy volunteers. In addition, T cells cultured with autologous 
dendritic cells pulsed with an autologous granulocyte lysate from 
B-CLL Patient I showed no significant increase in cytotoxicity 
against autologous B-CLL cells (see Table 3) and autologous 
granulocytes, or allogeneic B-ccll targets from a healthy volunteer 
(non-B-CLL). 
T-cells derived from Patient 14 and cultured with autotogotJs 
dendritic cells pulsed with an allogeneic B-CLL lysate 
patient IS did not demonstrate cytotoxicity to B-CLL targets 
patient 14 (Fig. Sa). However, T cells derived from patient 6 
cultured with autologous dendritic cells pulsed with allogeneic 
CLL lysates from patients 2 and 13 demonstrated 
cytotoxicity to B-CLL targets from patient 6 (P = 0·003 
P = 0·009). Allogeneic B-CLL lysates from B-CLL Patient 7 
not stimulate cytotoxicity to B-CLL targets from patient 
(Fig. Sb ). The allogeneic lysates used above had been shown 
generate specific cytotoxicity when used as autologous 
with autologous effectors and targets. These results are 
ized in Table 4. 
Cilaracterizatioll of responder cell immmropile11otypes 
Effector cells from B-CLL patients 14 and 16 were im1muno1phe 
notyped after 21 days in culture. The mean cell surface eXl>re!;sio 
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/-test. No significant specific cytotoxicity was measured 
autologous T cells, allogeneic B cells or al logeneic T ce lls. Each 
group was measured in duplicate per patient. 
was found to be 47% CD4 + cells and 13% CD8+ cells, the 
remaining cells being CD3 negative. CD 16 and CD 56 expression 
was absent. 
Antibody blocking studies 
Antibody blocking experiments were performed at the effector 
stage of the cytotoxicity assay on three patients chosen at random. 
Significant inhibition of cytotoxicity was demonstrated with anti-
class II but not wi th anti-class I monoclonal antibodies in patients 
2 (Fig. 6a) (P = 0·006) and 12 (P = 0 ·03 1) (Fig. 6b). Significant 
inhibition of cytotoxicity was demonstrated in patient 4 with anti-
pan TCR of3 and anti-CD4, but not with anti-CD8 monoclonal 
antibodies (P = 0·03 and P = 0·046) (Fig. 6c). 
DISCUSSIO N 
Chronic B cell malignancies represent a potential target for 
immunotherapy by virtue of the facl that they are derived from 
immune cells and thus have the capacity for interaction with T 
lymphocytes. In addition, each tumour is derived from a c lonal 
expansion of one malignant B cell and thus, each cell in the clone 
will share spec ific determinants, for example, those encoded by 
variable region sequences of rearranged immunoglobulin genes. 
Clinical studies in which patients with lymphoma and myeloma 
were vaccinated with idiotype protein have demonstrated the 
generation of anti-idiotypic T -ceU responses and a degree of 
clinical response [32-36). An alternative approach has been to 
load DC with idioty pe protein and subsequently use the pulsed DC 
as a form of immunotherapy. Such an approach has also been 
shown to induce anti-idiotypic immune responses in lymphoma 
[22,37] and myeloma [24,38], wi th some encouraging clinica l 
results. A similar rat ionale can therefore be proposed for 
immunotherapy in B-CLL, and this study was designed to 
determine whether DC loaded with B-CLL tumour protein could 
stimulate anti-B-CLL cell responses. S ince a previous study in 
melanoma had demonstrated the generation of equivalent anti-
melanoma responses after vaccination with either melanoma 
peptide- or tumour lysate-pulsed DC [23], we decided to load DC 
with soluble B-CLL cell lysate. 
Initial problems of generation of adequate numbers of DC 
from patients wi th B-CLL were overcome once the malignant B-
cells were removed . These DC were morphologically and 
numerically similar to tho e from healthy indjviduals. Immuno-
phenotyping DC generated from healthy individuals and patients 
with B-CLL demonstrated similar levels of expression of cell 
surface molecules, with the notable exception of CD40 and CD86. 
A previous study has demonstrated that DC generated from 
healthy individuals and patients with myeloma are phenotypicalJy 
and functionally s imilar; however, this did not include CD40 [39] . 
Although the s ignificance of Ihis finding is unclear at present, 
CD40+ DC have been found to be vital for the generation of anti-
tumour responses in mice [40]. Stimulatjon of CD40 by increased 
expression of CD40-Iigand has been shown to s timulate immune 
recognitio n of 8-CLL cells in v ivo [4 1] . TI1e decreased levels of 
CD86 in B-CLL patients differ s igni ficantly from the findings in 
myeloma paLients and may be linked to the disease. Since CD86 
has been shown to be a key eo-stimulatory molecule [42], its 
decreased expression upon the dendritic cells from B-CLL 
patients may affect the optimal presentation of antigens toT-ce lls. 
Our results demonstrate that patient-derived DC, when pulsed 
wi th soluble B-CLL lysate, stimulate autologous T cells to 
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Table 4. Summary of cytotoxic T cell generation and responses. 
T cells Dendritic cells Lysate 
B-CLL Autologous Autologous 
B-CLL B-CLL B-cells 
B-CLL NONE Autologous 
B-CLL B-cells 
Healthy Autologous Autologous 
volunteer healthy healthy B cells 
vo1unleer 
Allogeneic B-CLL 
B-cells 
B-CLL Autologous B-CLL Autologous B-CLL 
granulocytes 
B-CLL Autologous B-CLL Allogeneic healthy 
B-cells 
B-CLL Auwlogous B-CLL Allogeneic B-CLL 
B-cells 
proliferate, secrete IFN--y (but not !L-4) and lyse autologous B-
CLL targets. This suggests that our culture system has primed 
both a T helper I and a cytotoxic T -cell immune response. 
Antigen-presenting cells, such as DC, have the capacity to 
generate either aT helper I or aT helper 2 immune response [43). 
T helper I responses are associated with the secretion of particular 
cytokines, such as IFN--y and !L-12, and induce cell-mediated 
immunity, which is particularly important in the response against 
tumours. T helper 2 responses are associated with the secretion of 
cytokines such as !L-4 and !L-10. Tumours have been shown to 
secrete factors, such as !L-10 [44), transforming growth factor-13 
(TGF-13) [45] and vascular endothelial growth factor (VEGF) [46). 
wltich suppress DC and/or T cell function. Immature DC treated 
with !L-10 have been shown to induce anergy in melanoma 
antigen-specific CD8+ cytotoxic T -<:ells i11 vitro [47 ]. The T -cells 
used in our experiments were derived from patients with B-CLL 
and thus, were exposed i11 vivo to possible immunosuppressive 
factors secreted by the B-CLL cells. Recent data in our group 
suggests that the T cells of B-CLL patients show dysfunctional 
cell surface molecule expression [48]. Studies have shown that 
DC can be polarized towards stimulatory or inhibitory phenotype, 
IL-12 polarizing towards the induction of T helper I responses 
[49-51]. Pre-treatment of murine dendritic cells with !L-12 was 
shown to illicit responses to relatively unreactive tumour/self 
peptides [52]. In view of this, we pre-incubated the DC with IL-12 
just prior to the addition of antigen. Recently, !L-12 responsive-
Targets Response 
Auwlogous B-CLL Increase in IFN--y. 
Increase in specific cytoloxicity. 
Blocked by anti-MHC-<:lass 11. 
anti-TCR, anti-CD4. 
Autologous No response 
B-CLL T-<:ells 
Allogeneic No response 
healthy B-cells 
Autologous No response 
B-CLL B-cells 
Autologous No response 
healthy B cells 
Allogeneic B-CLL No response 
B-cells 
Autologous No cytotoxic or cylokine 
healthy B cells response, non-significant 
Allogeneic B-CLL increase in percentage 
B-<:ells activated T cells 
Autologous B-CLL No response 
B-cells 
Allogeneic healthy No response 
B-cells 
Autologous B -CLL No response 
granulocytes 
Allogeneic healthy No cytotoxic or cytokine 
B-cells response, non-significanl 
increase in percentage 
activated T cells 
Autologous B-CLL 2/4 patients showed 
B-<:ells increased specific 
cytotoxicity 
ness has been demonstrated in human monocyte-derived dendritic 
cells [53]. One preliminary experiment showed that without pre-
treatment with IL-12, monocyte-derived dendritic cells pulsed 
with B-CLL lysate could not stimulate significant T-cell 
responses. The specific T-cell responses to B-CLL generated in 
our culture system suggest that, if a state of anergy to the 
existed in vivo, the i11 virro culture with DC and nn,-tJ-eatment 
with IL-12 has reversed this state. 
The levels of IFN--y observed in our study are similar to 
generated by superantigen-pulsed DC cultured with T cells [54] 
but are higher than those generated by CD40L-stimulated 
B cells cultured with autologous T cells [55]. Although the 
of specific cytotoxicity (24% ), generated in our cultures at 
effector: target ratio of 40: I, seem low compared with those 
other i11 vilro studies [15,17-19,56). they are comparable 
levels shown by others [14,20,21,57-59]. These differences 
be due, in part, to the fact that different diseases were 
However, in a study of B-CLL, similar levels of 
cytotoxicity were generated when CD40L-stimulated B-CLL 
were cultured with allogeneic T cells, but not autologous T 
[55]. 
We attempted to increase the immunogenicity of our 
lysate by heat-shock treatment of the B-CLL cells 
preparation of the lysate, and by using combined fractions 
soluble and membrane-bound lysate. Neither of these tr<lllrntenl 
resulted in increased percentages of specific cytotoxicity. So 
«:> 2001 Blackwell Science Ltd, Clinical and Experimenlallmmunology, 126:1 
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we have been unable to generate stronger T-cell responses in vitro 
with additional immune manipulation during the cell culture 
period. Perhaps the modest level of tumour-specific cytotoxicity 
observed is due to the relatively low frequency of B-CLL-reactive 
cells within the patients' T-cell repertoire. However, the low 
levels of cytotoxicity may be due to the relatively immature slate 
of the monocyte-derived DC (CDSr) used to present lysate 
antigens to the T cells. After the loading of antigen onto the 
dendritic cell surface, a further 'danger signal' is required to 
achieve maximal presentation of that antigen to the T cell [91. 
Current work is testing whether treatment with lipopolysaccharide 
and polyriboinosinic polyribocytidylic acid can enhance further 
DC maturation after tumour lysate loading, and therefore 
stimulate higher levels of specific cy101oxicity to B-CLL cells. 
Of particular interest was the nature of the responding cell 
population. The responding cells in two patients were predomi-
nantly CD4 +. Although there is evidence that DC can directly 
trigger anti-tumour responses by Natural Killer (NK) cells [60], 
the effector cells in our assay did not express the NK markers 
CDI6 and CD56. Antibody blocking experiments in the three 
patients tested demonstrated significant inhibition of cytotoxicity 
with anti-class 11, anti-pan TCR 0<~ and anti-CD4, but not with 
anti-class I or anti-CD8 monoclonal antibodies. Overall, this 
suggests that CD4 + HLA cla>S 11-restricted cytotoxic T cells are 
responsible for the majority of lysis of B-CLL cells in our culture 
system. In general, it is thought that CD8+ class !-restricted T 
cells are responsible for anti-tumour immunity 119,21,61]. 
However, CD4+ cytotoxic T cells have been reponed in 
hepatocellular carcinoma [62) and p21-ras (12Val) mutated cells 
[63]. In general, it is thought that DC process and present 
exogenous proteins by the HLA class 11 pathway, and that 
internalizing antigen from apoptotic cells generates MHC class I 
restricted cytotoxic T lymphocytes [9]. B-CLL patients with 
decreased the numbers of CD4 + T cells due to recent therapy with 
fludarabine [64) may not exhibit a specific cytotoxic response in 
our culture system. 
One concern that has been raised with regard to dendritic cell 
vaccination is the possibility of inducing autoreactivity. In our 
culture system, reactivity was not demonstrated against auto-
logous B-CLL T -cells and granulocytes, or HLA matched and 
allogeneic B-cells from healthy individuals. Recently, T-cells 
generated by stimulation with CML-pulsed dendritic cells showed 
proliferation against autologous CML cells, but not an HLA-
identical sibling [65]. However, our system was unable to 
demonstrate strong T-cell responses to allogeneic lysates. We 
can only surmise that our system is not optimized for the 
presentation of allogeneic antigens via the indirect pathway. 
However, the system was able to present well characterized 
antigens such as tetanus toxin and tuberculin PPD. The lack of a 
specific response by T-cells from healthy volunteers presented 
with B-CLL lysate antigens by their own dendritic cells suggests 
the presence of a pre-existing pool of reactive T -cells in B-CLL 
patients not found in healthy volunteers. Recently, the existence of 
autologous T-lymphocytes capable of spontaneous specific 
recognition of B-cells from B-CLL patients has been demon-
strated [66]. Ideally, we would wish to test for cytotoxicity against 
autologous non-malignant B-cells from B-CLL patients, but due 
to the overabundance of the malignant B-cells in these patients, 
this was found to be impossible. Although T-cells make poor 
targets, we did not wish to introduce anti-viral epitopes into our 
system in the form of EBV-transfected targets. Clinical studies 
with DC vaccination have so far reported no evidence of 
autoimmune disease [22-24,26,29], although autoimmunity has 
been induced in mice in one study [67]. 
Our experiments have demonstrated specific T -cell responses 
to B-CLL. Although cytotoxicity was induced with some 
allogeneic B-CLL lysates, this was not the case with others. This 
suggests that, although a common antigen may be present in a 
proponion of B-CLL patients, other B-CLL patients may have 
unique amigens. This should not be surprising, as B-CLL is not a 
homogenous disease. However, despite the obstacles this hetero-
geneity may present, we believe that it is important to identify the 
anligen(s) within the B-CLL lysate responsible for the immune 
responses we have demonstrated, and this work is currently in 
progress. At the same time, this study provides evidence that a 
clinical trial of immunotherapy in B-CLL is feasible. 
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SUMMARY 
Immunotherapy using dendritic cells has shown encouraging results in both haemutological and non-
haematological malignancies. In this study, monocyte-derived dendritic cells from patients with B-CLL 
were cultured for 6 days in the presence of IL-4 and GM-CSF. Autologous B-CLL T-ceUs were cultured 
alone or with B-CLL lysate-pulsed and unpulsed autologous dendritic cells. IFN-'Y secretion was 
assessed using ELlS A. Cytotoxicity was assessed, after 21 days io culture and re-stimulation, using flow 
cytometry with and without blockade by anti-HLA class I, anti-HLA class 11, anti-CD4, anti-CD8 and 
anti-TCRal3 monoclonal antibodies. B-CLL T cells stimulated with B-CLL lysate-pulsed autologous 
dendritic cells showed a significant (P = 0·0004) increase in IFN-'Y secretion and a significant 
(P = 0·0008) increase in specific cytotoxicity to autologous B-ceU targets, but none to autologous T cell 
or B cell targets from healthy individuals. B-CLL T cells cultured with (non-B-CLL) B-cell lysate-
pulsed B-CLL dendritic cells showed oo significant response. Pulsing dendritic cells from healthy 
volunteers with an autologous (non-B-CLL) B-cell lysate did not stimulate proliferation, cytok.ine 
production or cytotoxicity by autologous T cells. Pulsing B-CLL dendritic cells with allogeneic B-CLL 
lysates and culturing with autologous T -cells elicited cytotoxicity against autologous B-CLL targets in 
some cases, but not in others. Cytotoxicity was significantly reduced by blocking with anti-HLA class II 
(P = 0·001), anti-TCRal3 (P = 0·03) and anti-CD4 (P = 0·046) antibodies. Pheootyping of the 
responding T-cell population demonstrated the majority to he CD4 positive. Our data demonstrate that 
HLA class 11-restricted proliferative and cytotoxic T-cell responses to B-CLL can be generated using 
autologous dendritic cells pulsed with tumour cell lysate. 
Keywords dendritic cells tumour lysate B-cell chronic lymphocytic leukaemia HLA class U 
INTRODUCTION 
B cell chronic lymphocytic leukaemia (B-CLL) is characterized 
by the accumulation of a clone of malignant B cells in lymphoid 
tissue, the bone marrow and the peripheral blood. Although 
chemotherapy can induce partial or complete remission [I), long-
term disease-free survival is unusual. Recent trials of bone 
marrow transplantation or monoclonal antibodies are promising 
[2]. However, new treatment modalities for this disease are 
required. In view of the fact that B-CLL is a tumour of the 
immune system, it seems challenging and logical to allempt to 
harness that system to treat this disease. 
The recent marked growth in our understanding of the immune 
system and its interaction with malignant disease includes the 
mechanism by which antigen is presented toT lymphocytes [3,4). 
Dendritic cells (DC) are now known to be essential for the 
iniliation of primary immune responses and are particularly 
efficient at capturing and presenting antigens toT cells [5-7). By 
priming them in vitro with tumour antigens, these 'professional' 
anligen-presenting cells (APCs) may bypass the state of ignorance 
in which the immune system appears to co-exist with most 
tumours [8]. Studies of DC vaccines in both animal models and 
man have demonstrated the generation of anti-tumour immune 
responses [9- 11]. Early allempts at cancer immunotherapy were relatively crude, 
including injecting patients with killed tumour cells or adjuvants 
such as Bacillus Calmelle Guerin and Corynebacterium paruum. 
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Reliable melhods for generating immature DC from peripheral 
blood mononuclear cells have facilitated their use in immunother-
apy [12,13). 111 vitro studies in man have demonstrated that DC 
loaded wilh tumour antigens can induce cytotoxic T-lymphocyte 
(CTL) responses against melanoma [ 14-16], chronic myeloid 
leukaemia [17-19], acute myeloid leukaemia [20) and pancreatic 
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